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ABSTRACT 
 
 Sulfur mustard (SM) is an alkylating agent which primarily targets the skin, eyes, 
and lungs.  Several challenges have hindered the development of drugs to counter SM 
effects including:  (1) the complex mechanism of action which is not yet fully 
understood, (2) the lack of reliable and reproducible animal models of SM vesication, and 
(3) the limited amount of data from SM-exposed humans.  Recent evidence suggests that 
inflammation via the upregulation of cyclooxygenase (COX) plays an important role in 
SM vesication.  The serine hydrolase, acetylcholinesterase (AChE), also regulates 
inflammatory processes via the cholinergic system.  This work involves the covalent 
linkage of a non-steroidal anti-inflammatory drug (NSAID) to an AChE inhibitor 
(AChEI) in order to target multiple aspects of dermal SM injury.     
 The structural optimization of three novel classes of NSAID-AChEI conjugates is 
presented.  Linkers incorporated into these molecules include derivatives of p-
hydroxybenzyl alcohol as well as amino acids with inherent anti-inflammatory properties.  
Many of these compounds inhibit AChE in the low micromolar range, have been shown 
to release the parent NSAIDs in plasma and skin homogenate, and suppress in vivo 
vesication at levels 2-3 times higher than the NSAIDs alone.  A structure-activity 
relationship (SAR) study revealed that NSAID-AChEI conjugates with aromatic linkers 
demonstrated potent anticholinesterase and anti-inflammatory activities while control 
compounds without the linker and conjugates with non-aromatic linkers were 
significantly less active.  In addition, the high anticholinesterase potencies of these 
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compounds can be explained by hydrophobic interactions with Trp, Tyr, and Phe residues 
along the active site gorge of AChE, a finding which was confirmed by docking studies.        
 Preliminary studies also suggest that NSAID-AChEI conjugates are viable drug 
candidates for the treatment of Alzheimer’s disease (AD).  These compounds have the 
potential to target multiple aspects of AD through the restoration of cholinergic balance, 
treatment of neuroinflammation, and inhibition of β-amyloid plaque formation.  
Moreover, many of these compounds should penetrate the blood-brain barrier based on 
quantitative SAR (QSAR) calculations.  This work indicates that multifunctional NSAID-
AChEI conjugates should effectively treat SM vesication, AD, and other inflammatory 
pathologies.   
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Chapter 1:  Introduction 
1.1 Sulfur Mustard  
1.1.1 History of Sulfur Mustard  
 Sulfur mustard (2,2’-dichloroethyl sulfide, SM) is a hazardous chemical vesicant 
which targets multiple organs and can lead to debilitating injuries.1, 2  Prior to the 
discovery of deadly nerve agents, SM led to the largest number of chemical casualties in 
World War I.3  In the 1980s, SM use during the Iraq-Iran Conflict resulted in an estimated 
45,000 Iranian casualties,4 with approximately 30% of the victims still suffering from 
chronic mustard effects.5   
 This haloalkyl chemical can be synthesized from inexpensive and readily 
available starting materials via a straightforward procedure and therefore presents an 
eminent national and global security threat to both army and civilian populations.  The 
Agency for Toxic Substances and Disease Registry (ATSDR) classifies SM as a warfare 
and terrorism agent.6  The carcinogenic properties of SM have also been recognized by 
the International Agency for Research on Cancer (IARC).7    
 When Despretz first synthesized SM in 1822, he immediately observed the 
vesicating properties of this agent.8  Mustard can be manufactured via the Levinstein 
process in which ethylene and sulfur dichloride (or disulfur dichloride) are reacted at 35 
o
C (Scheme 1.1).  Fuson et al. later proposed that 2-chloroethylsulfenyl chloride (I) is a 
synthetic intermediate in this process.9  Commonly observed polysulfide side products 
can be removed via distillation, and the US military uses the code HD, or “Hun-stuff 
distilled,” to designate distilled SM.  While pure SM is odorless, the synthetic impurities 
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often have a garlic or mustard odor which led to the name.5  Due to its high volatility, this 
agent can readily be vaporized and exposed to a large area where it may persist in the 
environment for days after the initial attack.3  This lipophilic vesicant is especially toxic 
because it can rapidly penetrate the skin and localize in various target tissues and mucous 
membranes.5         
Scheme 1.1:  Synthesis of Sulfur Mustard via the Levinstein Process.
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 In recent years, concerns over SM use have grown due to the stockpiles of the 
chemical weapon in countries such as Libya, Syria, Iraq, China, India, and Russia.  As a 
result, the dire need for an effective SM treatment is at the forefront of chemical defense.  
Despite over a century of research, there is no mustard antidote available in the event of 
mass SM exposure.  Several challenges have hindered the development of a 
countermeasure for SM exposure including:  (1) the complex mode of action which is not 
yet fully understood, (2) the lack of reliable and reproducible animal models of 
vesication, (3) the limited amount of data from SM-exposed humans, and (4) the 
elimination of Phase II and III clinical trials which explore the efficacy of potential 
treatments (in other words, it is illegal to intentionally expose humans to SM in order to 
obtain efficacy data).  In this dissertation, an investigation of the role of inflammation and 
cholinergic balance in SM vesication is presented.  The knowledge gained about the 
processes which contribute to SM injury has led to the development of several potential 
treatments which have proven effective against two different inflammatory stimuli.          
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1.1.2 Physiological Effects of Sulfur Mustard Exposure  
 SM targets several organs; however, the skin, eyes, and lungs are the most 
severely affected.  Of a known exposure, approximately 80% of SM evaporates prior to 
dermal penetration while 10-20% of the remaining vesicant covalently modifies a host of 
biological molecules (vide infra).  The rest of the mustard enters the circulatory system 
which can lead to systemic effects such as nausea, fever, and myelosuppression.10  The 
respiratory tract can also be affected, and mustard-induced pulmonary injury is the most 
common cause of death following high-dose exposure.1  Shortness of breath, airway 
inflammation, epithelial injury, and pulmonary infections11 are among the many acute 
symptoms of mustard gas inhalation.  Chronic lung effects including chronic obstructive 
pulmonary disorder,12 pulmonary fibrosis,13 mucosal thickening,14 and emphysema15 can 
be observed for the duration of the victim’s life.  Genotoxic and carcinogenic effects may 
occur following mustard-induced DNA damage, especially O6-guanine alkylation.16  The 
eyes are also commonly affected by SM, resulting in conjunctivitis and temporary 
blindness.17   
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Figure 1.1:  SM-induced Changes in Pigmentation (left) and Severe Blistering (right).
18
  
 The skin is among the most susceptible organs to SM damage, especially under 
extreme temperature and humidity conditions.  Following low-dose exposure, itching and 
erythema are observed while at higher doses, blister formation between the dermis and 
the epidermis occurs.19  Histopathologically, the blisters resemble chemical burns with 
hyperkeratosis of the epidermal basal layer and hypodermal connective tissue 
thickening.20  Chronic effects such as enhanced susceptibility to infection, scarring, and 
pigmentation changes (Figure 1.1) are common and may severely reduce a victim’s 
quality of life.1  With current treatment regimens (topical antibiotics, corticosteroids, anti-
histaminics, and analgesics) healing can take several weeks to months,5 depending on the 
degree of exposure.           
 The latency period following mustard exposure has perplexed scientists for 
decades.  Blister formation often does not commence until several hours post-exposure, 
depending on the dosage.  Consequently, victims exposed to SM do not always seek 
immediate medical treatment which can lead to further tissue damage.  The length of this 
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latency period depends upon the dosage, exposure time, and environmental conditions.  
For example, symptoms occur 4-8 h following dermal exposure of 200 mg·min/m
3
, while 
a 10,000 mg·min/m
3
 dosage results in a much shorter latent period (1-3 h).3  One viable 
approach to treat SM vesication is using a controlled-release drug which can treat the 
blister over several days.  In Chapters 2 and 3, the design, synthesis, and optimization of 
a sustained-release SM treatment are presented.      
1.1.3 Overview of the Mechanism of Sulfur Mustard Injury 
     Since the use of this debilitating vesicant in World War I, much research has 
focused on investigating the complex mechanism of SM injury in hopes of developing an 
effective antidote.  While a comprehensive and complete mechanism of SM injury has 
yet to be realized, various biological processes involved in mustard injury are well 
supported.19  Refer to Figure 1.2 for an overview of the processes involved in SM injury.  
(Many of these processes are described in detail in sections 1.2 and 1.3 of this Chapter.)  
Processes which may contribute to mustard injury include oxidative stress,21-25 
inflammation,19, 26, 27 and cholinergic down-regulation.28, 29  One of the most widely 
accepted hypotheses is that the alkylation of DNA by SM inhibits crucial cellular 
functions and results in cutaneous injury.30  Throughout lesion development, mustard may 
also alkylate other nucleophile-containing macromolecules such as RNA, proteins, and 
membrane lipids (Table 1.1).  Mechanistically, sulfur mustard cyclizes in vivo to form a 
highly electrophilic sulfonium ion which can be attacked by electron-rich nucleic acids, 
amino acids, and lipids (Scheme 1.2).  The second “arm” of the molecule can then form 
another sulfonium intermediate, leading to cytotoxic crosslinks.  Such alkylation results 
in oxidative stress, decreased cellular repair, and ultimately cell death via apoptosis and 
 8 
necrosis.5  Considering the complex mechanism of action of SM, the development of a 
treatment regimen which effectively targets each aspect of SM poisoning presents a true 
scientific challenge.         
 
Scheme 1.2:  Initiating Step of Sulfur Mustard Toxicity (Shown is N-alkylation of a 
guanine residue as an example).
5
 
 
Table 1.1:  Examples of Nucleophilic Targets of Mustard Action.  
Target Site(s) of Modification References 
Nucleic acids Guanine, N1-, N7-, O6-  15, 30-32 
 Adenine, N1- and N3-  16, 31, 32  
 DNA Cross-links 33-37  
Proteins Cysteine thiol 38 
 Histidine, N1- and N3 39, 40 
 N-terminal valine 40, 41 
 Selenocysteine 42, 43 
 Glutamic acid 39, 44 
 Aspartic acid 39, 44 
Peptides Glutathione thiol 40 
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Figure 1.2:  Summary of the Various Mechanisms of Sulfur Mustard Injury (Adapted 
from Reference 5). 
 
1.2 Specific Contributors to SM Injury and Related Treatments 
1.2.1 Inflammation 
1.2.1.1 Overview 
 Inflammation is the immune system’s primary defense against the response to 
external stimuli during an infection, injury, or disease.  During inflammation, changes in 
vascular flow and permeability result in the accumulation of fluid at the site of injury.  
The infiltration of mediators such as leukocytes and neutrophils also contributes to 
inflammatory pathology.45  Other endogenous mediators include prostaglandins, kinins, 
interleukins, tumor necrosis factor (TNF), and histamine.  The types and levels of the 
mediators released depend upon the site and nature of the injury.  The excessive release 
of proinflammatory mediators can result in a multitude of disorders such as multiple 
sclerosis, diabetes, rheumatoid arthritis, Alzheimer’s disease, and Parkinson’s disease.  
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Inflammation also plays a role in various forms of cancer and obesity.  In the subsequent 
sections of this Chapter, evidence suggesting the role of multiple inflammatory mediators 
in SM-induced vesication is presented.  Concomitant studies exploring the efficacy of 
three classes of anti-inflammatory compounds on SM injury is also described. 
1.2.1.2 Cyclooxygenase and Non-steroidal Anti-inflammatory Drugs 
 In the early 1970s, Vane et al. proposed that the therapeutic properties of aspirin 
(acetylsalicylic acid) are based on the drug’s inhibition of prostaglandin synthesis.46  
Prostaglandins are omnipresent hormones which regulate inflammatory processes, pain 
and fever, as well as other important physiological functions.47  Vane’s seminal work also 
revealed that cyclooxygenase (COX), an enzyme involved in the conversion of 
arachidonic acid to precursors of prostaglandins and thromboxanes, is targeted by aspirin.  
Chemically, COX catalyzes the conversion of arachidonic acid to the endoperoxides 
prostaglandin G2 (PGG2) and H2 (PGH2) via the formation of a bicyclic intermediate and 
subsequent reduction of the peroxide of PGG2 to an alcohol (Scheme 1.3).  PGH2 is an 
important precursor of prostaglandins E2 and D2 (PGE2 and PGD2), as well as 
thromboxanes A2 and B2 (TXA2 and TXB2).
48  
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Scheme 1.3:  The Biosynthesis of Prostaglandins from Arachidonic Acid.  (Adapted from 
Reference 48.) 
 Decades after the discovery of the native COX form (i.e. COX-1), COX-2, an 
inducible form of the enzyme, was discovered.49, 50  These two isoforms are approximately 
60% homologous; however, their distribution and expression vary significantly.  While 
COX-1 is expressed in most cells types and is involved in the regulation of various 
physiological processes, COX-2 is induced in cells such as macrophages, monocytes, and 
endothelial cells following an inflammatory stimulus.47  Both COX isoforms are 
therapeutic targets which have been extensively investigated.  
 One of the most common approaches to mitigate inflammation is using non-
steroidal anti-inflammatory drugs (NSAIDs; Figure 1.3) which target COX-1 and COX-2.  
Many of the NSAIDs are either phenylalkanoic acids (ibuprofen, naproxen) or oxicams 
(meloxicam, piroxicam).  NSAIDs are traditionally used to treat multiple forms of 
arthritis, postoperative inflammation, and psoriasis, among others.  Considering the range 
of therapeutic indications for NSAIDs, they are among the most frequently prescribed 
drugs, especially in patients older than 65.47  
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Figure 1.3:  Chemical Structures of Known NSAIDs.   
 Since the inhibition of COX-1 via the administration of NSAIDs can result in 
ulcerogenesis (refer to Section 1.2.1.3), it was hypothesized that selective inhibition of 
COX-2 would minimize side effects and provide a more potent anti-inflammatory effect.  
COX-2 selective NSAIDs such as celecoxib (Celebrex
®
, Pfizer; Figure 1.3) were put on 
the market in the 1990s; however, these drugs have recently received adverse attention 
for their cardiovascular side effects.  A related COX-2 selective inhibitor, rofecoxib 
(Vioxx
®
, Merck), was eventually withdrawn from the market in 2004.51  The NSAIDs 
investigated in this dissertation are all nonselective NSAIDs which target both COX-1 
and COX-2 since nonselective NSAIDs have shown high efficacy in models of 
vesication.   
1.2.1.3 Common Side Effects of NSAIDs    
 Although NSAIDs are effective against a range of inflammatory pathologies, 
chronic NSAID use can result in unwanted side effects.  The most common side effects 
are gastrointestinal (GI) irritation and bleeding, reduced kidney function, and disruption 
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of blood coagulation.  These negative effects are related to the decreased production of 
PGE2 and TXA2, molecules which stimulate GI production of mucus and regulate acid 
secretion.47  The carboxylic acid group of the NSAID can also directly interact with 
gastric mucosa leading to ulcer formation.52     
 One approach used to minimize the ulcerogenic properties of NSAIDs is to 
derivatize the GI-irritating carboxylic acid group.  Such derivatives are termed prodrugs 
and can be hydrolyzed to a pharmacologically active drug in vivo.52, 53  More detailed 
information regarding the rational design of NSAID prodrugs is presented in Chapter 2.  
The minimization of systemic exposure via local NSAID administration is another 
approach to mitigate GI toxicity.  Topical preparations of diclofenac and ketoprofen 
(Figure 1.3) are commonly prescribed for arthritis patients.54  Recent equivalence studies 
have revealed that topical diclofenac is better tolerated than oral diclofenac,55, 56 although 
irritation at the site of administration is an additional side effect.  In Chapters 2 and 3, a 
diverse set of topical NSAID prodrugs is described.  The utility of these agents against 
vesicant-induced edema and inflammation is also assessed.        
1.2.1.4 Sulfur Mustard Exposure Causes Inflammation 
 Since a pronounced inflammatory response is one of the hallmarks of SM injury, 
the role of various inflammatory pathways and the effects of anti-inflammatory 
treatments have been extensively investigated.  Following a 2 h exposure of synthetic 
human skin equivalents (Epiderm
®
 and Skin
2®
) to chloroethyl ethyl sulfide (CEES), a SM 
surrogate, inflammatory mediators interleukin (IL)-1α, IL-1 receptor antagonist, and 
PGE2 were upregulated by 73%, 33%, and 36%, respectively.
57  Additionally, Arroyo et 
al. found that normal human epidermal keratinocytes released excessive levels of 
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proinflammatory cytokines IL-8 and TNF-α following a 100 µM dose of SM.  At a higher 
dose (300 µM), additional cytokines such as IL-1 and IL-6 were released, suggesting a 
clear inflammatory response.58  Similar studies were carried out in both a model which 
investigates the effects of SM on the ears of mice (mouse ear vesicant model; MEVM) 
and a model which measures vesication on the backs of hairless mice (sham model).  In 
these in vivo models, though, no changes in TNF-α or IL-1β were observed.59                 
1.2.1.5 Efficacy of Anti-inflammatory Drugs Against SM  
 Because inflammation plays an important role in SM injury, anti-inflammatory 
agents have been extensively investigated as potential mustard treatments.  Out of 
hundreds of potential anti-vesicants screened at the US Army Medical Research Institute 
of Chemical Defense and Battelle Memorial Institute, a majority of the drugs which show 
greater than 50% efficacy against SM also directly or indirectly mediate inflammation.26  
Yourick et al. found that a 30 min pretreatment with a combination of anti-inflammatory 
drugs (niacinamide, promethazine, and indomethacin) resulted in a 91% reduction of 
vesicant-induced erythema at 4 h post-exposure.60  The same effects, however, were not 
observed at 24 h following exposure.  Both topical61 and systemic62 administration of 
known anti-inflammatory drugs such as indomethacin, olvanil, and hydrocortisone have 
also shown a protective effect against SM injury in a MEVM compared to a positive 
control (i.e. no anti-inflammatory treatment).  Such anti-inflammatory agents reduced 
vesicant-induced edema by 27-66%, and also suppressed subepidermal blister severity 
and contralateral epidermal necrosis by 84-100%.  Interestingly, these compounds proved 
significantly more effective than drugs of other treatment classes screened under the same 
conditions, including anti-proteases, radical scavengers, and inhibitors of poly(ADP-
 15 
ribose) polymerase (PARP) (treatments described in subsequent sections of this Chapter).  
Dachir and coworkers also found that treatment with the steroid Adexone and the NSAID 
diclofenac reduces levels of PGE2 by 30% compared to untreated mouse skin at 8 h 
following SM exposure.63  From these studies, it is clear that SM toxicity can be 
mitigated by targeting multiple inflammatory pathways.   
 In Chapter 3 of this dissertation, inflammation suppression is explored as an 
approach to address SM toxicity.  A detailed structure-activity relationship (SAR) study 
exploring the effects of several NSAID conjugates on two different types of inflammation 
is presented.  The role of the NSAID, drug lipophilicity, and the rate of NSAID release is 
also described.  Finally, computational studies investigating the potencies of these novel 
NSAID conjugates against both COX-1 and COX-2 is presented in Chapter 5.       
1.2.2 The Role of Oxidative Stress in SM Injury 
 The link between SM vesication and oxidative stress has also been extensively 
investigated.  It is well established that modifications of essential biomolecules by small 
molecular weight electrophiles such as SM induces oxidative stress.21-25  This process is 
initiated by either the stimulation of cellular processes (e.g. mitochondrial respiration and 
electron transport) which produce harmful levels of reactive oxygen and nitrogen species 
(ROS and RNS) or by the depletion of critical redox molecules and enzymes.21  
Endogenous molecules essential to redox balance include glutathione (GSH), thioredoxin 
reductase (TrxR), superoxide dismutase (SOD), catalase, ascorbic acid, melatonin, and 
the tocopherols (vitamin E; Figure 1.4).  Exogenous molecules with antioxidant 
properties include curcumin and N-acetylcysteine (NAc).  Species which contribute to 
oxidative stress at excessive concentrations include hydrogen peroxide (H2O2), hydroxyl 
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radical (·OH), peroxynitrite (ONOO
-
), and superoxide anion (O2
·-
).  Even a minor 
disruption of the levels of these redox molecules can be deleterious and may result in 
tissue damage.      
 
 
Figure 1.4:  Examples of Endogenous and Exogenous Antioxidant Molecules and 
Radical Scavengers. 
 SM alkylates antioxidant molecules such as GSH causing a disruption of the 
body’s homeostatic redox balance.40  In lung epithelial cells, CEES alkylates a TrxR 
selenocysteine residue in an irreversible and potent (IC50 of 4.5 µM) manner.
64  Mustard-
derived sulfonium ions also may be reduced to carbon-centered free radicals by 
oxidoreductases such as nicotinamide adenine dinucleotide phosphate (NADPH)-
cytochrome P450 reductase and TrxR (Scheme 1.4), a process which has been observed 
spectroscopically using electron paramagnetic resonance (EPR).65  The resulting free 
radical can initiate a cascade of reactions which promotes increased ROS/RNS 
production.  This increase in harmful radical species can lead to lipid peroxidation (a 
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process by which alkene-rich lipids participate in nucleophilic attack), electrophilic 
substitution, and addition-elimination reactions with ROS and RNS.66    
 
Scheme 1.4:  Proposed Mechanism for the Formation of a SM-Derived Free Radical.65 
1.2.3 Antioxidants and Radical Scavengers as Potential SM Treatments 
 Rational approaches to target SM-induced oxidative stress include:  (1) the direct 
scavenging of reactive oxygen and nitrogen species via antioxidant treatment, (2) the 
inhibition of enzymes which produce harmful ROS/RNS, (3) the upregulation of enzymes 
which mediate detoxification, and (4) the treatment of pathogenic effects which result 
from oxidative stress (e.g. inflammation).  Some antioxidants have shown promising 
activity against SM or CEES in animal models.  The GSH prodrug, NAc (Figure 1.4), 
provided 54% protection against CEES-induced lung injury in a rat model when 
administered up to 90 min following exposure.67  Similarly, reversals of GSH depletion 
and ROS formation in the lung were seen when a catalytic antioxidant, AEOL 10150 
(Figure 1.4), was administered via inhalation in a rat model.68  α-Tocopherol has also 
been frequently used either alone or as part of a drug cocktail to ameliorate SM-promoted 
lipid peroxidation and tissue injury.69-71  The radical scavenger, dimercaprol (Figure 1.4), 
has also been screened against SM in a MEVM, resulting in a statistically significant 
reduction of edema, subepidermal blister severity, and contralateral epidermal necrosis 
(by 43%, 85%, and 92%, respectively).  In the same model, though, other antioxidants 
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and radical scavengers including NAc, polyphenols, and sodium thiosulfate had no effect 
on SM damage,61 suggesting that the utility of antioxidants as SM treatments is limited.        
1.2.4 Anti-proteases  
 Upon mustard exposure, DNA-alkylation induces the release of proteolytic 
enzymes which attack and degrade structural proteins such as collagen and proteoglycan.  
In vitro and in vivo studies generally support the hypothesis that SM-induced proteolysis 
contributes to the development of the final lesion.72  Proteases also directly and indirectly 
activate inflammatory responses in the skin by damaging epidermal and dermal cells and 
further exacerbating the initial injury.  Powers and coworkers did an extensive 
investigation of the role of proteolysis in SM-induced cutaneous injury.  At 24 h post SM 
exposure, skin homogenates reflected significantly higher elastase, tryptase, and calpain 
activities (1900%, 220%, and 170%, respectively).  With this in mind, Powers et al. 
screened a set of inhibitors specifically targeting the aforementioned proteases and found 
that two peptide-based protease inhibitors effectively inhibited proteolytic activity in 
mustard-treated skin homogenate samples.27  When one of the peptide inhibitors was 
screened in a MEVM, however, only a slight reduction (16%) of vesicant-induced edema 
was observed and histopathological biomarkers remained statistically unchanged.61  
While inhibiting proteolysis is a rational approach for SM treatment, in vitro results do 
not seem to parallel in vivo outcomes.  Proteases may still be useful, but only as one 
component of a drug cocktail to ameliorate SM injury.  
1.2.5 Role of Poly(ADP-ribose) Polymerase 
 Both Berger30, 73 and Papirmeister19 have proposed that PARP type-1 (PARP-1), a 
chromosomal enzyme involved in DNA repair, plays a role in SM pathology.  Following 
 19 
SM-induced DNA alkylation and strand breakage, PARP-1 is activated and the substrate, 
nicotinamide adenine dinucleotide (NAD
+
), is subsequently diminished.  Since NAD
+
 
plays a pivotal role in cellular metabolism, depletion of this substrate disrupts cellular 
homeostasis and promotes cellular injury.   
 Meier and coworkers investigated the effects of the PARP-1 inhibitor, 3,4-
dihydro-5-3-(methylamino) propoxy-1-(2H)-isoquinolinone monohydrochloride (Figure 
1.5), on cellular viability in SM-treated peripheral blood lymphocytes.  Levels of lactate 
dehydrogenase (LDH) and propidium iodide exclusion, markers of cell viability and 
membrane integrity, were measured in control cells with no PARP inhibitor, cells treated 
with the inhibitor, and cells treated with the inhibitor followed by SM 15 min later.  In 
the untreated cells, both time- and concentration-dependent losses of cell viability were 
observed, as predicted.  Also, the adenosine-5'-triphosphate (ATP) levels of cells treated 
with the PARP inhibitor were only 15% lower than that of the control cells (without SM), 
while the ATP levels in untreated cells dropped by 62%.72  While the above results seem 
promising, isoquinolinone PARP inhibitors did not modulate SM injury when screened in 
a MEVM.61  Once again, in vitro results do not seem to effectively predict the in vivo 
efficacy of a given drug in this case.         
 
Figure 1.5:  Structure of 3,4-Dihydro-5-3-(methylamino)propoxy-1-(2H)-isoquinolinone 
Monohydrochloride, a Known PARP-1 Inhibitor. 
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1.2.6 Role of Matrix Metalloproteinases  
  Matrix metalloproteinases (MMP) are endopeptidases involved in the degradation 
of the extracellular matrix, a process which regulates tissue remodeling.74  MMP 
expression is controlled by cytokines, growth factors, and hormones, and the proteolytic 
activity of these enzymes is tightly regulated by endogenous molecules.  Following a 
negative stimulus such as SM, though, this balance is disrupted and structural damage 
may result.   
 Recent evidence suggests that MMPs, especially the gelatinases MMP-2 and 
MMP-9, 64
,75-78 play a role in SM-induced dermal-epidermal separation.  This hypothesis 
has been investigated by Ries and coworkers who used a human skin model to examine 
the effect of SM on dermal-epidermal cleavage and the subsequent release of MMPs 
from fibroblasts and keratinocytes.  They found that MMP-9 expression is upregulated 
following topical SM exposure, while other MMPs such as MMP-2 were unaffected. 79  
Mol et al. found that the nonspecific MMP inhibitor GM6001 (Ilomastat; Figure 1.6) 
suppressed epidermal damage in a human skin organ culture at a concentration of 100 
µM.80  Interestingly, this inhibitor was effective when administered up to 8 h post-
exposure, providing a clear advantage over many other treatment classes which are 
ineffective once blister development has begun.  
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Figure 1.6:  Structure of Ilomastat, a Nonspecific MMP Inhibitor. 
 
1.3 The Cholinergic Anti-inflammatory Pathway 
 While the release of inflammatory mediators by the immune system is a necessary 
response to external pathogens, the excessive release of such mediators can result in 
inflammation, tissue damage, and death.81  Extensive work from Tracey supports a 
physiological link between inflammation and cholinergic balance termed the cholinergic 
anti-inflammatory pathway.82  This mechanism is mediated by the α7 subunit of the 
nicotinic acetylcholine (ACh) receptor (α7-nAChR) and involves regulation of systemic 
cytokine release by the vagus nerve.  ACh has been shown to decrease the central and 
peripheral release of proinflammatory cytokines such as TNF, IL-1β, IL-6, and IL-8.83  
Potentiation of ACh through the inhibition of acetylcholinesterase (AChE), the enzyme 
which degrades ACh, results in inflammation suppression in models of sepsis, obesity, 
and endotoxemia.  For example, treatment with the AChE inhibitors (AChEIs) 
physostigmine and neostigmine improved survival time in a murine model of sepsis.84  
Centrally-acting galantamine also suppresses the release of TNF and IL-6 in a model of 
endotoxemia85 and alleviates obesity-associated inflammation.86  ACh is not only present 
in neurons, this neurotransmitter is also present in various types of immune cells,87-89 
keratinocytes,90 endothelial cells,91 and epithelial placenta cells.92  The cholinergic anti-
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inflammatory pathway could therefore be involved in the regulation of local 
inflammatory processes outside of the CNS.   
 Recent evidence suggests that non-neuronal cholinergic activity plays a role in the 
regulation of skin function.93  ACh is produced by keratinocytes and infiltrating 
leukocytes during inflammation and may regulate epidermal cell proliferation and 
differentiation.90  Steinritz and co-workers have observed elevated AChE levels during 
the apoptotic pathway of SM-exposed pulmonary cells, suggesting that the enzyme 
specifically plays a role in SM pathology.94  Considering recent evidence, AChE is a 
viable target to mitigate SM toxicity.   
 In Chapter 3 of this dissertation, the detailed role of AChE in SM injury is 
investigated using results from an anticholinesterase assay and a MEVM.  The detailed 
SAR study described also provides direct evidence supporting the cholinergic anti-
inflammatory pathway; a correlation was observed between AChE inhibition and 
inflammation suppression, although additional factors contributed to the observed 
activities.  This study is one of the first documented cases where topical inhibition of 
AChE resulted in an acute anti-inflammatory response.  In Chapter 4, the site and 
reversibility of AChE-inhibitor interactions is explored using in vitro methods.  Finally, 
Chapter 5 includes extensive in silico studies to support data presented in Chapters 3 and 
4.  These studies allowed for a more comprehensive understanding of the mechanism of 
action of the newly-designed anti-vesicants.  
1.4 Multifunctional Drugs as Sulfur Mustard Treatments  
 The complex nature of SM injury can best be targeted using either a 
multifunctional drug or a cocktail of drugs.  A promising approach appeared to be the 
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administration of two or more known anti-inflammatory drugs.  In that regard, a simple 
mixture of a steroid and an NSAID showed promising results by reducing SM-induced 
edema by 60-70% in a MEVM.  This mixture also promoted faster healing when 
administered twice a day for 48 h following SM exposure.  Protein levels in the skin were 
lower at 24 and 48 h post-exposure when treated with the mixture, whereas no effect was 
seen for 48 h in the mice treated with the NSAID or steroid alone.63  These studies 
suggest that the combination of two anti-inflammatory agents induces more rapid healing 
and may provide a greater benefit than treatment with either drug alone.  
 Another strategy to target SM poisoning is through the covalent linkage of two 
pharmacophores acting on different targets, an idea which was first explored by Amitai 
and coworkers.  In these studies, an NSAID linked via a simple hydrocarbon chain to the 
AChEI, pyridostigmine, provided protection against SM when screened in an in vivo 
mouse model.29  Diclofenac linked to pyridostigmine (DICLO-PD, Figure 1.7) was 
especially effective, showing about 49% protection against SM-induced edema as well as 
significantly reducing the severity of sub-epidermal blisters and epidermal necrosis.  
While these results are promising, the anti-inflammatory effect observed with DICLO-PD 
is comparable to that observed with topical ibuprofen (Ibuleve) and diclofenac (Voltaren) 
alone, as shown in Figure 1.8 (44% and 49%, respectively).  In vitro and in vivo release 
of the pharmacologic components of these conjugates was not investigated, making it 
unclear whether or not the anti-inflammatory activity observed is from the entire 
molecule or from the release of the NSAID and the AChEI.  Because edema and blister 
histology were measured 48 h following SM exposure, it is likely that both 
pharmacologic components had already been released prior to data collection.  In this 
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case, AChE inhibition via the release of pyridostigmine does not appear to significantly 
affect edema suppression.                      
 
 
Figure 1.7:  Examples of Bifunctional Compounds, DICLO-PD (left) and IBU-PO 
(right).
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Figure 1.8:  Percent increase in edema of mouse ear skin measured 48 hr following 
exposure to SM (HD), where PG is propylene glycol and Voltaren and Ibuleve are 
commercial diclofenac and ibuprofen.  * P < 0.01, ** P < 0.001.
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1.5 Overview of Doctoral Research  
 Based on the literature precedent discussed, it is clear that a multifaceted 
approach is needed to effectively treat SM poisoning.  In this research, drugs have been 
designed and studied which target both inflammation and cholinergic imbalance.  By 
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coupling an NSAID to either a known inhibitor or a pseudo-substrate of AChE, it was 
possible to improve upon the in vitro and in vivo activities of either component alone.  
This dissertation describes a detailed rational behind the use of dual-action 
anticholinergic NSAID prodrugs to target SM.  Three novel compound classes have been 
designed and screened for their anti-vesicant and anticholinesterase activities.95, 96  The 
results presented in Chapters 2 through 5 include:  (1) a discussion of the synthetic 
methods used for novel compounds, (2) an in depth SAR of in vitro anticholinesterase 
and in vivo anti-vesicant activities, (3) an investigation of the reversibility and site of 
AChE-inhibitor interactions, and (4) in silico investigations of anticholinesterase and 
anti-COX potencies.   
 Throughout the duration of this project, it became apparent that inflammation and 
cholinergic dysfunction play roles in many disease states, including Alzheimer’s disease 
(AD).  Chapter 6 presents evidence supporting the alternate use of NSAID-AChEI 
conjugates as anti-Alzheimer’s drugs.  Data presented in Chapter 6 suggest that these 
compounds have the potential to target multiple aspects of AD through the restoration of 
cholinergic balance, treatment of neuroinflammation, and inhibition of β-amyloid plaque 
formation.   
 Finally, in Chapter 7, a collaborative project with Professor Robert Flowers, 
Professor Darryl J. Bornhop (Vanderbilt University), and Gabrielle Haddad involving the 
utility of a novel technique, back-scattering interferometry (BSI), to detect small 
molecule-AChE interactions is described.  With a detection limit on the order of 22,000 
molecules of enzyme, BSI could be used to screen for potent anti-inflammatory 
compounds and AD treatments, to develop nerve agent sensors, and, most importantly, to 
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gain a fundamental understanding of the interactions between AChE and small 
molecules, peptides, and proteins of interest.            
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Chapter 2:  Synthesis and Characterization of Dual-Action SM Therapeutics 
2.1 Introduction 
 Prodrugs are derivatives of a pharmacologically active drug which are 
metabolized to the parent drug in vivo.  They are often designed to address undesirable 
side effects or sub-optimal solubility, stability, bioavailability, and permeability.  The 
prodrug approach can also be used to improve site specificity, minimize side effects, or 
provide a more sustained drug action.53, 97  Although the traditional definition of a prodrug 
is that of an inactive molecule which can be transformed into the active drug, this is not 
always the case; some prodrugs are also pharmacologically active.  For example, 
naproxen and ketoprofen 2-hydroxyethylmethacrylate co-polymerized prodrugs 
demonstrate more potent acute anti-inflammatory efficacy compared to the NSAIDs 
alone.98   
 The design of NSAID prodrugs is a common approach to mitigate the GI irritation 
observed with chronic NSAID use.52  Irritation is caused by the carboxylic acid of the 
NSAID, which can interact with gastric mucosa and ultimately lead to the formation of 
ulcers.  A tremendous number of ester and amide NSAID prodrugs have been explored 
over the past few decades to mask this GI-irritating carboxyl group.  NSAID esters are 
especially useful because they are sufficiently stable for formulation and storage, yet 
serum esterases can readily release the NSAID in vivo.99  In many cases, the prodrugs 
induce fewer and less severe GI side effects and are either as active as or more active 
than the NSAID alone.100   
 Topical NSAID prodrugs are also commonly explored in order to enhance dermal 
penetration and provide a more localized therapeutic effect.  Roy et al. investigated the in 
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vitro skin permeabilities of a class of ketorolac acid prodrugs and found that the [N,N-
(dimethylamino)carbonyl]methyl ester moiety (Figure 2.1) exhibited a higher skin flux 
relative to the ketorolac ethyl ester and ketorolac alone.101  Aminoacyloxyalkyl,102 
morpholinyl, and piperazinylalkyl103 ester prodrugs of naproxen (Figure 2.1) also have 
enhanced dermal penetration compared to naproxen alone.  Considering that a topical 
application would be most effective to treat SM-induced blisters and that inflammation is 
one of the underlying pathologies of SM injury, dermal NSAID prodrugs provide a 
reasonable approach towards mitigating SM toxicity.     
  
Figure 2.1:  Examples of [N,N-(Dimethylamino)carbonyl]methyl (left),101 Morpholinyl 
(center), and Piperazinylalkyl (right)103-Substituted NSAID Prodrugs.     
 Because SM toxicity involves a latency period of 2-20 h during which DNA-
alkylation and other morphological changes occur, a controlled-release, dual action agent 
should effectively treat mustard injury over an extended period of time.  Slow-release 
anti-bacterial104 and cytotoxic105
,106 agents have previously been developed (Figure 2.2), 
many consisting of a p-hydroxybenzyl alcohol linker with two sites for functional group 
attachment and thus two areas for potential in vivo hydrolysis.  Presumably, linking an 
anti-inflammatory agent such as an NSAID to an AChEI via an alkylaryl linker may 
provide a dual benefit against mustard lesions.   
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Figure 2.2:  Structures of Controlled-Release Antibacterial (left) and Cytotoxic (center 
and right) Drugs.  
2.2 Design and Synthesis of Class 1 Molecules 
 The main function of AChE is to catalyze the hydrolysis of the neurotransmitter 
ACh at neuromuscular junctions in a rapid and efficient manner (Refer to Chapter 4 for a 
more detailed discussion of the structure and function of AChE).107  Inhibitors of AChE 
are designed to lower enzyme activity via the reduction of ACh hydrolysis.  In the early 
1990s, Heindel et al. designed selective AChEIs containing a choline mimic (Figure 2.3) 
for use as insecticides.108  Charged and uncharged choline mimics have moderate 
affinities for AChE, with inhibition constants (Ki) of 0.4 mM (X = N
+
), 3.3 mM (X = Si), 
and 7.5 mM (X = C).109  With these molecules, AChE should theoretically recognize and 
bind to the -O-CH2CH2X(CH3)3 “choline-like” moiety and inhibit substrate hydrolysis.   
 
Figure 2.3:  Structure of Insecticides Designed by Heindel and Coworkers (X = C, Si, or 
N
+
).
108
 
 AChE-catalyzed substrate hydrolysis involves cleavage of the ester bond of ACh 
by a serine residue (Ser200) which is hydrogen-bonded to a proximal histidine (His440).  
In the active site, the quaternary nitrogen of ACh participates in electrostatic interactions 
with the carboxylate anion of a glutamic acid residue (Glu327).  Once choline is released, 
 30 
a water residue which is hydrogen bonded to His440 attacks the modified Ser200 and 
results in the release of acetic acid and regeneration of the active site serine (Scheme 
2.1).110      
 
Scheme 2.1:  Mechanism of AChE-Catalyzed Hydrolysis of ACh.  
 Based on kinetic and reversibility studies, the p-chloromethylphenyl carbonate 
insecticides (Figure 2.3) inhibit AChE activity via an irreversible pathway (Scheme 2.2).  
Heindel et al. proposed that the Ser200 attacks the electrophilic carbonate bond to release 
choline and covalently bind to the haloaryl portion of the inhibitor.  A proximal water 
residue then attacks the intermediate to release an electrophilic and toxic quinone 
methide.  The free Ser200 attacks the electrophilic sp
2
 carbon of this intermediate to 
result in a covalently- and irreversibly-modified enzyme.108  This mechanism of enzyme 
inhibition is termed “suicide” inhibition because the action of the enzyme results in 
enzyme deactivation via the release of a toxic moiety (in this case, a quinone methide).111   
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Scheme 2.2:  Suicide-Like Mechanism of AChE Inhibition via a Quinone-Methide 
Intermediate.
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 Based on the level of anticholinesterase activity of the p-chloromethylphenyl 
carbonates, we decided to develop a novel class by linking an anti-inflammatory 
component to a moiety for cholinergic recognition.  As part of a search for an effective 
SM treatment, Class 1 (Table 2.1, compounds 1-8) containing an NSAID linked via an 
ester bond to a methylphenyl carbonate was designed.95  Our initial hypothesis was that, 
because of the choline-like moiety of these compounds, Class 1 would inhibit AChE via a 
mechanism similar to the p-chloromethylphenyl carbonates (Scheme 2.2).  Reversibility 
and kinetic studies (presented in Chapter 4), however, revealed that these new 
compounds are reversible rather than suicide-type inhibitors.  In other words, the 
inhibitory action of Class 1 compounds does not involve covalent modification of AChE.  
These alkyl-aryl compounds inhibit substrate hydrolysis via an alternate mechanism 
which is described in detail in Chapter 4.     
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 The NSAIDs ibuprofen, (S)-naproxen, and indomethacin (Figure 2.4) were 
incorporated into the NSAID-AChEI conjugates because of their widespread use and 
well-developed safety profiles.  Indomethacin alone showed protection against CEES in 
an MEVM.61  More recently, the NSAID, diclofenac, was incorporated into Class 1 
because of its frequent use as a topical treatment for rheumatoid and osteoarthritis,112 mild 
sprains, and musculoskeletal disorders.113  Furthermore, Dachir found that topical 
diclofenac (Voltaren) suppressed SM-induced edema by 47% at 72 h post-SM exposure, 
an effect greater than that of many other anti-inflammatory drugs including ibuprofen 
(Ibuleve), indomethacin (Indoptic), hydrocortisone, and dexamethasone.114  Using the 
synthetic procedures described in Schemes 2.3 through 2.12, several novel NSAID-
AChEI conjugates were isolated and studied.  Refer to Tables 2.1 and 2.2 for a complete 
list of compounds, organized by class.    
 
Figure 2.4:  Structures of NSAIDs Incorporated into Bifunctional SM Treatments. 
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Table 2.1:  Class 1, 2, and 3 Compounds (X = C, Si, or N
+; R’ and R” are AA chains). 
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 The synthetic scheme initially used for Class 1 compounds (1-8) was a five-step 
process with overall yields ranging from 48-59%, depending on the NSAID and X 
(Scheme 2.3).  This scheme involved:  (1) formation of aliphatic chlorformate III via 
reaction of I (X = C, Si) with phosgene (II) and triethylamine (Et3N), (2) coupling of III 
to the phenol of p-hydroxybenzaldehyde (IV), (3) reduction of the aldehyde function of 
IV with aqueous sodium borohydride, and (4) coupling of the resulting benzyl alcohol 
(VI) to an NSAID acid chloride to form the final product (VII).  
  
Scheme 2.3: Original Synthetic Scheme for Class 1 Molecules (X = C, Si).   
 While Scheme 2.3 afforded the desired products in acceptable yields, some 
improvements were made to optimize the yield, minimize the number of synthetic steps, 
and improve safety (Scheme 2.4).  Selective coupling of chloroformate III to p-
hydroxybenzyl alcohol (IX) rather than IV (Scheme 2.3) eliminated the need for a 
reduction step.  The desired selectivity for the phenol over the benzylic hydroxyl group 
was achieved by adding one equivalent each of III and Et3N to IX at reduced 
temperature.  Pure products were obtained after an aqueous wash, with no need for 
chromatographic purification.  Additionally, the acid functionality of the NSAID could 
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be activated in situ using 1,1'-carbonyldiimidazole (CDI), N,N’-
dicyclohexylcarbodiimide (DCC), or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC·HCl) with 10 mol % of 4-dimethylaminopyridine (DMAP).  The 
EDC·HCl/DMAP coupling system was found to be the most convenient since the urea 
side product of EDC·HCl is water soluble and thus is easily removed by an aqueous 
wash.  By eliminating two synthetic steps, the overall yields of Class 1 compounds were 
increased from 53 to 68%.  Furthermore, the highly toxic reagent used in Scheme 2.3, II, 
was replaced with triphosgene (VIII), a safer alternative.       
  
Scheme 2.4: Modified Synthesis for Class 1 Molecules (X = C, Si).   
 Although Schemes 2.3 and 2.4 worked well for carbon and silicon analogues of 
Class 1 (1-8), synthesizing a bifunctional compound with a quaternary amine (X = N
+
) 
proved to be problematic due to the low reactivity of choline chloride.  Scheme 2.5 was 
proposed which involves protection of the phenolic hydroxyl group of IX, coupling of the 
benzylic hydroxyl group to an NSAID acid chloride, and deprotection of XI.  Then, 
formation of the phenyl chloroformate of XII, coupling of the resulting chloroformate to 
N,N-dimethylaminoethanol (DMAE), and methylation of the tertiary amine would form 
the final product (XIII).  Selective acylation of the benzylic over the phenolic hydroxyl 
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was considered as an alternative since it would eliminate the protection and deprotection 
steps.  Despite several attempts using coupling systems such as triphenylphosphine 
(TPP)/diisopropyl azodicarboxylate (DIAD),115 lithium perchlorate,116 and cerium (III) 
chloride,117 selective acylation was never achieved.  It is hypothesized that XII can easily 
eliminate the NSAID, making it unstable.  
 
Scheme 2.5:  Synthetic Scheme Used in the Synthesis of Class 1 Choline Analogues.   
2.3 Design and Synthesis of Class 2 Molecules:  Elimination of the Intermediate 
Linker 
 While several Class 1 compounds are potent AChEIs and anti-vesicants (Refer to 
Chapter 3), many questions remain as to which structural elements are essential for the 
observed Class 1 activities.  The linker that connects the NSAID and the choline mimic 
via ester and carbonate bonds (IX) may or may not be necessary for the high efficacy of 
Class 1 molecules.     
 To investigate the importance of the benzyl linker, a control class (Class 2) was 
designed containing NSAIDs directly linked via an ester linkage to choline mimics (X = 
C, Si, N
+
; compounds 9-19).  The synthetic scheme for the carbon and silicon analogues 
involved only one coupling step between the NSAIDs and I using EDC·HCl/DMAP 
coupling system (Scheme 2.6).  Since the direct coupling of choline chloride can be 
problematic, the synthesis of the Class 2 choline analogues (X = N
+
) involved three steps:  
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(1) synthesis of the DMAE lithium salt (XVI) using n-butyl lithium, (2) coupling of XVI 
to the corresponding NSAID using 2-chloro-1-methyl-pyridinium iodide (Mukaiyama’s 
reagent; XVII), and (3) methylation of XVIII, as described by Venuti and Young.118  In 
this approach, XVI was purified via recrystallization from hexanes, XVIII required a 
simple aqueous wash and, with the appropriate solvent, the final product (XIX) 
precipitated out of solution with addition of an equal volume of diethyl ether.  In 
Schemes 2.6 and 2.7, pure products were obtained without the need for column 
chromatography.  
 
Scheme 2.6: Synthetic Scheme for Class 2 Compounds (X = C, Si).  
 
 
 
Scheme 2.7: Synthetic Scheme for Class 2 Compounds (X = N
+
). 
 To further expand our library of compounds, NSAIDs conjugated directly to 
known AChEIs such as galantamine or to derivatives of pyridostigmine and neostigmine 
were also synthesized (Figure 2.5).  For galantamine esters 20, 23, and 26, the free base 
alkaloid was coupled to each NSAID to form the final products in good to high yields 
(81-95%).  In the same manner, pyridostigmine conjugates 21, 24, and 27 were formed 
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by EDC∙HCl/DMAP coupling of commercially available 3-hydroxypyridine (XX) to the 
desired NSAID to form XXI.  XXI is then methylated using excess methyl iodide for 
form the final product (Scheme 2.8).  Neostigmine conjugates 22, 25, and 28 were also 
accessed by EDC∙HCl/DMAP coupling of an NSAID to 3-(dimethylamino)phenol 
(XXIII), synthesized via the method of Grove et al.,119 followed by quaternization of 
XXIV to form XXV (Scheme 2.9).  Overall yields for the pyridostigmine conjugates 
ranged from 8 to 60% and yields for the neostigmine conjugates ranged from 37 to 83%. 
 
Figure 2.5:  Structures of Common AChEIs Galantamine (left), Pyridostigmine (center), 
and Neostigmine (right).   
 
 
 
Scheme 2.8:  Synthetic Scheme for Class 2 Pyridostigmine Analogues. 
 
 
 
Scheme 2.9:  Synthetic Scheme for Class 2 Neostigmine Analogues. 
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2.4 Limitations of Diclofenac Coupling Reactions  
 Although Scheme 2.7 was successfully used to synthesize ibuprofen, naproxen, 
and indomethacin derivatives (11, 14, and 17), the diclofenac choline ester was never 
obtained via this synthetic method.  Diclofenac has a unique secondary amine 
functionality which, under basic conditions, can cyclize to form 1-(2,6-diclorophenyl)-2-
indolinone (XXVIII).120  Upon activation of the carboxylic acid of diclofenac with XVII 
and Et3N, the secondary amine of diclofenac can intramolecularly attack the activated 
carbonyl carbon and eliminate HCl and 1-methyl-pyridinone (XXIX; Scheme 2.10).  
Formation of the desired product via attack of XVI on activated diclofenac species XXVI 
was never achieved despite variations in reaction conditions such as temperature and the 
order of reagent addition.     
 
Scheme 2.10:  Intramolecular Cyclization of Diclofenac to Form the Indolinone Side 
Product. 
 To avoid formation of side product XXVIII, several attempts were made to 
protect the secondary amine of diclofenac.  N-Protection with acetyl, trifluoroacetyl (tfa), 
tert-butyloxycarbonyl (BOC), and carbobenzyloxy (Cbz) groups was attempted.  Initially, 
direct acylation of the secondary amine was attempted; however, XXVIII was the only 
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species isolated in all cases.  Kaufmann et al. have successfully protected the amino 
group of 2-(phenylamino)-benzeneacetic acid, a molecule structurally similar to 
diclofenac, with benzyl-, tfa-, acetyl-, and methoxycarbonyl groups.120  According to 
Kaufmann et al., direct acylation of the secondary amine of 2-(phenylamino)-
benzeneacetic acid results in intramolecular cyclization via mixed anhydrides.  However, 
when the acidic portion of 2-(phenylamino)-benzeneacetic acid is protected with a benzyl 
group, the appropriate acyl protecting group can be added, followed by selective 
hydrolysis of the benzyl ester.     
 When identical reaction conditions were applied to the benzyl ester of diclofenac 
(XXX), no reaction occurred in all cases, even with reaction times greater than 48 h 
(Scheme 2.11).  It is likely that the two chlorine substituents of diclofenac can block the 
addition of a bulky acyl group.  Thus far, N-Boc protection of XXX using sodium 
bis(trimethylsilyl)amide (NaHMDS) and BOC anhydride ((BOC)2O) has been 
accomplished.  Cleavage of the benzyl group to free the acid, however, results in N-boc 
cleavage as well.  Additional protection-deprotection procedures must be explored for 
diclofenac as an effective procedure has not yet been discovered.   
 
 
Scheme 2.11: Attempted N-Protection of Diclofenac. (a) 1.6 eq BnBr, DMF, 24 
o
C, 4 h; 
(b) 2 eq TFAA, 1.5 eq Et3N, 5 mol % DMAP, CH2Cl2, 20-40 
o
C, 3.5 h; (c) 
n
BuLi, THF, 
Ac2O, -10 
o
C, 2 h. 
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2.5 Design and Synthesis of Class 3 Molecules:  Optimization of the Intermediate 
Linker 
 As was shown with Class 2 molecules, elimination of the intermediate linker led 
to a drastic decrease in both in vitro and in vivo activities (vide Chapter 3).  While Class 1 
compounds have high in vitro and in vivo efficacy, hydrolysis of the carbonate bond of 
such molecules may release an alkylating quinone methide (Figure 2.6).  With the need to 
optimize lipophilicity and eliminate the potentially toxic linker while maximizing 
potency, alternative linkers were explored (Class 3, Table 2.1).  These alternate linkers 
include 4-hydroxy-3-methoxybenzyl alcohol (HMBA) along with several amino acids 
(e.g. Val, Gly, and Phe).  These linkers are not only less toxic than the original alkylaryl 
linker, they also have inherent anti-inflammatory properties.121, 122  Additionally, there is 
literature precedent that amino acid prodrugs demonstrate improved pharmacokinetic 
(PK) properties compared to the parent drug.  For example, Val, Ile, and Phe prodrugs of 
guanidine-containing antiviral drugs have improved intestinal permeability compared to 
the drugs themselves.123  This prodrug strategy has been applied to several problematic 
antivirals including acyclovir,124 ganciclovir,125 zidovudine,126 and floxuridine.127  
Considering the anti-inflammatory properties and the PK profile of amino acid prodrugs, 
several amino acids were chosen as alternative linkers.    
 
Figure 2.6:  Example of the Formation of a Toxic Quinone Methide (Nu = nucleophile).   
  
 The same method used to synthesize Class 1 compounds (Scheme 2.4) was 
applied to the synthesis of HMBA derivatives 29 through 32.  Class 3 compounds 
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containing amino acid linkers (33-48) were synthesized using an alternate two step 
process (Scheme 2.12).  First, the amino acid was coupled to the desired choline mimic 
using p-toluenesulfonic acid.128  The resulting amino acid ester (XXXII) was then 
coupled to an NSAID using EDC·HCl with one equivalent of N-hydroxybenzotriazole 
(HOBt).  Overall yields for the entire synthesis ranged from 51-82%, with 
chromatographic purification required only for the final product.   
 
 
Scheme 2.12:  Synthetic Scheme for Class 3 Molecules Containing Amino Acid Linkers 
(For proline derivatives, R’ = (CH2)3-R”; for all other amino acid derivatives, R’ = H). 
 For proline conjugates 33 through 36, two structurally-related products were 
observed via nuclear magnetic resonance (NMR) spectroscopy, even following extensive 
chromatographic purification.  In all cases, the percentage of the second product ranged 
from 13 to 19%, depending on the NSAID.  Interestingly, the final products were a single 
spot on thin layer chromatography (tlc).  It was eventually determined that the sterically 
hindered proline amide bond undergoes cis-trans isomerization which can be detected via 
NMR (Figures 2.7 and 2.8).  Cis-trans isomerization of the proline peptide bond is well 
documented and plays an important role in protein folding.129, 130    
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  Figure 2.7:  Cis- and Trans-Isomers of Proline Conjugate 34. 
 
 
Figure 2.8:  
1
H NMR Spectrum of Proline Derivative 34. 
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2.6 Additional NSAID-Anticholinergics 
2.6.1 NSAID-Anticholinergic Amides  
 NSAID-Anticholinergic amides were explored as an alternative to the Class 2 
ester linkages.  To synthesize amides 49 through 52 (Table 2.2), the same method as that 
used for Class 2 compounds (Scheme 2.6) was used and yields ranging from 84-91% 
were obtained.  In addition, all of the NSAID amides were purified using 
nonchromatographic methods.  It should be noted that HOBt (1.1 eq) was used instead of 
DMAP in the synthesis of diclofenac derivative 52 in order to avoid base-catalyzed 
formation of XXVIII (Scheme 2.10).       
2.6.2 n-Butyl Derivatives of Class 1 and 2 Compounds 
 n-Butyl ester-carbonates and simple esters of ibuprofen, naproxen, indomethacin, 
and diclofenac were additionally prepared (Table 2.2).  To synthesize esters 53 through 
56, the same one step EDC·HCl/DMAP coupling procedure was used (Scheme 2.6) 
which resulted in very high yields (90-97%).  To synthesize ester-carbonates 57 through 
60, the three step procedure described for Class 1 molecules was used (Scheme 2.4) and 
35-53% overall yields were obtained.  Column chromatography using hexanes and ethyl 
acetate (gradient elution) was used to purify many of the n-butyl derivatives.       
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Table 2.2:  List of Additional n-Butyl and Amide Bifunctionals Studied. 
 
 
2.7 Conclusions 
 Using the straightforward and high yielding synthetic methods above, 90 
bifunctional compounds and precursors were synthesized to generate a diverse anti-
vesicant library.  The synthetic procedure for Class 1 compounds was optimized to 
maximize the yield, minimize the number of synthetic steps, and eliminate the use of 
toxic reagents.  Similarly, Class 2 compounds were accessed via one- or two-step 
coupling procedures, often without the need for chromatographic purification.  Finally, 
the amino acid conjugates of Class 3 were synthesized via a two-step procedure and 
required purification only for the final products.  Owing to the high synthetic yields and 
facile purification procedures of Schemes 2.3 through 2.12, many of the compounds 
presented in this Chapter are amenable to large-scale production.  
 Unfortunately, not all synthetic procedures, especially those in Schemes 2.6 
through 2.8, provided access to diclofenac derivatives because of formation of cyclic side 
product XXVIII (Scheme 2.10).  Additional work must be done to find an appropriate 
protection-deprotection procedure for diclofenac.  Also, Schemes 2.4 and 2.5 were not 
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effective syntheses for Class 1 choline analogues.  Since preliminary studies suggest that 
direct choline conjugates are less potent anticholinergics and anti-vesicants compared to 
their uncharged carbon and silicon counterparts (vide Chapter 3), the synthesis of choline 
analogues of Class 1 was not explored further.   
2.8 Experimental 
2.8.1 General 
 All reactants and solvents used were of the highest purity commercial grade and 
were employed without further purification.  Galantamine∙HBr was purchased from Altan 
Biochemicals (Milford, CT) and the free base of galantamine was formed from the HBr 
salt via a previously described method.131  All amino acids used herein were the L-amino 
acids and were purchased from Sigma-Aldrich (Saint Louis, MO).  The 2-(2-
methoxynaphthalene-6-yl)propanoic acid (naproxen) used was the (S)-enantiomer.  All 
other reagents were used as racemates.  N,N,N-Trimethyl-2-[2-[4-(2-
methylpropyl)phenyl]-1-oxopropoxy]- ethanaminium iodide (11), (S)-2-(2-(6-
methoxynaphthalen-2-yl)propanoyloxy)-N,N,N-trimethylethanaminium iodide (14), and 
2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]oxy]-N,N,N-
trimethyl-ethanaminium iodide (17) were all synthesized according to their literature 
preparations, as described by J. Young et al.132  3,3-Dimethylbutyl carbonochloridate133 
and 2-(trimethylsilyl)ethyl carbonochloridate134 (Schemes 2.3 and 2.4, compound III) 
were synthesized according to their respective literature preparations.  
 All reactions were performed in oven-dried apparatus under a nitrogen 
atmosphere, unless otherwise noted.  All solvents used, including methylene chloride 
(CH2Cl2) and tetrahydrofuran (THF), were anhydrous unless otherwise noted.  NMR 
 47 
spectra were recorded on a Brüker multinuclear spectrometer and chemical shifts are 
reported as ppm using tetramethylsilane (TMS) as an internal standard.  
1
H NMR spectra 
were recorded at 500 MHz, while 
13
C NMR spectra were recorded at 125 MHz.  
Elemental analyses were performed at Quantitative Technologies (QTI), Inc 
(Whitehouse, NJ).  Tlc was performed on Analtech silica gel plates (250 microns).   
2.8.2 Synthetic Procedure for Class 1 Molecules  
 Scheme 2.4 was used as follows:  3,3-Dimethylbutanol or 2-
(trimethylsilyl)ethanol (I, 3.3 mmol) was added to a pre-cooled solution (-5 
o
C) of p-
hydroxybenzyl alcohol (IX, 0.41 g, 3.3 mmol) in THF (5 mL).  Triethylamine (0.33 g, 
3.3 mmol) was then added to the reaction mixture over a 20 min period.  Following 
complete addition of base, the reaction contents were slowly warmed up to 20 
o
C and left 
stirring for 14 h.  Distilled water (40 mL) was added and the aqueous layer was extracted 
with ethyl acetate (3 x 40 mL).  The combined organic extracts were then washed with 
brine and dried over anhydrous MgSO4.  Solvent was removed by rotary evaporation 
under reduced pressure, resulting in light yellow oil as the final product.  
 The appropriate NSAID free acid (5.7 mmol), VI (Scheme 2.3, X = C or Si, 5.7 
mmol), and DMAP (70 mg, 0.57 mmol) were combined in CH2Cl2 (15 mL).  The 
solution was cooled to 0 
o
C and EDC·HCl (0.93 g, 6.0 mmol) was added.  Following 
addition of EDC·HCl, the reaction contents were slowly warmed up to room temperature 
and left stirring for 4 h.  Distilled water (150 mL) was added and the organic components 
were extracted with CH2Cl2 (2 x 150 mL), washed with 1 M HCl, sat. NaHCO3, and brine 
(300 mL each), dried over MgSO4, filtered, and concentrated. The resulting residue was 
 48 
purified by passing through a silica gel column using a gradient elution:  Hexane (100-
50%):Ethyl acetate (0-50%).   
2.8.3 Physical Data for Starting Materials and Class 1 Molecules    
3,3-Dimethylbutyl 4-(Hydroxymethyl)phenyl Carbonate (VI, X = C):   
 
White solid, 91% yield, mp 62-63 
o
C, Rf 0.24 (75% hexane:25% ethyl acetate);  
1
H NMR 
(CDCl3)  0.94 (s, 9H), 1.66 (t, 2H, J = 7.63 Hz), 1.84 (bs, 1H), 4.28 (t, 2H, J = 7.54 Hz), 
4.64 (d, 2H, J = 5.91 Hz), 7.13 (d, 2H, J = 8.54 Hz), 7.34 (d, 2H, J = 8.56 Hz); 
13
C NMR 
(CDCl3)  29.52, 29.65, 41.63, 64.63, 66.67, 121.14, 128.01, 138.64, 150.53, 153.74.   
Calcd. for C14H20O4 (252.31):  C, 66.65; H, 7.99.  Found: C; 66.29; H, 7.82. 
4-(Hydroxymethyl)phenyl 2-(Trimethylsilyl)ethyl Carbonate (VI, X = Si): 
 
Colorless oil, 88% yield, Rf  0.25 (Hex:EtOAc; 41:9); 
1
H NMR (CDCl3)  0.05 (s, 9H), 
1.11 (t, 2H, J = 6.71 Hz), 2.29 (bs, 1H), 4.33 (t, 2H, J = 7.30 Hz), 4.65 (s, 2H), 7.13 (d, 
2H, J = 8.85 Hz), 7.32 (d, 2H, J = 8.70 Hz); 
13
C NMR (CDCl3)  -1.61, 17.46, 64.47, 
67.36, 121.10, 127.96, 138.59, 150.43, 153.70.  Calcd. for C13H20O4Si (268.38):  C, 
58.18; H, 7.51.  Found: C, 57.74; H 7.49. 
4-((3,3-Dimethylbutoxy)carbonyloxy)benzyl 2-(4-Isobutylphenyl)propanoate (1):   
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Colorless oil, 48% yield; Rf 0.43 (90% hexane: 10% ethyl acetate); 
1
H NMR (CDCl3)  
0.92 (d, 6H, J = 6.60 Hz), 0.99 (s, 9H), 1.51 (d, 3H, J = 7.17 Hz), 1.69 (t, 2H, J = 7.47 
Hz), 1.86 (m, 1H), 2.46 (d, 2H, J = 7.17 Hz), 3.75 (q, 1H, J = 7.13), 4.32 (t, 2H, J = 7.65 
Hz), 5.09 (s, 2H), 7.09 (d, 2H, J = 7.96 Hz), 7.11 (d, 2H, J = 8.43 Hz), 7.19 (d, 2H, J = 
8.12 Hz), 7.22 (d, 2H, J =8.86 Hz);  
13
C NMR (CDCl3)  18.23, 22.24, 29.41, 29.51, 
30.03, 41.51, 44.89, 44.96, 65.35, 66.47, 120.91, 127.07, 128.82, 129.19, 133.72, 137.43, 
140.39, 150.70, 153.45, 174.16.  Calcd. for C27H36O5 
.
 0.5 H2O (449.58):  C, 72.11; H, 
8.28.  Found:  C, 72.22, H, 8.08. 
4-((2-(Trimethylsilyl)ethoxy)carbonyloxy)benzyl 2-(4-Isobutylphenyl)propanoate (2):   
 
Colorless oil, 56% yield; Rf  0.62 (85% hexane: 15% ethyl acetate);  
1
H NMR (CDCl3)  
0.09 (s, 9H), 0.91 (d, 6H, J = 6.65 Hz), 1.14 (t, 2H, J = 7.85 Hz), 1.51 (d, 3H, J = 7.15 
Hz), 1.86 (m, 1H), 2.46 (d, 2H, J = 7.15 Hz), 3.74 (q, 1H, J = 7.15 Hz), 4.35 (t, 2H, J = 
8.75 Hz), 5.08 (s, 2H), 7.09 (d, 2H, J = 7.95 Hz), 7.11 (d, 2H, J = 8.5 Hz), 7.19 (d, 2H, J 
= 8.05 Hz), 7.23 (d, 2H, J = 8.60 Hz);  
13
C NMR (CDCl3)  -1.60, 17.47, 18.30, 22.31, 
30.11, 44.97, 45.05, 65.49, 67.34, 121.04, 127.14, 128.92, 129.27, 133.75, 137.49, 
140.52, 150.80, 153.51, 174.32.  Calcd. for C26H36O5Si (456.65):  C 68.39; H 7.95.  
Found:  C 68.37, H 7.94.  
(S)-4-((3,3-Dimethylbutoxy)carbonyloxy)benzyl 2-(6-Methoxynaphthalen-2-
yl)propanoate (3):   
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White solid, 62% yield; mp 63-64 
o
C;  Rf 0.44 ( 80% hexane: 20% ethyl acetate); 
1
H 
NMR (CDCl3)  0.96 (s, 9H), 1.57 (d, 3H, J = 7.16 Hz), 1.67 (t, 2H, J = 7.59 Hz), 3.89 
(q, 1H, J = 7.14 Hz), 3.94 (s, 3H), 4.29 (t, 2H, J = 7.48 Hz), 5.08 (q, 2H, J = 12.55 Hz), 
7.08 (br d, 2H, J = 8.52 Hz), 7.10 (d, 1H, J = 2.41 Hz), 7.13 (dd, 1H, J = 2.52, 8.87 Hz), 
7.23 (br d, 2H, J =  8.49 Hz), 7.37 (dd, 1H, J = 1.79, 8.5 Hz), 7.63 (bs, 1H), 7.67 (d, 1H, J 
=  8.77 Hz), 7.68 (d, 1H, J =  8.39 Hz); 
13
C NMR (CDCl3)  18.44, 29.53, 29.66, 41.65, 
45.44, 55.28, 65.70, 66.68, 105.64, 118.97, 121.09, 125.97, 126.21, 127.15, 128.93, 
129.13, 129.27, 133.72, 133.76, 135.46, 150.89, 153.58, 157.68, 174.32.  Calcd. for 
C28H32O6 (464.55): C, 72.39; H, 6.94.  Found: C, 72.37; H, 7.13. 
(S)-4-((2-(Trimethylsilyl)ethoxy)carbonyloxy)benzyl 2-(6-Methoxynaphthalen-2-
yl)propanoate (4):   
 
White solid, 64% yield; mp 58-59 
o
C; Rf  0.49 (80% hexane: 20% ethyl acetate); 
1
H NMR 
(CDCl3)  0.06 (s, 9H), 1.12 (t, 2H, J = 8.70 Hz), 1.56 (d, 3H, J = 7.16 Hz), 3.87 (q, 1H, 
J = 7.16 Hz), 3.90 (s, 3H), 4.32 (t, 2H, J = 8.68 Hz), 5.08 (q, 2H, J = 12.54 Hz), 7.07 (br 
d, 2H, J = 8.52 Hz), 7.10 (d, 1H, J = 2.39 Hz), 7.12 (dd, 1H, J = 2.51, 8.88 Hz), 7.22 (br 
d, 2H, J = 8.44 Hz), 7.37 (dd, 1H, J = 1.78, 8.50 Hz), 7.62 (brs, 1H), 7.66 (d, 1H, J = 8.78 
Hz), 7.68 (d, 1H, J = 8.40 Hz); 
13
C NMR (CDCl3)  -1.55, 17.54, 18.45, 45.46, 55.30, 
65.73, 67.42, 105.66, 118.98, 121.13, 125.98, 126.22, 127.16, 128.94, 129.14, 129.28, 
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133.72, 135.48, 150.92, 153.55,157.69, 174.33.  Calcd. for C27H32O6Si (480.62O:  C, 
67.47; H, 6.71. Found:  C, 67.91; H 7.03. 
4-((3,3-Dimethylbutoxy)carbonyloxy)benzyl 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-
1H-indol-3-yl)acetate (5):   
 
Yellow liquid, 55% yield; Rf 0.5 (75% hexane: 25% ethyl acetate); 
1
H NMR (CDCl3)  
0.96 (s, 9H), 1.67 (t, 2H, J = 7.56 Hz), 2.33 (s, 3H), 3.67 (s, 2H), 3.72 (s, 3H), 4.29 (t, 
2H, J = 7.46 Hz), 5.09 (s, 2H), 6.64 (dd, 1H, J = 2.52, 9.01 Hz), 6.87 (d, 1H, J = 9.0Hz), 
6.92 (d, 1H, J = 2.48 Hz), 7.11 (dd, 2H, J = 1.9, 6.59 Hz), 7.27 (d, 2H, J = 8.59 Hz), 7.41 
(dd, J = 1.82, 2H, 6.70 Hz), 7.60 (dd, 2H, J = 1.87, 6.64 Hz); 
13
C NMR (CDCl3)  13.09, 
29.32, 29.42, 30.09, 41.42, 55.33, 65.71, 66.44, 101.04, 111.58, 112.18, 114.73, 120.94, 
128.84, 129.10, 130.32, 130.58, 130.91, 133.32, 133.73, 135.63, 138.87, 150.81, 153.30, 
155.86, 167.88, 170.22; Calcd. for C33H34ClNO7 (592.08):  C, 66.94; H, 5.79; N, 2.37.  
Found:  C, 66.64; H, 5.97; N, 2.42. 
4-((2-(Trimethylsilyl)ethoxy)carbonyloxy)benzyl 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetate (6):   
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Yellow liquid, 59% yield; Rf 0.55 (75% hexane: 25% ethyl acetate); 
1
H NMR (CDCl3)  
0.07 (s, 9H), 1.13 (t, 2H, J = 8.66 Hz), 2.35 (s, 3H), 3.69 (s, 2H), 3.75 (s, 3H), 4.34 (t, 
2H, J = 8.65 Hz), 5.10 (s, 2H), 6.65 (dd, 1H, J = 2.53, 9.0 Hz), 6.87 (d, 1H, J = 9.03 Hz), 
6.91 (d, 1H, J = 2.49 Hz), 7.12 (dd, 2H, J = 1.91, 8.58 Hz), 7.29 (d, 2H, J = 8.57 Hz), 
7.44 (dd, 2H, J = 1.84, 8.86 Hz), 7.63 (dd, 2H, J = 1.89, 8.89 Hz); 
13
C NMR (CDCl3)  -
1.62, 13.25, 17.45, 30.29, 55.55, 65.93, 67.38, 101.17, 111.75, 112.31, 114.88, 121.15, 
129.02, 129.28, 130.46, 130.73, 131.07, 133.38, 133.85, 135.84, 139.13, 150.99, 153.44, 
156.00, 168.14, 170.44; Calcd. for C32H34ClNO7Si (608.15): C, 63.20; H, 5.64; N, 2.30.  
Found:  C, 63.06; H, 5.67; N, 2.30. 
4-((3,3-Dimethylbutoxy)carbonyloxy)benzyl 2-(2-(2,6-
Dichlorophenylamino)phenyl)acetate (7):   
 
Colorless oil, 53% yield; Rf  0.47 (90% hexane: 10% ethyl acetate); 
1
H NMR (CDCl3):  δ 
7.31 (d, 2H, J = 8.06 Hz), 7.23 (dd, 4H, J = 8.67, 100.3 Hz), 7.21 (dd, 1H, J = 1.43, 7.50 
Hz), 7.13 (dt, 1H, J = 1.53, 6.82 Hz), 6.95 (m, 2H), 6.84 (bs, 1H), 6.54 (d, 1H, J = 8.03 
Hz), 5.14 (s, 2H), 4.29 (t, 2H, J = 7.54 Hz), 3.84 (s, 2H), 1.66 (t, 2H, J = 7.62 Hz), 0.95 
(s, 9H); 
13
C NMR (CDCl3):  δ 29.57, 29.70, 38.61, 41.64, 66.33, 66.78, 118.39, 121.29, 
122.12, 124.01, 124.20, 128.07, 128.87, 129.47, 129.60, 130.92, 133.32, 137.81, 142.72, 
151.10, 153.60, 172.09; Calcd. for C28H29Cl2NO5 (530.44):  C, 63.40; H, 5.51; N, 2.64.  
Found:  C, 63.22; H, 5.45; N, 2.63. 
 53 
4-((2-(Trimethylsilyl)ethoxy)carbonyloxy)benzyl 2-(2-(2,6-
Dichlorophenylamino)phenyl)acetate (8):   
 
Colorless oil, 37% yield; Rf 0.58 (90% hexane: 10% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 7.30-7.34 (m, 4H), 7.21 (dd, 1H, J = 1.43, 7.54 Hz), 7.09-7.15 (m, 3H), 6.92-
6.98 (m, 2H), 6.84 (bs, 1H), 6.52-6.55 (m, 1H), 5.14 (s, 2H), 4.30-4.34 (m, 2H), 3.83 (s, 
2H), 1.10-1.14 (m, 2H), 0.05 (s, 9H); 
13
C NMR (CDCl3):  δ -1.52, 17.54, 38.61, 66.35, 
67.51, 118.39, 121.32, 122.11, 124.01, 124.20, 128.07, 128.87, 129.47, 129.60, 130.92, 
133.26, 137.81, 142.72, 151.12, 153.55, 172.09; Calcd. for C27H29Cl2NO5Si (546.51):  C, 
59.34; H, 5.35; N, 2.56.  Found:  C, 59.03; H, 5.47; N, 2.53. 
2.8.4 Synthetic Procedure for Class 2 Molecules (Esters of Choline Mimics)   
 For X = N
+
, Scheme 2.7 was used as previously described.132  For X = C and Si, 
Scheme 2.6 was used as follows:  The appropriate NSAID (3 mmol), 3,3-dimethylbutanol 
or 2-(trimethylsilyl)ethanol (I, 6 mmol) and DMAP (40 mg, 0.3 mmol) were combined in 
CH2Cl2 (6 mL). The reaction contents were cooled to 0 
o
C and EDC·HCl (0.51 g, 3.3 
mmol) in CH2Cl2 (2 mL) was added. The reaction was slowly warmed up to room 
temperature and left stirring overnight. Distilled water (80 mL) was added and the 
organic reaction components were extracted with CH2Cl2 (2 x 80 mL), washed with sat. 
NaHCO3 and brine (160 mL each) then dried over anhydrous MgSO4. Products were 
purified by passing crude material through a silica gel column using MeOH:CH2Cl2 (0.3-
1.0% MeOH) as the eluent. 
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2.8.5 Physical Data for Class 2 Molecules (Esters of Choline Mimics) 
3,3-Dimethylbutyl 2-(4-Isobutylphenyl)propanoate (9):   
 
Clear liquid, 83% yield; Rf 0.95 (75% hexane: 25% ethyl acetate); 
1
H NMR (CDCl3):  δ 
0.85 (s, 9H), 0.86-0.88 (d, 6H, J = 6.60 Hz), 1.45-1.47 (d, 3H, J = 4.95 Hz), 1.46-1.53 
(m, 2H), 1.80-1.84 (m, 1H), 2.41-2.43 (d, 2H, J = 7.20 Hz), 3.62-3.65 (m, 1H), 4.06-4.12 
(m, 2H), 7.05-7.08 (d, 2H, J = 8.10 Hz), 7.16-7.18 (d, 2H, J = 8.05 Hz); 
13
C NMR 
(CDCl3):  δ 18.51, 22.39, 29.55, 29.69, 30.20, 41.66, 45.05, 45.27, 62.46, 127.19, 129.28, 
137.83, 140.45, 174.87; Calcd. for C19H30O2·0.1 H2O (292.24): C, 78.03; H, 10.38. 
Found: C, 78.06; H, 10.22.   
2-(Trimethylsilyl)ethyl 2-(4-Isobutylphenyl)propanoate (10):   
 
Clear liquid, 65% yield; Rf 0.96 (75% hexane: 25% ethyl acetate); 
1
H NMR (CDCl3):  δ 
0.00 (s, 9H), 0.86-0.90 (d, 6H, J = 6.60 Hz), 0.88-0.96 (m, 2H), 1.44-1.47 (d, 3H, J = 
7.15 Hz), 1.79-1.85 (m, 1H), 2.41-2.43 (d, 2H, J = 7.15 Hz), 3.61-3.66 (m, 1H), 4.06-4.16 
(m, 2H), 7.05-7.08 (d, 2H, J = 8.00 Hz), 7.16-7.19 (d, 2H, J = 8.10 Hz); 
13
C NMR 
(CDCl3):  δ -1.51, 17.17, 18.62, 22.39, 30.19, 45.05, 45.30, 62.95, 127.17, 129.29, 
137.94, 140.43, 174.94; Calcd. for C18H30O2Si (306.52): C, 70.53; H, 9.86. Found: C, 
70.53; H, 9.72.  
N,N,N-Trimethyl-2-[2-[4-(2-methylpropyl)phenyl]-1-oxopropoxy]- ethanaminium Iodide 
(11):   
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White solid, 18% yield; mp 113-114 
o
C; 
1H NMR (MeOD): δ 0.86-0.88 (d, 6H, J = 5.10 
Hz), 1.45-1.49 (d, 3H, J = 7.15 Hz), 1.78-1.83 (m, 1H), 2.42-2.44 (d, 2H, J = 7.15 Hz), 
3.00 (s, 9H), 3.55-3.83 (m, 2H), 4.08 (s, 1H), 4.37-4.56 (m, 2H), 7.09-7.12 (m, 2H), 7.18-
7.23 (m, 2H); 
13
C NMR (CDCl3): δ 18.02, 18.28, 22.37, 30.17, 44.90, 44.92, 45.00, 
54.61, 58.14, 65.04, 127.27, 129.36, 136.85, 141.18, 173.55; Calcd. for 
C18H30NO2I·0.75H2O (432.85):  C, 51.56; H, 7.21; N, 3.34. Found: C, 49.94; H, 7.33; N, 
3.24.  
 (S)-3,3-Dimethylbutyl 2-(6-Methoxynaphthalen-2-yl)propanoate (12):   
 
White solid, 94% yield; mp 92-94 
o
C; Rf 0.75 (75% hexane:25% ethyl acetate); 
1
H NMR 
(CDCl3):  δ 0.85 (s, 9H), 1.46-1.50 (t, 2H, J = 7.45 Hz), 1.55 (d, 3H, J = 7.15 Hz), 3.78-
3.82 (m, 1H), 3.89 (s, 3H), 4.07-4.13 (m, 2H), 7.07-7.13 (m, 2H), 7.37-7.39 (dd, 1H, J = 
1.85, 8.45 Hz), 7.63-7.70 (m, 3H); 
13
C NMR (CDCl3):  δ 18.56, 29.55, 29.70, 41.68, 
45.59, 55.31, 62.59, 105.59, 118.94, 125.98, 126.31, 127.10, 128.95, 129.29, 133.68, 
135.79, 157.61, 174.80; Calcd. for C20H26O3 (314.42): C, 76.40; H, 8.33. Found: C, 
76.74; H, 8.14. 
(S)-2-(Trimethylsilyl)ethyl 2-(6-Methoxynaphthalen-2-yl)propanoate (13):   
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White solid, 80% yield; mp 81.5-82.5 
o
C; Rf 0.90 (75% hexane:25% ethyl acetate); 
1
H 
NMR (CDCl3):  δ 0.00 (s, 9H), 0.87-0.97 (m, 2H), 1.54-1.56 (d, 3H, J = 7.20 Hz), 3.74-
3.83 (m, 1H), 3.89 (s, 3H), 4.08-4.16 (m, 2H), 7.09-7.14 (m, 2H), 7.38-7.41 (dd, 1H, J = 
1.65, 8.48 Hz), 7.64-7.70 (m, 3H); 
13
C NMR (CDCl3):  δ -1.52, 17.24, 18.62, 45.64, 
55.31, 63.07, 105.59, 118.93, 125.97, 126.30, 127.11, 128.96, 129.29, 133.68, 135.90, 
157.60, 174.86; Calcd. for C19H26O3Si (330.50): C, 69.05; H, 7.93. Found: C, 69.18; H, 
7.75. 
(S)-2-(2-(6-Methoxynaphthalen-2-yl)propanoyloxy)-N,N,N-trimethylethanaminium Iodide 
(14):   
 
White solid, 44% yield; mp 202-204 
o
C; 
1H NMR (500 MHz, MeOD): δ 1.55-1.57 (d, 
3H, J = 7.15 Hz), 2.93 (s, 9H), 3.3.50-3.67 (m, 2H), 3.88 (s, 3H), 3.90-3.97 (m, 1H), 
4.40-4.60 (m, 2H), 7.10-7.13 (dd, 1H, J = 2.50, 8.93 Hz), 7.19-7.20 (d, 1H, J = 2.45 Hz), 
7.35-7.39 (dd, 1H, J = 1.85, 8.50 Hz), 7.68-7.75 (m, 3H); 
13C NMR (DMSO):  δ 18.61, 
44.84, 53.28, 55.68, 58.80, 106.20, 119.33, 126.30, 126.83, 127.51, 128.83, 129.59, 
133.84, 135.68, 157.72, 160.25, 173.72; Calcd. for C19H26NO3I (443.32): C, 51.48; H, 
5.91; N, 3.16. Found: C, 51.54; H, 5.96; N, 3.07. 
3,3-Dimethylbutyl 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate 
(15):   
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Yellow oil, 96% yield; Rf 0.68 (75% hexane:25% ethyl acetate); 
1
H NMR (CDCl3):  δ 
0.89 (s, 9H), 1.51-1.55 (t, 2H, J = 7.50 Hz), 2.36 (s, 3H), 3.63 (s, 2H), 3.82 (s, 3H), 4.12-
4.16 (t, 2H, J = 7.35 Hz), 6.63-6.66 (dd, 1H, J = 2.55, 9.00 Hz), 6.83-6.86 (d, 1H, J = 8.95 
Hz), 6.93-6.95 (d, 1H, J = 2.50 Hz), 7.44-7.46 (m, 2H), 7.62-7.65 (m, 2H);  
13
C NMR 
(CDCl3):  δ 13.39, 29.56, 29.74, 30.52, 41.77, 55.72, 62.85, 101.27, 111.72, 112.72, 
114.95, 129.12, 130.71, 130.81, 131.19, 133.95, 135.90, 139.26, 156.05, 168.30, 170.96; 
Calcd. for C25H28ClNO4 (441.95): C, 67.94; H, 6.39; N, 3.17. Found: C, 68.25; H, 6.48; 
N, 3.15. 
2-(Trimethylsilyl)ethyl 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetate (16):   
 
Yellow oil, 97% yield; Rf 0.64 (75% hexane:25% ethyl acetate); 
1
H NMR (CDCl3):  δ 
0.00 (9H), 0.94-0.99 (m, 2H), 2.36 (s, 3H), 3.62 (s, 2H), 3.82 (s, 3H), 4.15-4.19 (m, 2H), 
6.63-6.66 (dd, 1H, J = 2.55, 9.00 Hz), 6.83-6.86 (d, 1H, J = 8.95 Hz), 6.94-6.95 (d, 1H, J 
= 2.50 Hz), 7.43-7.47 (m, 2H), 7.63-7.66 (m, 2H); 
13
C NMR (CDCl3):  δ -1.51, 13.41, 
17.37, 30.59, 55.72, 63.36, 101.33, 111.68, 112.79, 114.95, 129.12, 130.74, 130.83, 
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131.19, 133.97, 135.90, 139.24, 156.05, 168.31, 171.03; Calcd. for C24H28NO4ClSi 
(458.03): C, 62.94; H, 6.16; N, 3.06.  Found: C, 63.07; H, 6.19; N, 3.05. 
2-[[2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]oxy]-N,N,N-
trimethyl-ethanaminium Iodide (17):   
 
Yellow solid, 47% yield; mp 206-208 
o
C; 
1H NMR (500 MHz, MeOD): δ 2.33 (s, 3H), 
3.08 (s, 9H), 3.65-3.68 (m, 2H), 3.79 (s, 3H), 3.84 (s, 2H), 4.53-4.56 (m, 2H), 6.66-6.70 
(dd, 1H, J = 2.50, 9.05 Hz), 6.85-6.89 (d, 1H, J = 9.00 Hz), 7.00-7.01 (d, 1H, J = 2.50 
Hz), 7.54-7.58 (m, 2H), 7.64-7.67 (m, 2H); 
13
C NMR (CDCl3) δ 13.70, 29.71, 53.38, 
55.95, 58.85, 64.11, 102.26, 111.85, 112.71, 114.91, 129.60, 130.67, 131.68, 132.80, 
134.51, 136.12, 138.25, 156.06, 167.31, 170.24; Calcd. for C24H28N2O4ClI·0.15 H2O 
(573.55): C, 50.25; H, 4.97; N, 4.88. Found: C, 49.92; H, 4.93; N, 4.87.   
3,3-Dimethylbutyl 2-(2-(2,6-Dichlorophenylamino)phenyl)acetate (18):   
 
Clear oil, 55% yield; Rf 0.83 (75% hexane:25% ethyl acetate); 
1
H NMR (CDCl3):  δ 0.90 
(s, 9H), 1.56-1.60 (t, 2H, J = 7.60 Hz), 3.77 (s, 2H), 4.16-4.20 (t, 2H, J = 7.50 Hz), 6.52-
6.54 (m, 1H), 6.91-6.98 (m, 3H), 7.08-7.12 (td, 1H, J = 1.34, 7.18 Hz), 7.19-7.21 (m, 
1H), 7.31-7.34 (d, 2H, J = 8.05 Hz); 
13
C NMR (CDCl3):  δ 29.56, 29.73, 38.84, 41.73, 
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63.16, 118.26, 121.98, 123.98, 124.45, 127.92, 128.88, 129.52, 130.88, 137.87, 142.74, 
172.45; Calcd. for C20H23NO2Cl (380.31): C, 63.16; H, 6.10; N, 3.68. Found: C, 63.24; 
H, 5.95; N, 3.74. 
2-(Trimethylsilyl)ethyl 2-(2-(2,6-Dichlorophenylamino)phenyl)acetate (19):   
 
Clear oil, 79% yield; Rf 0.94 (75% hexane:25% ethyl acetate); 
1
H NMR (CDCl3):  δ 0.00 
(s, 9H), 0.96-1.00 (m, 2H), 3.74 (s, 2H), 4.17-4.19 (m, 2H), 6.49-6.51 (m, 1H), 6.88-6.96 
(m, 3H), 7.05-7.09 (m, 1H), 7.17-7.19 (m, 1H), 7.29-7.31 (d, 2H, J = 8.05 Hz); 
13
C NMR 
(CDCl3): δ -1.50, 17.40, 38.96, 63.69, 118.22, 121.95, 123.97, 124.49, 127.90, 128.87, 
129.54, 130.88, 137.88, 142.76, 172.49; Calcd. for C19H23NO2Cl2Si (396.39):  C, 57.57; 
H, 5.85; N, 3.53. Found: C, 57.73; H, 5.91; N, 3.51. 
2.8.6 Synthetic Procedure for Class 2 Molecules (Neostigmine Conjugates) 
 
  
 
 3-(Dimethylamino)phenol (XXIII) was prepared using the method of Grove et al. 
and subsequently used in Scheme 2.9 as follows:  Step A – The desired NSAID (2.3 
mmol), XXIII (1.8 mmol, 0.25 g), and DMAP (30 mg, 0.23 mmol) were combined in 
CH2Cl2 (8 mL) under nitrogen.  The reaction contents were cooled to 0 
o
C and EDC·HCl 
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(0.39 g, 2.5 mmol) was added.  The reaction contents were slowly warmed up to room 
temperature and left stirring for 3 h.  When complete consumption of XXIII was 
observed, distilled water (80 mL) was added and the organic components were extracted 
with CH2Cl2 (2 x 80 mL), washed with 1 M HCl, sat. NaHCO3, and brine (160 mL each), 
dried over anhydrous MgSO4, filtered and evaporated to yield the crude product.  The 
crude product was purified by passing through a silica gel column using a gradient 
elution with ethyl acetate (0 to 60%) and hexanes (100 to 40%) as the solvent.   
 Step B - XXIV (0.90 mmol) was dissolved in CH2Cl2 (5 mL) under nitrogen.  
Methyl iodide (281 µL, 4.5 mmol) was then added drop-wise at room temperature.  The 
reaction contents were left stirring for 8 h, after which only a small amount of product 
was observed by tlc.  Additional methyl iodide (1 mL, 16.1 mmol) was then added and 
the reaction contents were left stirring overnight.  Upon return, a precipitate was observed 
which was filtered and washed with a small amount of cold diethyl ether.  
1
H NMR 
analysis revealed that the pure product had been formed. 
2.8.7 Physical Data for Class 2 Neostigmine Conjugates 
 3-(Dimethylamino)phenyl 2-(4-isobutylphenyl)propanoate (22a): 
 
Clear liquid, 69% yield, Rf 0.82 (80% hexanes:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.85-0.88 (d, 6H, J = 13.4 Hz), 1.57-1.59 (d, 3H, J = 7.15 Hz), 1.81-1.88 (m, 
1H), 2.44-2.46 (d, 2H, J = 7.15 Hz), 2.87 (s, 6H), 3.87-3.92 (q, 1H, J = 7.15, 14.3 Hz), 
6.27-6.29 (m, 1H), 6.29-6.32 (dd, 1H, J = 2.40, 7.90 Hz), 6.50-6.53 (dd, 1H, J = 2.40, 
8.38 Hz), 7.10-7.13 (d, 2H, J = 7.85 Hz), 7.13-7.16 (d, 2H, J = 8.20 Hz), 7.27-7.30 (d, 
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2H, J = 8.05 Hz); 
13
C NMR (CDCl3):  δ 18.62, 22.41, 30.21, 40.45, 45.07, 45.34, 105.29, 
109.10, 109.85, 127.28, 129.45, 129.52, 137.45, 140.70, 151.65, 151.98, 173.34; Calcd. 
for C21H27NO2 (325.44): C, 77.50; H, 8.36; N, 4.30. Found: C, 77.72; H, 8.87; N, 4.41. 
3-(2-(4-Isobutylphenyl)propanoyloxy)-N,N,N-trimethylbenzenaminium iodide (22):  
 
White Powder, 54% yield; Rf 0.17 (90% methylene chloride:10% methanol); mp 156-157 
o
C; 
1H NMR (500 MHz, DMSO):  δ 0.82-0.84 (d, 6H, J = 6.60 Hz), 1.48-1.51 (d, 3H, J = 
7.10 Hz), 1.76-1.82 (m, 1H), 2.39-2.42 (d, 2H, J = 7.20 Hz), 3.55 (s, 9H), 4.03-4.08 (q, 
1H, J = 7.10 Hz), 7.13-7.16 (d, 2H, J = 8.05 Hz), 7.24-7.26 (dd, 1H, J = 1.45, 7.98 Hz), 
7.27-7.30 (d, 2H, J = 8.10 Hz), 7.61-7.65 (t, 1H, J = 8.35 Hz), 7.73-7.75 (t, 1H, J = 2.20 
Hz), 7.81-7.84 (dd, 1H, J = 2.30, 8.33 Hz).  Calcd. for C22H30INO2 (467.39): C, 56.54; H, 
6.47; N, 3.00. Found: C, 56.74; H, 6.58; N, 2.97. 
(S)-3-(Dimethylamino)phenyl 2-(6-methoxynaphthalen-2-yl)propanoate (25a): 
 
White solid, 89% yield; Rf 0.49 (80% hexanes:20% ethyl acetate); mp 102-106 
o
C; 
1
H 
NMR (500 MHz, CDCl3):  δ 1.57-1.59 (d, 3H, J = 7.10 Hz), 2.87 (s, 6H), 3.91 (s, 3H), 
4.04-4.09 (q, 1H, J = 7.15, 14.2 Hz), 6.27-6.31 (m, 2H), 6.50-6.53 (dd, 1H, J = 2.50, 8.40 
Hz), 7.11-7.15 (m, 3H), 7.48-7.51 (dd, 1H, J = 1.55, 8.50 Hz), 7.70-7.76 (m, 3H); 
13
C 
NMR (CDCl3):  δ 18.68, 40.45, 45.66, 55.34, 66.68, 105.27, 105.62, 109.06, 109.88, 
119.04, 126.17, 126.27, 127.30, 129.02, 129.35, 129.54, 133.79, 135.39, 151.65, 151.95, 
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157.71, 173.29; Calcd. for C22H23NO3 (349.42): C, 75.62; H, 6.63; N, 4.01. Found: C, 
75.53; H, 6.92; N, 4.09. 
(S)-3-(2-(6-Methoxynaphthalen-2-yl)propanoyloxy)-N,N,N-trimethylbenzenaminium 
iodide (25):  
 
White powder, 53% yield; Rf 0.18 (90% methylene chloride:10% methanol); mp 184-185 
o
C; 
1H NMR (500 MHz, DMSO):  δ 1.58-1.61 (d, 3H, J = 7.10 Hz), 3.54 (s, 9H), 3.84 (s, 
3H), 4.20-4.26 (q, 1H, J = 6.75 Hz), 7.13-7.17 (dd, 1H, J = 2.45, 8.88 Hz), 7.27-7.30 (m, 
2H), 7.48-7.51 (d, 1H, J = 8.55 Hz), 7.61-7.65 (t, 1H, J = 8.35 Hz), 7.72-7.74 (m, 1H), 
7.80-7.83 (d, 4H, J = 8.50 Hz).  Calcd. for C23H26NO3I (491.37): C, 56.22; H, 5.33; N, 
2.85. Found: C, 56.33; H, 5.45; N, 2.61. 
3-(Dimethylamino)phenyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetate (28a): 
 
White solid, 83% yield; Rf 0.43 (80% hexanes:20% ethyl acetate); mp 92-94 
o
C;
 1
H NMR 
(500 MHz, CDCl3):  δ 2.42 (s, 3H), 2.90 (s, 6H), 3.82 (s, 3H), 3.87 (s, 2H), 6.34-6.38 (m, 
2H), 6.52-6.55 (dt, 1H, J = 1.00, 8.50 Hz), 6.66-6.69 (m, 1H), 6.88-6.91 (d, 1H, J = 9.00 
Hz), 7.05-7.06 (d, 1H, J = 2.25 Hz), 7.14-7.18 (t, 1H, J = 7.95 Hz), 7.44-7.46 (dd, 2H, J = 
0.75, 8.35 Hz), 7.64-7.67 (dd, 2H, J = 0.80, 8.35 Hz); 
13
C NMR (CDCl3):  δ 13.51, 30.67, 
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40.44, 55.75, 101.27, 105.21, 108.97, 110.01, 111.86, 112.29, 115.01, 129.16, 129.65, 
130.61, 130.88, 131.22, 133.90, 136.13, 139.32, 151.68, 151.83, 156.12, 168.36, 169.48; 
Calcd. for C27H25ClN2O4 (476.95): C, 67.99; H, 5.28; N, 5.87. Found: C, 68.34; H, 5.44; 
N, 5.93. 
3-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetoxy)-N,N,N-
trimethylbenzenaminium iodide (28): 
 
Yellow powder, 37% yield; Rf 0.13 (90% methylene chloride:10% methanol); mp 179.5-
180.5 
o
C; 
1H NMR (500 MHz, DMSO):  δ 2.28 (s, 3H), 3.57 (s, 9H), 3.72 (s, 3H), 4.10 
(s, 2H), 6.70-6.73 (dd, 1H, J = 2.40, 9.00 Hz), 6.88-6.91 (m, 1H), 7.13-7.15 (m, 1H), 
7.37-7.39 (m, 1H), 7.61-7.69 (m, 5H), 7.79-7.86 (m, 2H).  Calcd. for C28H28ClIN2O4·0.25 
H2O (623.39):  C, 53.95; H, 4.61; N, 4.49.  Found:  C, 53.65; H, 4.54; N, 4.45.   
2.8.8 Synthetic Procedure for Class 2 Molecules (Pyridostigmine Conjugates)  
 Scheme 2.8 was used to prepare these molecules as follows:  The desired NSAID 
(3 mmol), 3-hydroxypyridine (XX, 0.29 g, 3 mmol), and DMAP (36 mg, 0.3 mmol) were 
combined in a 25 mL round bottom flask and dissolved in methylene chloride (CH2Cl2) 
(5 mL).  The reaction contents were cooled to 0 
oC and EDC∙HCl (0.47 g, 3.3 mmol) was 
added.  The reaction contents were slowly warmed up to room temperature and left 
stirring for 3-5 h.  Upon completion of the reaction, distilled water (50 mL) was added 
and the organic components were extracted twice with CH2Cl2 (50 mL each) and washed 
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with 1 M HCl, sat. NaHCO3, and brine (100 mL each).  The combined organic extracts 
were dried over anhydrous MgSO4, filtered, and concentrated to yield XXI.  The ester 
was then re-dissolved in either CH2Cl2, diethyl ether or THF and a large excess of methyl 
iodide (> 10 equiv.) was added.  The reaction contents were left stirring overnight (16 h).  
The precipitate that had formed was filtered through a Büchner funnel and washed with a 
small amount of cold ether to yield substantially pure product (> 98% purity based on 
NMR).  For compound 27, precipitation was achieved upon addition of an equal volume 
of diethyl ether.  
2.8.9 Physical Data for Class 2 Precursors and Final Products (Pyridostigmine 
Conjugates) 
3-(2-(4-Isobutylphenyl)propanoyloxy)-1-methylpyridinium iodide (21): 
 
White powder, 8.4% yield, mp 120-122 
o
C, Rf 0.36 (96% CH2Cl2:2% methanol:2% H2O), 
1
H NMR (CDCl3):  δ 0.88 (d, 6H, J = 6.60 Hz), 1.62 (d, 2H, J = 7.15 Hz), 1.79-1.86 (m, 
1H), 2.44 (d, 2H, J = 7.15 Hz), 4.02-4.06 (m, 1H), 4.67 (s, 3H), 7.14 (d, 2H, J = 8.0 Hz), 
7.25 (d, 2H, J = 8.0 Hz), 8.07-8.14 (m, 2H), 9.01 (bs, 1H), 9.31 (m, 1H), 
13
C NMR 
(CDCl3):  δ 18.4, 22.4, 30.2, 45.0, 45.1, 50.1, 127.4, 128.9, 129.9, 135.5, 138.4, 139.2, 
141.6, 143.1, 149.6, 171.5, Calcd. for C19H24NO2I (425.30): C, 53.66; H, 5.69; N, 3.29. 
Found: C, 53.65; H, 5.60; N, 3.36. 
(S)-3-(2-(6-Methoxynaphthalen-2-yl)propanoyloxy)-1-methylpyridinium iodide (24): 
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White powder, 51% yield, mp 178-180 
o
C (dec), Rf 0.41 (96% CH2Cl2:2% MeOH:2% 
H2O), 
1H NMR (DMSO):  δ 1.63 (d, 3H, J = 7.10 Hz), 3.86 (s, 3H), 4.33 (s, 3H), 4.34-
4.38 (m, 1H), 7.17-7.19 (dd, 1H, J = 2.50, 8.95 Hz), 7.33 (d, 1H, J = 2.30 Hz), 7.51-7.53 
(dd, 1H, J = 1.65, 8.50 Hz), 7.84-7.87 (m, 3H), 8.16-8.19 (m, 1H), 8.48-8.51 (m, 1H), 
8.90 (d, 1H, J = 5.95 Hz), 9.08 (s, 1H), 
13C NMR (DMSO):  δ 18.4, 44.4, 48.2, 55.3, 
105.8, 119.0, 126.1, 126.2, 127.4, 128.2, 128.5, 129.3, 133.6, 134.2, 138.8, 140.1, 143.5, 
148.6, 157.4, 171.7, Calcd. for C20H20NO3I·0.6 H2O (510.09): C, 52.21; H, 4.64; N, 3.04. 
Found: C, 51.71; H, 4.23; N, 2.96.  
3-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetoxy)-1-
methylpyridinium iodide (27): 
 
Light yellow powder, 60% yield, mp 188-190 
o
C (dec), Rf 0.44 (96% CH2Cl2:2% 
MeOH:2% H2O), 
1H NMR (DMSO):  δ 2.31 (s, 3H), 3.78 (s, 3H), 4.23 (s, 2H), 4.36 (s, 
3H), 6.73-6.75 (dd, 1H, J = 2.55, 9.03 Hz), 6.90-6.93 (m, 1H), 7.19 (d, 1H, J = 2.45 Hz), 
7.64-7.70 (m, 4H), 8.19-8.23 (m, 1H), 8.53-8.56 (dd, 1H, J = 1.50, 8.58 Hz), 9.14 (s, 1H), 
13
C NMR (MeOD):  δ 12.0, 29.1, 54.9, 101.0, 101.2, 110.9, 111.28, 111.4, 112.7, 114.5, 
114.6, 128.2, 128.9, 128.9, 130.8, 130.9, 131.0, 135.5, 138.7, 139.0, 156.2, 156.3, 168.1, 
Calcd. for C25H22N2O4ClI (579.81): C, 51.79; H, 3.82; N, 4.83. Found: C, 51.95; H, 3.70; 
N, 4.78.  
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2.8.10 Synthetic Procedure for Class 2 Molecules (Galantamine Conjugates)  
 The HBr salt of galantamine was converted to the free base using a procedure 
derived from Han and coworkers.131  Briefly, galantamine·HBr (1.0 g, 2.72 mmol) was 
dissolved in distilled water (60 mL).  The clear solution was cooled to 0 
o
C and NH4OH 
(2.2 mL) was slowly added.  pH paper revealed that the pH was greater than 10.  (The 
pKa of the amino group of galantamine is 8.9).  The reaction was held at 0 
o
C for 30 min 
then at room temperature for 2 h.  Ether (70 mL) was added followed by solid NaCl.  The 
aqueous layer was extracted with ether (2 x 70 mL) and the combined organic extracts 
were washed with brine, dried over MgSO4, and concentrated to yield a fluffy white solid 
(0.61 g, 78%). 
 Scheme 2.6 was used as follows:  Galantamine free base (0.30 g, 1.0 mmol), the 
appropriate NSAID (0.87 mmol), and DMAP (11 mg, 0.087 mmol) were combined in 
CH2Cl2 (3 mL).  The reaction contents were cooled to 0 
oC and EDC∙HCl (0.15 g, 0.96 
mmol) was added.  The reaction medium was slowly warmed to room temperature and 
left overnight, after which tlc reflected complete consumption of the NSAID.  Distilled 
water (50 mL) was added and the organic contents were extracted with CH2Cl2 (2 x 50 
mL), washed with 1 M HCl, sat. NaHCO3 and brine (100 mL each), dried over MgSO4, 
and concentrated.  The crude product was then passed through a silica gel column using 
CH2Cl2:MeOH (9:1) as the eluent. 
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2.8.11 Physical Characterization of Class 2 Molecules (Galantamine Conjugates) 
([4aS,6R,8aS)-5,6,9,10,11,12-Hexahydro-3-methoxy-11-methyl-4aH-
[1]benzofuro[3a,3,2-ef]-[2] benzazepin-]6-[2-(4-isobutylphenyl)propanoate] (20): 
 
Light yellow oil, 96% yield, Rf 0.75 (90% CH2Cl2:10% MeOH),
 1
H NMR (CDCl3): δ 
0.81-0.89 (m, 6H), 1.43-1.47 (m, 3H), 1.53-1.56 (br d, 1H, J = 13.0 Hz), 1.75-1.82 (m, 
1H), 2.02-2.12 (m, 2H), 2.35-2.42 (m, 5H), 2.53-2.64 (m, 1H), 3.01-3.05 (br d, 1H, J = 
14.5 Hz), 3.26-3.29 (m, 1H), 3.63-3.68 (m, 2H), 3.83-3.85 (m, 3H), 4.06-4.13 (br t, 1H, J 
= 15.2 Hz), 4.53-4.56 (br d, 1H, J = 8.95 Hz), 5.24-5.27 (m, 1H), 5.86-5.90 (m, 1H), 
6.16-6.25 (dd, 1H, J = 10.4, 32.1 Hz), 6.55-6.59 (dd, 1H, J = 6.40, 7.95 Hz), 6.65-6.68 
(dd, 1H, J = 2.00, 8.18 Hz), 6.93-6.96 (d, 1H, J = 8.10 Hz), 6.98-7.01 (d, 1H, J = 8.10 
Hz), 7.16-7.21 (m, 2H), 
13
C NMR (CDCl3):  δ 17.8, 18.1, 22.3, 22.4, 30.1, 44.9, 45.0, 
45.1, 45.3, 47.2, 56.1, 56.2, 62.8, 62.9, 86.1, 86.2, 112.5, 123.3, 127.3, 129.1, 129.2, 
129.3, 137.4, 140.3, 140.4, 146.0, 174.2, Calcd. for C30H37NO4·1.75 H2O (507.16): C, 
71.04; H, 8.05; N, 2.26. Found: C, 71.16; H, 7.76; N, 2.51. 
([4aS,6R,8aS)-5,6,9,10,11,12-Hexahydro-3-methoxy-11-methyl-4aH-
[1]benzofuro[3a,3,2-ef]-[2] benzazepin-]6-[2-(6-methoxynaphthalen-2-yl)propanoate] 
(23): 
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White solid, 81% yield, mp 76-77 
o
C, Rf 0.71 (90% CH2Cl2:10% MeOH:0.1%  H2O) w/ 1 
drop H2O), 
1
H NMR (CDCl3): δ 1.53-1.55 (d, 3H, J = 7.10 Hz), 1.55 (s, 1H), 1.99-2.01 
(m, 1H), 2.00-2.03 (m, 1H), 2.38 (s, 3H), 2.53-2.57 (br d, 1H, J = 15.9 Hz), 3.03-3.05 (m, 
1H), 3.27-3.29 (m, 1H), 3.65-3.69 (d, 1H, J = 15.2 Hz), 3.78-3.82 (m, 4H), 3.88 (s, 3H), 
4.10-4.14 (d, 1H, J = 15.2 Hz), 4.53 (bs, 1H), 5.26-5.29 (m, 1H), 5.86-5.90 (m, 1H), 
6.24-6.27 (d, 1H, J = 10.4 Hz), 6.57-6.60 (d, 1H, J = 8.15 Hz), 6.66-6.69 (d, 1H, J = 8.10 
Hz), 7.06-7.09 (m, 2H), 7.41-7.44 dd, 1H, J = 1.55, 8.45 Hz), 7.58-7.61 (d, 2H, J = 8.40 
Hz), 7.65 (s, 1H), Calcd. for C31H33NO5·1.25 H2O (522.12): C, 71.31; H, 6.85; N, 2.68. 
Found: C, 71.63; H, 6.68; N, 2.70. 
([4aS,6R,8aS)-5,6,9,10,11,12-Hexahydro-3-methoxy-11-methyl-4aH-
[1]benzofuro[3a,3,2-ef]-[2] benzazepin-]6-[2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
1H-indol-3-yl)acetate] (26): 
 
Yellow solid, 81% yield, mp 100-101 
o
C, Rf 0.67 (95% CH2Cl2:5% methanol:0.1%  
H2O), 
1
H NMR (CDCl3): δ 1.57-1.61 (br d, 1H, J = 13.1 Hz), 2.02-2.13 (m, 2H), 2.29 (s, 
3H), 2.37 (s, 3H), 2.66-2.70 (br d, 1H, J = 16.2 Hz), 3.06-3.10 (br d, 1H, J = 14.3 Hz), 
3.31-3.38 (br t, 1H, J = 13.4 Hz), 3.63 (s, 2H), 3.70 (s, 3H), 3.77 (s, 3H), 4.08-4.12 (m, 
1H), 4.55 (bs, 1H), 5.31-5.34 (t, 1H, J = 5.05 Hz), 5.81-5.85 (dd, 1H, J = 4.65, 10.3 Hz), 
6.26-6.29 (d, 1H, J = 10.3 Hz), 6.56-6.64 (m, 3H), 6.86-6.89 (d, 1H, J = 9.00 Hz), 6.93-
.6.94 (d, 1H, J = 2.45 Hz), 7.39-7.42 (d, 2H, J = 8.55 Hz), 7.58-7.61 (d, 2H, J = 8.40 Hz), 
13
C NMR (CDCl3):  δ 13.3, 27.8, 30.6, 34.4, 41.9, 48.0, 53.8, 55.6, 55.8, 60.5, 63.9, 86.2, 
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101.0, 111.2, 112.0, 112.8, 115.0, 121.5, 122.6, 129.0, 129.2, 130.7, 130.8, 131.0, 131.2, 
132.0, 134.0, 136.1, 139.1, 144.0, 146.6, 156.1, 168.3, 170.7, Calcd. for 
C36H35N2O6Cl·H2O (645.14): C, 67.01; H, 5.78; N, 4.34. Found: C, 67.19; H, 5.59; N, 
4.35. 
2.8.12 Synthetic Procedure for Class 3 Molecules (HMBA Derivatives) 
 Scheme 2.4 was used as follows:  HMBA (0.5 mmol, 77.1 mg) was dissolved in 
THF (5 mL) under nitrogen and cooled to -10 
o
C using an acetone-ice-salt bath.  VI (X = 
C, 0.5 mmol, 80 µL) was added followed by the gradual addition of triethylamine (0.5 
mmol, 70 µL).  Additional THF was then added to facilitate stirring.  The reaction vessel 
was slowly warmed up to room temperature and left stirring overnight.  Once the reaction 
was complete, the THF was removed using rotary evaporation and the crude product was 
re-dissolved in CH2Cl2 (50 mL).  The organic layer was washed with distilled water and 
brine (50 mL each), dried over anhydrous MgSO4, filtered, and concentrated to yield light 
yellow oil.  A side product was observed via NMR as a result of coupling between I and 
III.  The bis(3,3-dimethylbutyl) carbonate side product was removed by distillation using 
a KugelRohr system (110 
o
C hot air bath) to yield the purified final product.  
 3,3-Dimethylbutyl-4-(hydroxymethyl)-2-methoxyphenylcarbonate (XXXIV, 0.25 
g, 0.89 mmol), the appropriate NSAID (0.75 mmol), and DMAP (11 mg, 0.09 mmol) 
were combined in CH2Cl2 (8 mL) under nitrogen.  The reaction contents were cooled to 0 
o
C and EDC·HCl (0.15 g, 0.98 mmol) was added.  The reaction contents were then 
slowly warmed up to room temperature and left stirring overnight.  Upon return, distilled 
water (25 mL) was added and the organic layer was separated out.  The aqueous layer 
was extracted with CH2Cl2 (25 mL).  The organic extracts were combined and washing 
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with 1 M HCl (2 x 50 mL), saturated NaHCO3 (50 mL), and brine (50 mL), then dried 
over MgSO4.  Column chromatography with hexanes (100-50%) and ethyl acetate (0-
50%) as the eluting solvent mixture was used to purify the final compounds.        
2.8.13 Physical Data for Class 3 Molecules (HMBA Derivatives) 
3,3-Dimethylbutyl-4-(hydroxymethyl)-2-methoxyphenylcarbonate (XXXIV): 
 
Light yellow oil, 96% yield; Rf 0.48 (50% hexane:50% ethyl acetate); 
1
H NMR (500 
MHz, CDCl3):  δ 0.95 (s, 9H), 1.64-1.68 (t, 2H, J = 7.55 Hz), 3.85 (s, 3H), 4.27-4.30 (t, 
2H, J = 7.50 Hz), 4.55 (s, 2H), 6.91-6.94 (dd, 1H, J = 1.95, 8.10 Hz), 6.98 (d, 1H, J = 
1.90 Hz), 7.07 (d, 1H, J = 8.10 Hz); 
13
C NMR (CDCl3):  δ 29.6, 29.7, 41.6, 56.0, 65.0, 
66.8, 111.1, 118.9, 122.4, 139.5, 140.1, 151.3, 153.5; Calcd. for C15H22O5·H2O (300.16): 
C, 59.98; H, 8.05. Found: C, 60.31; H, 7.24. 
4-((3,3-Dimethylbutoxy)carbonyloxy)-3-methoxybenzyl 2-(4-Isobutylphenyl)propanoate 
(29): 
 
 Clear oil, 93% yield; Rf 0.50 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.88 (d, 6H, J = 7.75 Hz), 0.94 (s, 9H), 1.49 (d, 3H, J = 7.20 Hz), 1.64-1.67 (t, 
2H, J = 3.90 Hz), 1.78-1.84 (m, 1H), 2.41 (d, 2H, J = 7.15 Hz), 3.72 (s, 3H), 3.70-3.76 (q, 
1H, J = 7.15 Hz), 4.26-4.30 (m, 2H), 5.02-5.09 (m, 2H), 6.77 (s, 1H), 6.78 (d, 1H, J = 
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1.90 Hz), 7.01 (d, 1H, J = 8.15 Hz), 7.06 (d, 2H, J = 8.10 Hz), 7.18 (d, 2H, J = 8.05 Hz); 
13
C NMR (CDCl3):  δ 18.4, 22.4, 29.6, 29.7, 30.2, 41.6, 45.0, 45.2, 55.8, 65.8, 66.9, 
111.8, 119.9, 122.3, 127.3, 129.4, 135.2, 137.6, 139.8, 140.6, 151.1, 153.3, 174.4; Calcd. 
for C28H38O6 (470.60):  C, 71.46; H, 8.14. Found:  C, 71.75; H, 8.47. 
(S)-4-((3,3-Dimethylbutoxy)carbonyloxy)-3-methoxybenzyl 2-(6-Methoxynaphthalen-2-
yl)propanoate (30): 
 
Clear oil, 98% yield; Rf 0.37 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.94 (s, 9H), 1.56 (d, 3H, J = 7.20 Hz), 1.62-1.66 (t, 2H, J = 7.60 Hz), 3.53 (s, 
3H), 3.90 (s, 3H), 3.87-3.91 (q, 1H, J = 7.15 Hz), 4.24-4.28 (m, 2H), 5.03-5.11 (q, 2H, J 
= 12.6 Hz), 6.67 (d, 1H, J = 1.80 Hz), 6.76-6.79 (dd, 1H, J = 1.85, 8.13 Hz), 6.99 (d, 1H, 
J = 8.10 Hz), 7.08 (d, 1H, J = 2.45 Hz), 7.10-7.13 (dd, 1H, J = 2.55, 8.88 Hz), 7.36-7.39 
(dd, 1H, J = 1.80, 8.50 Hz), 7.64 (s, 1H), 7.65-7.68 (dd, 2H, J = 3.90, 8.65 Hz); 
13
C NMR 
(CDCl3):  δ 18.4, 29.6, 29.7, 41.6, 45.5, 55.3, 55.7, 65.9, 66.8, 105.5, 111.7, 119.1, 119.9, 
122.3, 126.1, 126.3, 127.2, 128.9, 129.3, 133.7, 135.2, 135.5, 139.7, 151.1, 153.3, 157.7, 
174.4; Calcd. for C29H34O7 (494.58):  C, 70.43; H, 6.93. Found:  C, 70.12; H, 7.23. 
4-((3,3-Dimethylbutoxy)carbonyloxy)-3-methoxybenzyl 2-(1-(4-Chlorobenzoyl)-5-
methoxy-2-methyl-1H-indol-3-yl)acetate (31): 
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Yellow oil, 97% yield; Rf 0.20 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.94 (s, 9H), 1.64-1.68 (t, 2H, J = 7.55 Hz), 2.36 (s, 3H), 3.69 (s, 3H), 3.70 (s, 
2H), 3.75 (s, 3H), 4.26-4.30 (t, 2H, J = 7.45 Hz), 5.09 (s, 2H), 6.63-6.66 (dd, 1H, J = 
2.50, 9.00 Hz), 6.82 (d, 1H, J = 1.70 Hz), 6.85 (d, 2H, J = 9.15 Hz), 6.92 (d, 1H, J = 2.50 
Hz), 7.05 (d, 1H, J = 8.05 Hz), 7.43-7.46 (m, 2H), 7.60-7.64 (m, 2H); 
13
C NMR (CDCl3):  
δ 13.4, 29.6, 29.7, 30.5, 41.6, 55.7, 55.8, 66.3, 66.9, 101.3, 111.7, 112.2, 112.4, 115.0, 
120.3, 122.4, 129.2, 130.6, 130.8, 131.2, 133.9, 134.8, 136.0, 139.3, 140.0, 151.2, 153.3, 
156.1, 168.3, 170.6; Calcd. for C34H36ClNO8 (622.10): C, 65.64; H, 5.83; N, 2.25. Found: 
C, 65.15; H, 6.09; N, 2.14. 
4-((3,3-Dimethylbutoxy)carbonyloxy)-3-methoxybenzyl 2-(2-(2,6-Dichlorophenylamino)-
phenyl)acetate (32): 
 
Clear oil, 86% yield; Rf 0.51 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.94 (s, 9H), 1.64-1.67 (t, 2H, J = 7.55 Hz), 3.74 (s, 3H), 3.85 (s, 2H), 4.26-
4.30 (m, 2H), 5.13 (s, 2H), 6.53 (d, 1H, J = 8.10 Hz), 6.83 (bs, 1H), 6.86 (d, 1H, J = 1.70 
Hz), 6.87-6.90 (dd, 1H, J = 1.85, 8.00 Hz), 6.92-6.95 (m, 1H), 6.94-6.98 (t, 1H, J = 8.05 
Hz), 7.06 (d, 1H, J = 8.00 Hz), 7.09-7.13 (m, 1H), 7.21-7.24 (m, 1H), 7.31 (d, 2H, J = 
8.05 Hz); 
13
C NMR (CDCl3):  δ 29.6, 29.7, 38.7, 41.6, 55.9, 66.6, 66.9, 112.3, 118.3, 
120.5, 122.0, 122.5, 124.1, 128.1, 128.9, 129.5, 131.0, 134.7, 137.7, 140.0, 142.7, 151.3, 
153.3, 172.0; Calcd. for C29H31Cl2NO6 (560.47): C, 62.15; H, 5.58; N, 2.50. Found: C, 
62.70; H, 5.93; N, 2.41. 
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2.8.14 Synthetic Procedure for Class 3 Molecules Containing Amino Acid Linkers 
 Scheme 2.12 was used as follows:  The desired amino acid (5 mmol), p-
toluenesulfonic acid monohydrate (1.5 equiv., 1.427 g), and I (1 equiv., 605 µL) were 
combined in toluene (50 mL) and placed in a 100 mL round bottom flask equipped with a 
Dean Stark trap.  The reaction contents were heated to a reflux at 150 
o
C for 5 h until the 
accumulation of water had ceased.  After cooling, the remaining toluene was washed with 
saturated sodium carbonate (2 x 50 mL) and water (50 mL), dried over anhydrous 
MgSO4, filtered, and concentrated to yield the final amino acid ester (XXXII) as a free 
base. 
 Amino acid ester XXXII (0.6 mmol), the desired NSAID (138 mg, 0.6 mmol), 
and HOBt (1.1 equiv., 89 mg, 0.66 mmol) were combined in CH2Cl2 (5 mL) under 
nitrogen.  The reaction contents were stirred at room temperature for 15 min, until the 
solution became clear.  EDC·HCl (1.1 equiv., 126 mg, 0.66 mmol) was then added and 
the reactions contents were left stirring at room temperature overnight (16 h).  Distilled 
water was added and the organic layer was separated out.  The distilled water was then 
extracted with CH2Cl2 (25 mL) and the two organic layers were combined and washed 
with 1 M HCl (2 x 50 mL), saturated NaHCO3 (50 mL), and brine.  The organic layer 
was then dried over anhydrous MgSO4, filtered, and concentrated to yield the final 
product, which was purified via column chromatography using hexanes (100 to 50%) and 
ethyl acetate (0 to 50%) as the eluting solvent mixture.      
2.8.15 Physical Data for Class 3 Molecules Containing Amino Acid Linkers 
(S)-3,3-Dimethylbutylpyrrolidine-2-carboxylate (XXXV): 
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Light yellow liquid, 85% yield; Rf 0.12 (Hexanes:ethyl acetate 1:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.92 (s, 9H), 1.53-1.57 (t, 2H, J = 7.15 Hz), 1.70-1.76 (m, 2H), 1.79-1.84 (m, 
1H), 270, 2.05-2.11 (m, 1H), 2.85-2.90 (m, 1H), 3.03-3.08 (m, 1H), 3.69-3.72 (dd, 1H, J 
= 5.70, 8.60 Hz), 4.14-4.17 (dt, 2H, J = 1.70, 3.70 Hz); 
13
C NMR (125 MHz, CDCl3): δ 
25.5, 29.6, 29.7, 30.3, 41.8, 47.1, 59.9, 62.7, 175.6; HRMS (m/z): calc. for C11H21NO2 
200.1645; meas. 200.1638. 
(S)-3,3-Dimethylbutyl 1-(2-(4-isobutylphenyl)propanoyl)pyrrolidine-2-carboxylate (33): 
 
Clear liquid, 93% yield; Rf 0.74 (Hexanes:ethyl acetate 1:1); according to 
1
H NMR, 
19.2% of the cis isomer of the proline peptide bond is present:  
1
H NMR trans isomer 
(500 MHz, CDCl3): δ 0.85-0.89 (m, 6H), 0.92 (s, 9H), 1.38-1.42 (q, 3H, J = 10.9 Hz), 
1.54-1.57 (t, 2H, J = 7.55 Hz), 1.69-1.90 (m, 4H), 1.93-2.02 (m, 1H), 2.38-2.42 (dd, 2H, 
J = 2.55, 7.18 Hz), 3.17-3.50 (m, 2H), 3.64-3.76 (m, 1H), 4.10-4.20 (m, 2H), 4.39-4.49 
(m, 1H), 7.02-7.08 (m, 2H), 7.13-7.19 (m, 2H); cis isomer:  δ 0.85-0.89 (m, 6H), 0.87 (s, 
9H), 1.38-1.42 (q, 3H, J = 10.9 Hz), 1.47-1.50 (t, 2H, J = 7.50 Hz), 1.69-1.90 (m, 4H), 
2.05-2.15 (m, 1H), 2.38-2.42 (dd, 2H, J = 2.55, 7.18 Hz), 3.17-3.50 (m, 2H), 3.64-3.76 
(m, 1H), 4.10-4.15 (m, 1H), 4.21-4.25 (m, 1H), 4.39-4.53 (m, 1H), 7.02-7.08 (m, 2H), 
7.13-7.19 (m, 2H); 
13
C NMR trans isomer (125 MHz, CDCl3): δ 20.3, 22.4, 22.5, 24.9, 
29.6, 29.8, 30.1, 41.6, 44.5, 45.1, 46.8, 59.2, 62.7, 127.3, 129.4, 138.4, 140.0, 172.3, 
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172.6; cis isomer:  δ 20.4, 22.3, 22.5, 24.8, 29.0, 30.2, 31.2, 41.7, 44.6, 45.0, 46.6, 58.9, 
62.8, 127.0, 127.3, 129.5. 129.6, 172.8, 172.9; Calcd. for C24H37NO3·0.25H2O (392.06): 
C, 73.53; H, 9.64; N, 3.57.  Found: C, 73.86; H, 9.41; N, 3.47. 
 (S)-3,3-Dimethylbutyl 1-((S)-2-(6-methoxynaphthalen-2-yl)propanoyl)pyrrolidine-2-
carboxylate (34): 
 
White solid, 73% yield; MP 111.5-112.5 
o
C; Rf 0.62 (Hexanes:ethyl acetate 1:1); 
according to 
1
H NMR, 13.4% of the cis isomer of the proline peptide bond is present:  
1
H 
NMR, trans isomer (500 MHz, DMF): δ 0.99 (s, 9H), 1.52-1.57 (m, 5H), 1.92-1.97 (m, 
2H), 2.04-2.07 (m, 1H), 2.33-2.36 (m, 1H), 3.35-3.39 (m, 1H), 3.87-3.92 (m, 1H), 4.07 
(s, 3H), 4.17-4.26 (m, 3H), 4.55-4.57 (dd, 1H, J = 4.20, 8.60 Hz), 7.31-7.34 (dd, 1H, J = 
2.50, 9.00 Hz), 7.50 (d, 1H, J = 2.50 Hz), 7.61-7.64 (dd, 1H, J = 1.75, 8.45 Hz), 7.94-
7.98 (t, 3H, J = 8.65 Hz); cis isomer: δ 1.12 (s, 9H), 1.52-1.57 (m, 5H), 1.76-1.80 (t, 2H, 
J = 7.25 Hz), 1.92-1.97 (m, 2H), 1.91-1.97 (m, 1H), 2.19-2.23 (m, 1H), 3.55-3.60 (m, 
1H), 3.87-3.92 (m, 1H), 4.07 (s, 3H), 4.43-4.45 (m, 2H), 7.31-7.34 (dd, 1H, J = 2.50, 9.00 
Hz), 7.50 (d, 1H, J = 2.50 Hz), 7.61-7.64 (dd, 1H, J = 1.75, 8.45 Hz), 7.91 (bs, 1H), 7.94-
7.98 (t, 2H, J = 8.65 Hz); 
13
C NMR, trans isomer (125 MHz, DMF): δ 20.1, 22.4, 31.1, 
24.9, 41.7, 44.0, 46.9, 55.2, 59.4, 62.1, 63.2, 106.1, 118.9, 126.3, 126.9, 127.4, 129.3, 
129.4, 133.9, 137.3, 157.9, 172.0, 172.4; cis isomer: δ 20.1, 22.4, 31.1, 41.8, 44.3, 46.6, 
55.2, 59.2, 62.1, 63.2, 106.0, 119.1, 125.9, 126.3, 126.9, 127.6, 129.3, 129.4, 134.0, 
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137.1, 157.9, 172.5, 172.8; Calcd. for C25H33NO4 (411.53): C, 72.96; H, 8.08; N, 3.40. 
Found: C, 73.22; H, 7.98; N, 3.47.   
 (S)-3,3-Dimethylbutyl 1-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetyl) pyrrolidine-2-carboxylate (35): 
 
Yellow oil, 96% yield; Rf 0.47 (Hexanes:ethyl acetate 1:1); according to 
1
H NMR, 18.5% 
of the cis isomer of the proline peptide bond is present:  
1
H NMR, trans isomer (500 
MHz, CDCl3): δ 0.88 (s, 9H), 1.41-1.45 (t, 2H, J = 7.55 Hz), 1.93-2.03 (m, 2H), 2.05-
2.09 (m, 1H), 2.18-2.20 (m, 1H), 2.36 (s, 3H), 3.62-3.71 (m, 2H), 3.70 (s, 2H), 3.77 (s, 
3H), 4.03-4.07 (m, 2H), 4.30-4.33 (dd, 1H, J = 4.55, 8.60 Hz), 6.63-6.66 (dd, 1H, J = 
2.50, 9.00 Hz), 6.94-6.97 (m, 1H), 6.99 (d, 1H, J = 2.50 Hz), 7.52 (d, 2H, J = 8.45 Hz), 
7.61-7.64 (m, 2H); cis isomer:  δ 0.89 (s, 9H), 1.47-1.51 (t, 2H, J = 7.40 Hz), 1.84-1.90 
(m, 1H), 1.93-2.03 (m, 2H), 2.21 (s, 3H), 3.45-3.49 (m, 3H), 3.70 (s, 2H), 3.77 (s, 3H), 
4.08-4.13 (m, 2H), 4.58-4.61 (dd, 1H, J = 1.95, 8.60 Hz), 6.63-6.66 (dd, 1H, J = 2.50, 
9.00 Hz), 6.94-6.97 (m, 1H), 6.99 (d, 1H, J = 2.50 Hz), 7.52 (d, 2H, J = 8.45 Hz), 7.61-
7.64 (m, 2H);  
13
C NMR, trans isomer (500 MHz, CDCl3):  δ 13.6, 25.0, 29.5, 29.6, 29.7, 
31.2, 41.6, 47.3, 55.7, 59.3, 62.9, 101.7, 111.6, 112.9, 114.8, 129.1, 130.8, 130.9, 131.2, 
134.0, 135.6, 139.2, 156.0, 168.3, 168.8, 172.3; cis isomer:  δ 13.5, 22.3, 25.0, 29.1, 29.7, 
31.7, 41.7, 46.8, 53.5, 59.6, 63.5, 101.6, 111.7, 112.9, 114.8, 129.1, 130.8, 130.9, 131.2, 
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134.0, 135.6, 139.2, 156.1, 168.3, 168.9, 172.3; Calcd. for C30H35ClN2O5·0.5CH2Cl2 
(581.53): C, 63.00; H, 6.24; N, 4.82.  Found: C, 63.34; H, 5.69; N, 4.81. 
(S)-3,3-dimethylbutyl 1-(2-(2-(2,6-dichlorophenylamino)phenyl)acetyl)pyrrolidine-2-
carboxylate (36): 
 
Clear oil, 82% yield; Rf 0.31 (Hexanes:ethyl acetate, 4:1); according to 
1
H NMR, 22.1% 
of the cis isomer of the proline peptide bond is present:  
1
H NMR, trans isomer (500 
MHz, CDCl3): δ 0.86 (s, 9H), 1.41-1.45 (t, 2H, J = 15.0 Hz), 1.99-2.01 (m, 2H), 2.05-
2.11 (m, 1H), 2.11-2.17 (m, 1H), 3.62-3.71 (m, 2H), 3.72-3.87 (m, 3H), 4.06-4.14 (m, 
2H), 4.48-4.51 (dd, 1H, J = 3.50, 8.60 Hz), 6.48 (d, 1H, J = 7.75 Hz), 6.84-6.89 (t, 1H, J 
= 7.25 Hz), 6.91-6.94 (t, 1H, J = 8.00 Hz), 7.06 (d, 1H, J = 7.40 Hz), 7.15 (d, 1H, J = 
7.50Hz), 7.29 (d, 2H, J = 8.00 Hz); 
1
H NMR, cis isomer (500 MHz, CDCl3): δ 0.90 (s, 
9H), 1.52-1.56 (t, 2H, J = 7.45 Hz), 1.88-1.94 (m, 2H), 2.13-2.19 (m, 1H), 2.23-2.32 (m, 
1H), 3.54-3.62 (m, 2H), 3.72-3.87 (m, 3H), 4.18-4.28 (m, 2H), 4.63-4.66 (dd, 1H, J = 
2.55, 8.53 Hz), 6.49-6.51 (m, 1H), 6.85-6.88 (m, 1H), 6.91-6.95 (t, 1H, J = 8.00 Hz), 
7.04-7.08 (m, 2H), 7.30 (d, 2H, J = 8.00 Hz); 
13
C NMR, trans isomer (125 MHz, CDCl3): 
δ 24.9, 29.2, 29.6, 29.7, 39.2, 41.5, 47.6, 60.1, 62.9, 117.8, 121.2, 123.8, 124.5, 127.6, 
128.8, 130.0, 130.7, 138.1, 143.7, 170.2, 172.2; 
13
C NMR, cis isomer (125 MHz, CDCl3): 
δ 22.6, 29.6, 29.7, 31.6, 39.1, 41.7, 46.9, 60.1, 63.7, 117.8, 121.2, 123.8, 124.7, 127.7, 
128.8, 129.9, 130.6, 138.1, 143.7, 170.8, 172.3; HRMS (m/z): calcd. for C25H31N2O3 
477.1706; meas. 477.1723. 
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3,3-Dimethylbutyl 2-aminoacetate (XXXVI): 
 
Light yellow liquid, 58% yield; Rf 0.55 (Methylene chloride:methanol, 9:1 w/ 3 drops 
NH4OH); 
1
H NMR (500 MHz, CDCl3): δ 0.91 (s, 9H), 1.42-1.47 (bs, 2H), 1.52-1.56 (t, 
2H, J = 7.50 Hz), 3.38 (s, 2H), 4.13-4.18 (t, 2H, J = 7.45 Hz); 
13
C NMR (125 MHz, 
CDCl3): δ 29.7, 29.8, 41.8, 44.1, 62.7, 174.3;  HRMS (m/z): calcd. for C8H17NO2 [M+1]: 
160.1332; meas. 160.1321. 
3,3-Dimethylbutyl 2-(2-(4-isobutylphenyl)propanamido)acetate (37): 
 
Clear liquid, 91% yield; Rf 0.37 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.88 (d, 6H, J = 6.60 Hz), 0.89 (s, 9H), 1.51 (d, 3H, J = 7.15 Hz), 1.49-1.54 (t, 
2H, J = 5.80 Hz), 1.80-1.86 (m, 1H), 2.43 (d, 2H, J = 7.20 Hz), 3.55-3.60 (q, 1H, J = 7.15 
Hz), 3.87-4.00 (dq, 2H, J = 5.00, 18.5 Hz), 4.12-4.16 (t, 2H, J = 7.50 Hz), 5.83 (bs, 1H), 
7.10 (d, 2H, J = 8.00 Hz), 7.19 (d, 2H, J = 8.00 Hz); 
13
C NMR (125 MHz, CDCl3): δ 
18.4, 22.4, 29.5, 29.7, 30.2, 41.6, 44.9, 45.0, 46.6, 63.2, 127.4, 129.7, 138.1, 140.9, 170.0, 
174.6; Calcd. for C21H33NO3·0.25H2O (351.99): C, 71.66; H, 9.59; N, 3.98.  Found: C, 
71.84; H, 9.35; N, 4.02. 
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 (S)-3,3-Dimethylbutyl 2-(2-(6-methoxynaphthalen-2-yl)propanamido)acetate (38): 
 
Clear oil, 99% yield; Rf 0.20 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, CDCl3): δ 
0.87 (s, 9H), 1.45-1.49 (t, 2H, J = 7.50 Hz), 1.59 (d, 3H, J = 7.20 Hz), 3.71-3.77 (q, 1H, J 
= 7.15 Hz), 3.87-4.00 (dq, 2H, J = 5.40, 18.4 Hz), 3.90 (s, 3H), 4.09-4.14 (t, 2H, J = 7.40 
Hz), 5.85 (bs, 1H), 7.10 (d, 1H, J = 2.45 Hz), 7.12-7.15 (dd, 1H, J = 2.55, 8.88 Hz), 7.36-
7.39 (dd, 1H, J = 1.70, 8.43 Hz), 7.67 (s, 1H), 7.68-7.73 (t, 2H, J = 8.55 Hz); 
13
C NMR 
(125 MHz, CDCl3): δ 18.4, 29.5, 29.7, 41.5, 41.6, 46.8, 55.3, 63.2, 105.7, 119.2, 126.2, 
126.3, 127.6, 129.0, 129.3, 133.8, 136.0, 157.8, 169.9, 174.5; Calcd. for C22H29NO4 
(371.47): C, 71.13; H, 7.87; N, 3.77.  Found: C, 70.97; H, 7.69; N, 3.80. 
3,3-Dimethylbutyl 2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido) Acetate (39): 
 
Yellow solid, 89% yield; MP 118.5-120 
o
C; Rf 0.11 (Hexanes:ethyl acetate 4:1); 
1
H NMR 
(500 MHz, CDCl3): δ 0.89 (s, 9H), 1.48-1.51 (t, 2H, J = 7.55 Hz), 2.36 (s, 3H), 3.67 (s, 
2H), 3.82 (s, 3H), 3.95 (d, 2H, J = 5.40 Hz), 4.11-4.15 (t, 2H, J = 7.50 Hz), 6.07-6.09 (t, 
1H, J = 5.00 Hz), 6.68-6.71 (dd, 1H, J = 2.55, 8.95 Hz), 6.91 (s, 1H), 6.90-6.94 (d, 1H, J 
= 1-.2 Hz), 7.45-7.48 (m, 2H), 7.64-7.67 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 13.4, 
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29.5, 29.7, 32.0, 41.5, 41.6, 55.8, 63.3, 100.8, 112.5, 112.5, 115.1, 129.2, 130.2, 131.0, 
131.3, 133.6, 136.4, 139.5, 156.3, 168.3, 169.7, 170.2; Calcd. for C27H31ClN2O5 (499.00): 
C, 64.99; H, 6.26; N, 5.61. Found: C, 64.63; H, 5.94; N, 5.50. 
3,3-Dimethylbutyl 2-(2-(2-(2,6-dichlorophenylamino)phenyl)acetamido)acetate (40): 
 
White solid, 70% yield; mp 118-119 
o
C; Rf 0.36 (Hexanes:ethyl acetate 4:1); 
1
H NMR 
(500 MHz, CDCl3): δ 0.89 (s, 9H), 1.49-1.53 (t, 2H, J = 7.50 Hz), 3.72 (s, 2H), 4.01 (d, 
2H, J = 5.05 Hz), 4.15-4.18 (t, 2H, J = 7.45 Hz), 6.42-6.48 (bs, 1H), 6.49 (d, 1H, J = 8.05 
Hz), 6.88-6.92 (t, 1H, J = 7.40 Hz), 6.93-6.97 (t, 1H, J = 8.15 Hz), 7.07-7.11 (t, 1H, J = 
7.85 Hz), 7.17 (d, 1H, J = 7.40 Hz), 7.31 (d, 3H, J = 8.10 Hz); 
13
C NMR (125 MHz, 
CDCl3): δ 29.1, 29.2, 40.2, 41.1, 41.3, 62.9, 117.2, 121.2, 123.7, 124.0, 127.6, 128.4, 
129.5, 130.2, 137.2, 142.5, 169.4, 171.3; Calcd. for C22H26Cl2N2O3 (437.36): C, 60.42; H, 
5.99; N, 6.41. Found: C, 60.36; H, 6.09; N, 6.26. 
(S)-3,3-Dimethylbutyl 2-amino-3-phenylpropanoate (XXXVII): 
 
Light yellow liquid, 36% yield; Rf 0.43 (Methylene chloride:hexanes:ethanol, 90:8:2); 
1
H 
NMR (500 MHz, CDCl3): δ 0.91 (s, 9H), 1.42-1.45 (bs, 2H), 1.49-1.52 (t, 2H, J = 7.70 
Hz), 2.80-3.08 (dd, 1H, J = 7.95, 128 Hz), 2.83-3.06 (dd, 1H, J = 7.95, 102 Hz), 3.65-
3.70 (dd, 1H, J = 5.30, 7.93 Hz), 4.11-4.16 (m, 2H), 7.15-7.19 (d, 2H, J = 7.15 Hz), 7.21-
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7.24 (m, 1H), 7.26-7.30 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 29.6, 29.7, 41.2, 41.7, 
56.0, 62.7, 126.8, 128.6, 129.3, 137.4, 175.1; HRMS (m/z): calcd. for C15H23NO2 
250.1802; meas. 250.1791. 
(S)-3,3-Dimethylbutyl 2-(2-(4-isobutylphenyl)propanamido)-3-phenylpropanoate (41): 
 
Clear oil, 73% yield; Rf 0.59 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, CDCl3): δ 
0.82-1.01 (m, 15H), 1.34-1.53 (m, 5H), 1.78-1.90 (m, 1H), 2.42-2.50 (dd, 2H, J = 7.20, 
10.9 Hz), 2.94-2.97 (t, 1H, J = 3.80 Hz), 2.91-3.07 (m, 1H), 3.44-3.53 (m, 1H), 4.01-4.16 
(m, 2H), 4.73-4.84 (m, 1H), 5.71-5.74 (m, 1H), 6.74 (d, 1H, J = 7.20 Hz), 6.90-6.93 (m, 
1H), 7.05-7.16 (m, 5H), 7.15-7.20 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 18.19, 22.42, 
29.52, 29.53, 29.65, 29.69, 30.20, 30.24, 37.72, 37.76, 41.55, 41.60, 45.06, 45.08, 46.62, 
46.72, 52.92, 53.15, 63.16, 63.20, 126.89, 126.96, 127.40, 127.41, 128.37, 128.45, 
129.24, 129.29, 129.60, 129.62, 135.63, 135.85, 137.67, 138.27, 140.74, 171.40, 171.49, 
173.59, 173.96; Calcd. for C28H39NO3 (437.61): C, 76.85; H, 8.98; N, 3.20. Found: C, 
76.90; H, 9.19; N, 3.17.   
 (S)-3,3-Dimethylbutyl 2-((S)-2-(6-methoxynaphthalen-2-yl)propanamido)-3-
phenylpropanoate (42): 
 
Clear oil, 82% yield; Rf 0.42 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, CDCl3): δ 
0.83 (s, 9H), 1.36-1.40 (t, 2H, J = 7.45 Hz), 1.57 (d, 3H, J = 7.25 Hz), 2.94-3.05 (dq, 2H, 
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J = 5.75, 13.8 Hz), 3.65-3.70 (q, 1H, J = 7.20 Hz), 3.91 (s, 3H), 3.99-4.10 (m, 2H), 4.73-
4.78 (m, 1H), 5.78 (d, 1H, J = 7.75 Hz), 6.83-6.86 (m, 2H), 7.02-7.06 (t, 2H, J = 7.65 
Hz), 7.09-7.15 (m, 3H), 7.29-7.32 (dd, 1H, J = 1.80, 8.50 Hz), 7.58 (s, 1H), 7.66 (dd, 2H, 
J = 4.05, 8.68 Hz); 
13
C NMR (125 MHz, CDCl3): δ 18.1, 29.5, 29.6, 37.7, 41.5, 47.0, 
53.1, 55.4, 63.2, 105.6, 119.1, 126.2, 126.4, 126.9, 127.5, 128.4, 129.0, 129.2, 129.3, 
133.8, 135.6, 135.7, 157.8, 171.3, 173.9; Calcd. for C29H35NO4 (461.59): C, 75.46; H, 
7.64; N, 3.03. Found: C, 75.03; H, 7.59; N, 3.03. 
 (S)-3,3-Dimethylbutyl 2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)-3-phenylpropanoate (43): 
 
Light yellow oil, 92% yield; Rf 0.21 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.87 (s, 9H), 1.43-1.49 (t, 2H, J = 7.50 Hz), 2.19 (s, 3H), 2.94-3.03 (m, 2H), 
3.55-3.63 (q, 2H, J = 17.5, 18.6 Hz), 3.80 (s, 3H), 4.06-4.15 (m, 2H), 4.78-4.82 (m, 1H), 
5.97 (d, 1H, J = 8.05 Hz), 6.72-6.75 (dd, 1H, J = 2.55, 9.03 Hz), 6.77 (d, 2H, J = 7.15 
Hz), 6.86 (d, 1H, J = 2.45 Hz), 6.99-7.03 (m, 3H), 7.06-7.12 (m, 1H), 7.42 (d, 2H, J = 
8.75 Hz), 7.53 (d, 2H, J = 7.75 Hz); 
13
C NMR (125 MHz, CDCl3): δ 13.3, 29.5, 29.7, 
32.1, 37.6, 41.6, 52.9, 55.8, 63.3, 100.7, 112.5, 112.6, 115.2, 127.0, 128.4, 129.1, 129.2, 
130.2, 131.0, 131.2, 133.7, 135.4, 136.0, 139.4, 156.4, 168.2, 169.3, 171.1; Calcd. for 
C34H37ClN2O5 (589.12): C, 69.32; H, 6.33; N, 4.76. Found: C, 68.85; H, 6.13; N, 4.60.   
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(S)-3,3-Dimethylbutyl 2-(2-(2-(2,6-dichlorophenylamino)phenyl)acetamido)-3-
phenylpropanoate (44): 
 
Light yellow oil, 92% yield; Rf 0.65 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.89 (s, 9H), 1.45-1.50 (m, 2H), 3.04-3.13 (m, 2H), 3.59-3.72 (q, 2H, J = 14.4, 
45.4 Hz), 4.06-4.18 (m, 2H), 4.83-4.87 (m, 1H), 6.13 (d, 1H, J = 7.80 Hz), 6.50 (d, 1H, J 
= 7.90 Hz), 6.89-6.98 (m, 3H), 6.95-6.98 (t, 1H, J = 8.00 Hz), 7.10 (d, 2H, J = 7.40 Hz), 
7.16-7.19 (m, 3H), 7.32 (d, 2H, J = 8.05 Hz), 7.36 (bs, 1H); 
13
C NMR (125 MHz, 
CDCl3): δ 29.5, 29.7, 37.7, 41.0, 41.6, 53.3, 63.4, 117.7, 121.6, 124.2, 124.4, 127.1, 
128.0, 128.5, 128.8, 129.4, 130.1, 130.6, 135.6, 137.7, 143.0, 170.9, 171.3; Calcd. for 
C29H32Cl2N2O3·0.5H2O (536.49): C, 64.92; H, 6.20; N, 5.22. Found: C, 64.99; H, 5.78; 
N, 5.05. 
(S)-3,3-Dimethylbutyl 2-amino-3-methylbutanoate (XXXVIII): 
 
Light yellow liquid, 64% yield; Rf 0.16 (hexanes:ethyl acetate: 4:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.87 (d, 3H, J = 6.85 Hz), 0.92 (s, 9H), 0.95 (d, 3H, J = 6.90 Hz), 1.38-1.45 
(bs, 2H), 1.53-1.57 (t, 2H, J = 7.70 Hz), 1.97-2.02 (m, 1H), 3.23 (d, 1H, J = 4.95 Hz), 
4.13-4.16 (t, 2H, J = 7.35 Hz); 
13
C NMR (125 MHz, CDCl3): δ 17.2, 19.4, 29.6, 29.7, 
32.1, 41.8, 60.0, 62.5, 175.7; HRMS (m/z): calcd. for C11H23NO2 202.1802; meas. 
202.1784. 
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(S)-3,3-Dimethylbutyl 2-(2-(4-isobutylphenyl)propanamido)-3-methylbutanoate (45): 
 
Clear liquid, 92% yield; Rf 0.55 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, 
CDCl3): δ 0.64 (d, 1.5H, J = 6.90 Hz), 0.71-0.75 (dd, 3H, J = 6.85, 9.20 Hz), 0.83 (d, 
1.5H, J = 6.85 Hz), 0.85-0.87 (m, 6H), 0.89 (s, 4.5H), 0.90 (s, 4.5H), 1.46-1.53 (m, 5H), 
1.79-1.86 (m, 1H), 1.99-2.10 (m, 1H), 2.43 (d, 2H, J = 7.20 Hz), 3.53-3.57 (q, 0.5H, J = 
7.15 Hz), 3.57-3.62 (q, 0.5H, J = 7.30 Hz), 4.07-4.14 (m, 2H), 4.43-4.49 (m, 1H), 5.70-
5.78 (dd, 1H, J = 8.80, 24.8 Hz), 7.09-7.12 (m, 2H), 7.17-7.22 (m, 2H); 
13
C NMR (125 
MHz, CDCl3): δ 17.3, 17.5, 18.1, 18.3, 18.9, 19.0, 22.2. 22.3, 29.5, 29.6, 29.7, 30.2, 31.2, 
31.3, 41.6, 41.7, 45.0, 45.1, 46.8, 46.9, 56.8, 56.9, 62.9, 63.0, 127.3, 127.4, 129.7, 138.6, 
140.8, 140.9, 171.9, 172.1, 174.1, 174.4; Calcd. for C24H39NO3 (389.57): C, 73.99; H, 
10.09; N, 3.60. Found: C, 73.90; H, 10.50; N, 3.52. 
 (S)-3,3-Dimethylbutyl 2-((S)-2-(6-methoxynaphthalen-2-yl)propanamido)-3-
methylbutanoate (46): 
 
Clear oil, 99% yield; Rf 0.30 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, CDCl3): δ 
0.73 (d, 3H, J = 6.90 Hz), 0.84 (s, 9H), 0.85 (d, 3H, J = 7.00 Hz), 1.38-1.42 (t, 2H, J = 
7.65 Hz), 1.54 (s, 3H), 1.60 (d, 3H, J = 7.20 Hz), 2.05-2.10 (m, 1H), 3.71-3.77 (m, 1H), 
3.90 (s, 3H), 4.02-4.06 (t, 2H, J = 7.45 Hz), 4.46-4.49 (dd, 1H, J = 4.75, 8.73 Hz), 7.09-
7.14 (m, 2H), 7.36-7.40 (dd, 1H, J = 1.65, 8.48 Hz), 7.68 (s, 1H), 7.69-7.72 (dd, 2H, J = 
5.50, 8.60 Hz); 
13
C NMR (125 MHz, CDCl3): δ 17.7, 18.5, 19.0, 20.8, 29.5, 29.6, 31.3, 
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41.6, 47.1, 55.3, 57.1, 62.9, 105.7, 119.1, 126.2, 126.4, 127.5, 129.0, 129.3, 133.8, 135.9, 
157.7, 174.2, 186.2; Calcd. for C25H35NO4 (413.55): C, 72.61; H, 8.53; N, 3.39. Found: 
C, 72.62; H, 8.87; N, 3.29.  
 (S)-3,3-Dimethylbutyl 2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)-3-methylbutanoate (47): 
 
White solid, 93% yield; mp 119-120 
o
C, Rf 0.16 (Hexanes:ethyl acetate 4:1); 
1
H NMR 
(500 MHz, CDCl3): δ 0.69 (d, 3H, J = 6.90 Hz), 0.83 (d, 3H, J = 6,85 Hz), 0.88 (s, 9H), 
1.44-1.48 (t, 2H, J = 7.55 Hz), 2.05-2.10 (m, 1H), 2.35 (s, 3H), 3.65 (m, 2H), 3.80 (s, 
3H), 4.08-4.11 (t, 2H, J = 7.50 Hz), 4.48-4.52 (dd, 1H, J = 4.75, 8.83 Hz), 6.07 (d, 1H, J 
= 8.80 Hz), 6.68-6.71 (dd, 1H, J = 2.50, 9.00 Hz), 6.89 (d, 1H, J = 2.45 Hz), 6.94 (d, 1H, 
J = 9.00 Hz), 7.44-7.48 (m, 2H), 7.63-7.66 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 
13.4, 17.6, 19.0, 29.5, 29.7, 31.2, 32.3, 41.6, 55.7, 57.1, 63.1, 100.6, 100.9, 112.6, 112.7, 
115.2, 129.2, 130.2, 131.0, 131.2, 133.7, 136.2, 139.5, 156.3, 169.7, 171.7; Calcd. for 
C30H37ClN2O5 (541.08): C, 66.59; H, 6.89; N, 5.18. Found: C, 66.48; H, 7.12; N, 5.10. 
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(S)-3,3-Dimethylbutyl 2-(2-(2-(2,6-dichlorophenylamino)phenyl)acetamido)-3-
methylbutanoate (48): 
 
Clear oil, 100% yield; Rf 0.54 (Hexanes:ethyl acetate 4:1); 
1
H NMR (500 MHz, CDCl3): 
δ 0.85 (d, 3H, J = 6.90 Hz), 0.88 (d, 3H, J = 6.85 Hz), 0.90 (s, 9H), 1.49-1.53 (t, 2H, J = 
7.55 Hz), 2.11-2.15 (m, 1H), 3.72 (s, 2H), 4.12-4.16 (m, 2H), 4.53-4.57 (dd, 1H, J = 4.90, 
8.83 Hz), 6.16 (d, 1H, J = 8.90 Hz), 6.50 (d, 1H, J = 7.95 Hz), 6.89-6.92 (td, 1H, J = 
0.95, 7.45 Hz), 6.93-6.97 (t, 1H, J = 8.00 Hz), 7.07-7.11 (td, 1H, J = 1.55, 9.18 Hz), 7.16-
7.19 (dd, 1H, J = 1.35, 7.50 Hz), 7.31 (d, 2H, J = 8.05 Hz), 7.36 (s, 1H); 
13
C NMR (125 
MHz, CDCl3): δ 17.8, 18.9, 29.6, 29.7, 31.4, 41.0, 41.7, 57.2, 63.1, 117.8, 121.6, 124.1, 
124.8, 128.0, 128.8, 129.9, 130.5, 137.8, 143.0, 171.4, 171.9; Calcd. for C25H32Cl2N2O3 
(479.44): C, 62.63; H, 6.73; N, 5.84.  Found: C, 62.46; H, 6.48; N, 5.66. 
2.8.16 Synthetic Procedure for NSAID-AChEI Molecules Containing Amide 
Linkages 
 3,3-Dimethylbutyl amine (1.5 mmol, 202 µL), the desired NSAID (1.5 mmol), 
and DMAP (10 mol %, 18 mg) (for diclofenac derivative 52, 1.1 eq of HOBt was used in 
place of DMAP) were combined in CH2Cl2 under nitrogen.  The reaction contents were 
stirred and then cooled to 0 
o
C.  EDC·HCl (1.1 equiv, 1.65 mmol, 0.256 g) was then 
added and the reaction contents were slowly warmed up to room temperature.  The 
reaction was left stirring overnight and, upon return, the NSAID starting material had 
been fully consumed.  Distilled water (25 mL) was added and the organic contents were 
extracted with CH2Cl2 (2 x 25 mL).  The combined organic extracts were washed with 1 
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M HCl (2 x 50 mL), saturated Na2CO3, and brine, then dried over anhydrous MgSO4, 
filtered, and concentrated to yield a pure product requiring no further purification.   
2.8.17 Physical Data for NSAID-AChEI Molecules Containing Amide Linkages 
N-(3,3-Dimethylbutyl)-2-(4-isobutylphenyl)propanamide (49): 
 
White solid, 84% yield; mp 70-73 
o
C; Rf 0.53 (80% hexane:20% ethyl acetate); 
1
H NMR 
(500 MHz, CDCl3):  δ 0.83 (s, 9H), 0.87 (d, 6H, J = 4.05 Hz), 1.24-1.28 (t, 2H, J = 7.80 
Hz), 1.48 (d, 3H, J = 7.25 Hz), 1.80-1.86 (m, 1H), 2.43 (d, 2H, J = 7.20 Hz), 3.14-3.20 
(m, 2H), 3.45-3.50 (q, 1H, J = 7.25 Hz), 5.15-5.18 (bs, 1H), 7.09 (d, 2H, J = 8.10 Hz), 
7.15 (d, 2H, J = 8.05 Hz); 
13
C NMR (CDCl3):  δ 18.5, 22.4, 29.4, 29.9, 30.2, 36.4, 43.1, 
45.0, 46.8, 127.4, 129.6, 138.6, 140.7, 174.3; Calcd. for C19H31NO·0.25H2O (293.96): C, 
77.63; H, 10.80; N, 4.76. Found: C, 77.98; H, 10.22; N, 5.05. 
(S)-N-(3,3-Dimethylbutyl)-2-(6-methoxynaphthalen-2-yl)propanamide (50): 
 
White solid, 88% yield; mp 112-114 
o
C; Rf 0.36 (80% hexane:20% ethyl acetate); 
1
H 
NMR (500 MHz, CDCl3):  δ 0.80 (s, 9H), 1.22-1.26 (t, 2H, J = 8.20 Hz), 1.57 (d, 3H, J = 
7.20 Hz), 3.13-3.21 (m, 2H), 3.62-3.67 (q, 1H, J = 7.15 Hz), 3.90 (s, 3H), 5.23-5.27 (bs, 
1H), 7.10 (d, 1H, J = 2.40 Hz), 7.12-7.15 (dd, 1H, J = 2.55, 8.93 Hz), 7.33-7.36 (dd, 1H, 
J = 1.80, 8.48 Hz), 7.63 (s, 1H), 7.68-7.72 (dd, 2H, J = 7.05, 8.45 Hz); 
13
C NMR 
(CDCl3):  δ 18.5, 29.4, 29.9, 36.4, 43.1, 47.1, 53.5, 55.4, 105.6, 119.2, 126.2, 126.4, 
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127.6, 129.0, 129.2, 133.7, 136.6, 157.8, 174.1; Calcd. for C20H27NO2 (313.43): C, 76.64; 
H, 8.68; N, 4.47. Found: C, 76.12; H, 9.02; N, 4.62. 
2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(3,3-
dimethylbutyl)acetamide (51): 
 
Yellow solid, 91% yield, mp 138-140 
o
C; Rf 0.06 (80% hexane:20% ethyl acetate); 
1
H 
NMR (500 MHz, CDCl3):  δ 0.82 (s, 9H), 1.24-1.28 (m, 2H), 1.54 (s, 2H), 2.36 (s, 3H), 
3.18-3.23 (m, 2H), 3.60 (s, 2H), 3.80 (s, 3H), 5.43-5.46 (bs, 1H), 6.66-6.70 (dd, 1H, J = 
2.45, 9.00 Hz), 6.83 (s, 1H), 6.85 (d, 1H, J = 3.00 Hz), 7.47 (d, 2H, J = 8.40 Hz), 7.65 (d, 
2H, J = 8.40 Hz); 
13
C NMR (CDCl3):  δ 13.3, 29.4, 29.9, 32.3, 36.4, 43.2, 55.8, 100.8, 
112.5, 112.9, 115.1, 129.3, 130.3, 130.9, 131.2, 133.6, 136.3, 139.6, 156.3, 168.4, 169.6; 
Calcd. for C25H29ClN2O3 (440.96): C, 68.09; H, 6.63; N, 6.35. Found: C, 67.93; H, 6.60; 
N, 6.19. 
2-(2-(2,6-Dichlorophenylamino)phenyl)-N-(3,3-dimethylbutyl)acetamide (52): 
 
White solid, 89% yield, mp 149-150 
o
C; Rf 0.63 (80% hexane:20% ethyl acetate); 
1
H 
NMR (500 MHz, CDCl3):  δ 0.89 (s, 9H), 1.37-1.42 (m, 2H), 3.26-3.29 (m, 2H), 3.66 (s, 
2H), 5.65-5.72 (bs, 1H), 6.51 (d, 1H, J = 8.00 Hz), 6.91-6.93 (t, 1H, J = 7.40 Hz), 6.98-
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7.02 (t, 1H, J = 8.10 Hz), 7.10-7.16 (m, 2H), 7.23-7.25 (bs, 1H), 7.35 (d, 2H, J = 8.05 
Hz); 
13
C NMR (CDCl3):  δ 29.4, 29.9, 36.6, 41.2, 43.2, 117.3, 121.4, 124.4, 127.5, 128.0, 
128.9, 130.2, 130.7, 137.4, 142.8, 171.1; Calcd. for C20H24Cl2N2O·0.25 H2O (383.82): C, 
62.53; H, 6.40; N, 7.30. Found: C, 62.77; H, 6.30; N, 7.16. 
2.8.18 Synthetic Procedure for NSAID n-Butyl Esters 
 
 The appropriate NSAID (3 mmol), n-butanol (3 mmol, 275 µL), and DMAP (0.3 
mmol, 40 mg) were combined in CH2Cl2 (7 mL) under nitrogen.  The solution was 
cooled to 0 
o
C and EDC·HCl (3.3 mmol, 0.63 g) was added.  The reaction contents were 
slowly warmed up to room temperature and left stirring overnight.  Upon return, distilled 
water and CH2Cl2 (25 mL each) were added and the organic layer was separated out.  The 
aqueous layer was extracted with CH2Cl2 (25 mL) and the combined organic extracts 
were washed with 1N HCl (2 x 50 mL), sat. NaHCO3 (50 mL), and brine (50 mL).  The 
organic layer was then dried over anhydrous MgSO4, filtered and concentrated to yield 
the final product. 
2.8.19 Physical Data for NSAID n-Butyl Esters 
Butyl 2-(4-isobutylphenyl)propanoate (53): 
 
Clear liquid, 97% yield; Rf 0.86 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.82-0.86 (t, 3H, J = 7.35 Hz), 0.87 (d, 6H, J = 6.60 Hz), 1.21-1.29 (m, 2H), 
1.46 (d, 3H, J = 7.15 Hz), 1.49-1.56 (m, 2H), 1.78-1.87 (m, 1H), 2.42 (d, 2H, J = 7.20 
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Hz), 3.63-3.68 (q, 1H, J = 7.20 Hz), 4.02-4.06 (t, 2H, J = 6.65 Hz), 7.06 (d, 2H, J = 8.05 
Hz), 7.18 (d, 2H, J = 8.05 Hz); 
13
C NMR (CDCl3):  δ 13.7, 18.5, 19.0, 22.4, 30.2, 30.6, 
45.1, 45.2, 64.5, 127.2, 129.3, 137.9, 140.4, 174.9; Calcd. for C17H26O2 (262.39): C, 
77.82; H, 9.99.  Found: C, 77.66; H, 10.42. 
 (S)-Butyl 2-(6-Methoxynaphthalen-2-yl)propanoate (54): 
 
White solid, , 90% yield, mp 69-70 
o
C; Rf 0.70 (80% hexane:20% ethyl acetate); 
1
H 
NMR (500 MHz, CDCl3):  δ 0.82-0.86 (t, 3H, J = 7.40 Hz), 1.23-1.31 (m, 2H), 1.50-1.55 
(m, 2H), 1.55 (d, 3H, J = 7.15 Hz), 3.80-3.85 (q, 1H, J = 7.20 Hz), 3.89 (s, 3H), 4.01-4.10 
(m, 2H), 7.09 (d, 1H, J = 2.40 Hz), 7.10-7.13 (dd, 1H, J = 2.50, 8.85 Hz), 7.37-7.41 (dd, 
1H, J = 1.75, 8.45 Hz), 7.64-7.69 (m, 3H); 
13
C NMR (CDCl3):  δ 13.7, 18.6, 19.1, 30.6, 
45.6, 55.3, 64.7, 105.6, 118.9, 125.9, 126.3, 127.1, 129.0, 129.3, 133.7, 135.9, 157.6, 
174.8; Calcd. for C18H22O3 (286.37): C, 75.50; H, 7.74. Found: C, 75.77; H, 7.96. 
Butyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (55): 
 
Yellow oil, 90% yield; Rf 0.63 (80% hexane:20% ethyl acetate); 
1
H NMR (500 MHz, 
CDCl3):  δ 0.87-0.90 (t, 3H, J = 7.40 Hz), 1.28-1.36 (m, 2H), 1.55-1.62 (m, 2H), 2.36 (s, 
3H), 3.63 (s, 2H), 3.82 (s, 3H), 4.06-4.10 (t, 2H, J = 6.65 Hz), 6.63-6.66 (dd, 1H, J = 
2.55, 9.00 Hz), 6.85 (d, 1H, J = 9.00 Hz), 6.94 (d, 1H, J = 2.50 Hz), 7.43-7.46 (m, 2H), 
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7.62-7.65 (m, 2H); 
13
C NMR (CDCl3):  δ 13.4, 13.5, 19.1, 30.4, 30.6, 55.7, 64.9, 101.3, 
111.7, 112.8, 115.0, 129.1, 130.7, 130.8, 131.2, 134.0, 135.9, 139.3, 156.1, 168.3, 171.0; 
Calcd. for C23H24ClNO4 (413.91): C, 66.74; H, 5.84; N, 3.38.  Found: C, 66.76; H, 5.73; 
N, 3.39. 
Butyl 2-(2-(2,6-Dichlorophenylamino)phenyl)acetate (56): 
 
Light yellow oil, 90% yield; Rf 0.82 (80% hexane:20% ethyl acetate); 
1
H NMR (500 
MHz, CDCl3):  δ 0.88-0.92 (t, 3H, J = 7.35 Hz), 1.31-1.39 (m, 2H), 1.59-1.66 (m, 2H), 
3.79 (s, 2H), 4.11-4.15 (t, 2H, J = 6.75 Hz), 6.53 (d, 1H, J = 8.05 Hz), 6.91-6.97 (m, 3H), 
7.08-7.12 (dt, 1H, J = 1.30, 7.45 Hz), 7.21 (d, 1H, J = 7.50 Hz), 7.32 (d, 2H, J = 8.05 
Hz); 
13
C NMR (CDCl3):  δ 13.7, 19.1, 30.7, 38.7, 65.3, 118.3, 122.0, 124.0, 124.5, 127.9, 
128.9, 129.5, 130.9, 137.9, 142.8, 172.5; Calcd. for C18H19Cl2NO2 (352.25): C, 61.38; H, 
5.44; N, 3.98. Found: C, 61.91; H, 5.65; N, 3.91. 
2.8.20 Synthetic Procedure for n-Butyl Ester-Carbonates 
 
 Scheme 2.4 was used as follows:  n-Butyl chloroformate (1.0 eq, 1 mmol, 129 
µL) was added to a pre-cooled solution of p-hydroxybenzyl alcohol (1.1 eq, 1.1 mmol, 
0.137 g) in THF (~5 mL) under nitrogen atmosphere.  Triethylamine (1.0 eq, 1 mmol, 
139 µL) was added over a 20 min period via syringe.  Upon precipitation, ~3 mL of THF 
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was added to the reaction mixture to ensure efficient stirring.  The reaction mixture was 
slowly warmed up to 18-20 
o
C and kept stirring for 12 h.  Distilled water (~8 mL) was 
added and the organic layer was separated from the aqueous layer.  The aqueous layer 
was then extracted with ethyl acetate (3 x 15 mL).  The combined organic extracts were 
washed with brine and dried over anhydrous magnesium sulfate.  The solvent was 
removed by rotary evaporation under reduced pressure to yield pure product.  
Clear oil, 90% yield, 
1
H NMR (500 MHz, CDCl3):  δ 7.36 (d, 2H, J = 7.97 Hz), 7.15 (d, 
2H, J = 7.97 Hz), 4.67 (d, 2H, J = 5.71 Hz), 4.24 (t, 2H, J = 7.90 Hz), 1.67 (m, 2H), 1.41 
(m, 2H), 0.94 (t, 2H);
 13
C NMR (CDCl3):  δ 13.7, 18.9, 30.6, 68.0, 68.8, 121.2, 128.1, 
138.7, 150.5, 153.8. 
  
 Step 2 – The desired NSAID (0.83 mmol) and CDI (0.16 g, 1.0 mmol) were 
combined in dry CH2Cl2 (3 mL) and left stirring for 15 min.  4-(Hydroxymethyl)phenyl 
n-butyl carbonate (0.32 g, 1.4 mmol) in CH2Cl2 (2 mL) was added to the clear solution 
and the reaction was refluxed at 57 
o
C for 16 h.  Distilled water (30 mL) was added and 
the organic phase was extracted with CH2Cl2 (3 x 30 mL), washed with brine, and dried 
over anhydrous MgSO4.  The solvent was concentrated to yield 0.60 g of clear oil 
containing a small amount of CDI urea.  The oil was redissolved in 8 mL CH2Cl2 and the 
urea was filtered out using vacuum filtration.  The crude oil was purified by passing 
through a silica gel column using 16.5% ethyl acetate in hexane as the eluent.   
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2.8.21 Physical Characterization of n-Butyl Carbonates 
4-(Butoxycarbonyloxy)benzyl 2-(4-isobutylphenyl)propanoate (57): 
 
Clear oil, 35% yield; Rf 0.73 (1:4 EtOAc:Hexane); 
1
H NMR (500 MHz, CDCl3):  δ 7.22 
(d, 2H, J = 8.48 Hz), 7.17 (d, 2H, J = 7.81 Hz), 7.08 (m, 4H, J = 8.95 Hz), 5.07 (dd, 2H, J 
= 12.5, 17.6 Hz), 4.24 (t, 2H, J = 6.68 Hz), 3.72 (q, 1H, J = 7.12 Hz), 2.44 (d, 2H, J = 
7.14 Hz), 1.83 (m, 1H), 1.70 (m, 2H), 1.50 (d, 3H, J = 14.8 Hz), 1.45 (m, 2H), 0.95 (t, 
3H, J = 7.35 Hz), 0.88 (d, 6H, J = 6.62 Hz); 
13
C NMR (CDCl3):  δ 13.7, 18.4, 18.5, 18.9, 
22.4, 30.2, 30.6, 45.0, 65.6, 68.7, 121.1, 127.2, 128.9, 129.5, 133.9, 137.5, 140.6, 150.8, 
153.7, 174.5; HRMS (m/z): calcd. for C25H32NaO5 435.2142; meas. 435.2175. 
(S)-4-(Butoxycarbonyloxy)benzyl 2-(6-methoxynaphthalen-2-yl)propanoate (58): 
 
Clear oil, 36% yield; Rf 0.65 (1:4 EtOAc:Hexane); 
1
H NMR (500 MHz, CDCl3):  δ 7.65-
7.68 (dd, 2H, J = 5.68, 8.52 Hz), 7.62 (bs, 1H), 7.36 (dd, 1H, J = 8.48 Hz), 7.22 (d, 2H, J 
= 8.42 Hz), 7.06-7.13 (m, 4H), 5.03-5.11 (dd, 2H, J = 12.5, 29.3 Hz), 4.23 (t, 2H, J = 
6.67 Hz), 3.90 (s, 3H), 3.86-3.90 (q, 1H), 1.66-1.73 (m, 2H), 1.56 (d, 3H, J = 7.15 Hz), 
1.41-1.46 (m, 2H), 0.95 (t, 3H, J = 7.40 Hz); 
13
C NMR (CDCl3):  δ 13.7, 18.5, 18.9, 30.6, 
45.5, 55.3, 65.8, 68.8, 105.6, 119.0, 121.1, 126.0, 126.3, 127.2, 128.9, 129.2, 129.3, 
133.7, 133.8, 135.5, 150.9, 153.7, 157.7, 174.4; Calcd. for C26H28O6 (436.50):  C, 71.54,; 
H, 6.47; Found:  C, 71.11; H, 6.33.  
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4-(Butoxycarbonyloxy)benzyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetate (59): 
 
Yellow oil, 49% yield; Rf 0.40 (1:4 EtOAc:Hexane); 
1
H NMR (500 MHz, CDCl3):  δ 
7.62 (d, 2H, J = 8.53 Hz), 7.44 (d, 2H, J = 8.54 Hz), 7.30 (d, 2H, J = 8.56 Hz), 7.13 (d, 
2H, J = 8.58 Hz), 6.90 (d, 1H, J = 2.48 Hz), 6.85 (d, 1H, J = 9.00 Hz), 6.65 (dd, 1H, J = 
2.53, 9.00 Hz), 5.10 (s, 2H), 4.24 (t, 2H, J = 6.68 Hz), 3.75 (s, 3H), 3.69 (s, 2H), 2.35 (s, 
3H), 1.69-1.74 (m, 2H), 1.40-1.46 (m, 2H), 0.96 (t, 3H, J = 7.39 Hz); 
13
C NMR (CDCl3):  
δ 13.4, 13.5, 19.0, 30.4, 30.6, 55.7, 66.1, 68.8, 101.2, 111.9, 112.4, 115.0, 121.3, 129.2, 
129.5, 130.6, 130.8, 131.2, 133.5, 133.9, 136.0, 139.3, 151.0, 153.6, 156.1, 168.3, 170.6; 
Calcd. for C31H30ClNO7 (564.03):  C, 66.01; H, 5.36; N, 2.48; Found:  C, 66.03; H, 5.53; 
N 2.42.  
4-(Butoxycarbonyloxy)benzyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate (60): 
 
Clear oil, 53% yield; Rf 0.71 (1:4 EtOAc:Hexane); 
1
H NMR (500 MHz, CDCl3):  δ 7.31-
7.35 (m, 4H), 7.21 (dd, 1H, J = 1.41, 7.52 Hz), 7.13-7.15  (m, 2H), 7.10 (dd, 1H, J = 
1.52, 7.65 Hz), 6.90-6.97 (m, 2H), 6.85 (bs, 1H), 6.54 (d, 1H, J = 8.01 Hz), 5.15 (s, 2H), 
4.24 (t, 2H, J = 6.68 Hz), 3.84 (s, 2H), 1.70-1.74 (m, 2H), 1.40-1.46 (m, 2H), 0.96 (t, 3H, 
 95 
J = 7.38 Hz); 
13
C NMR (CDCl3):  δ 13.7, 19.0, 30.6, 38.6, 66.4, 68.8, 118.4, 121.3, 122.1, 
124.0, 124.2, 128.1, 128.9, 129.5, 129.6, 130.9, 133.3, 137.8, 142.7, 151.1, 153.6, 172.1; 
Calcd. for C26H25Cl2NO5 (502.39):  C, 62.16; H, 5.02; N, 2.79; Found:  C, 62.07; H, 5.06; 
N 2.72.  
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Chapter 3:  In Vitro and In Vivo Investigation of SM Drugs     
3.1 Introduction 
3.1.1 The Ellman Assay 
 The activities of esterases such as acetyl- and butyrylcholinesterase can be easily 
determined using the colorimetric Ellman assay.135  In this assay, 5,5’-dithiobis(2-nitro-
benzoic acid) (DTNB) is used as the colorimetric reagent and acetylthiocholine (ATCh), 
a derivative of ACh, is used as the substrate.  Upon enzymatic hydrolysis of the substrate, 
a thiol is released which cleaves the dithiol of DTNB to yield a yellow dianion, as shown 
in Scheme 3.1.  Visible absorption at 412 nm is dependent upon the concentration of the 
dianion (based on Beer’s Law) and therefore absorption correlates directly with enzyme 
activity.  Half maximal inhibitory concentrations (IC50) for a given inhibitor can then be 
determined by comparing enzyme activity with and without a range of inhibitor 
concentrations (Figure 3.1).  A known inhibitor of AChE can be used as a standard to 
ensure that the assay is functioning correctly.  In the experiments presented in this 
Chapter, the potent AChEI tacrine hydrochloride was used as a standard.136   
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Scheme 3.1: Chemical Reaction Between Thiocholine and DTNB in an Ellman Assay.
135
 
 
 
Figure 3.1:  Dose-Response Curve of Compound 41 (IC50 of 4.34 µM). 
3.1.2 Mouse Ear Vesicant Model  
 Several models exist to evaluate the anti-inflammatory properties of a given 
compound.  One of the most commonly used methods to screen for SM drugs is the 
MEVM which is used to measure the protective or therapeutic effect of a given drug 
against vesicant-induced edema and inflammation.61  CEES, a SM analogue commonly 
termed “one-armed mustard”, is a vesicant which induces tissue damage that is 
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comparable, yet less severe, to that of SM.  CEES is commonly used to simulate mustard 
effects since the use of SM for such purposes is restricted to government labs.   
 For a more general investigation of the inflammatory properties of these 
molecules, a second mouse ear model was used with 12-O-tetradecanoylphorbol-13-
acetate (TPA), or “phorbol ester”, as the proinflammatory agent.137  Screening against this 
agent is used as the “gold standard” to search for effective anti-inflammatory drugs.  TPA 
is a phorbol ester which activates protein kinase C and induces the release of histamine, 
proteases, and other proinflammatory mediators.138, 139  Unlike SM and related haloalkyl 
vesicants, the biological action of TPA is not based on DNA alkylation.  Hence, TPA was 
chosen to assay the library of NSAID-AChEI conjugates for a wider range of anti-
inflammatory properties.  All MEVM results presented in this Chapter are against either 
CEES or TPA.  These results were obtained from collaborators at Rutgers University.     
 MEVM results are traditionally expressed as a percentage suppression of edema 
relative to a positive control (i.e. vesicant without treatment).  In these studies, between 3 
and 5 female cluster of differentiation-1 (CD-1) mice are used per treatment group.  For a 
given treatment group, there are control ears (treated with CH2Cl2 or acetone vehicle 
only), exposed ears (exposed to CEES/TPA only), and experimental ears (pretreatment 
with drug followed by CEES/TPA exposure).  The masses of ear punches taken 5 h 
following CEES or TPA exposure are then averaged and the percent reduction of edema 
is calculated using Equations 3.1 and 3.2.62  
       100*
c
ce
W
WW
REW

                                      (3.1) 
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   100*%
u
ut
REW
REWREW
reduction

                    (3.2) 
where REW is the relative ear weight, We is the weight of the CEES- or TPA-exposed ear 
(with or without drug pretreatment), Wc is the weight of the control ear (exposed to 
solvent vehicle only), REWt is the mean REW of the pretreated ears, and REWu is the 
mean REW of the untreated CEES- or TPA-exposed ears.   
3.1.3 Statistical Significance of MEVM Data 
 Because there can be substantial variation of the ear punch biopsy weights within 
treatment classes,61-63 determining the statistical significance of our MEVM data proved 
problematic.  Analysis of variance (ANOVA) methods are commonly used to determine 
the probability that two groups are statistically the same (or different).140  In other words, 
it is a test of the null hypothesis which states that there are no differences between the 
means of different populations.  One-way ANOVA is a straightforward statistical 
technique which can be performed using common software such as Microsoft Excel and 
GraphPad Prism.  Moreover, this method has been previously used to analyze MEVM 
data.62, 63  With the one-way ANOVA, a P-value is calculated which reflects the statistical 
probability that the null hypothesis is true.  Acceptable P-values are less than 0.05, 
meaning that there is a 5% chance that the means of the populations of interest are the 
same.  Statistical significance of all MEVM data presented herein is indicated based on 
calculated P-values, where 
*
 signifies a P-value of less than 0.05 and 
**
 signifies a P-value 
of less than 0.005.   
 One of the challenges of this project has been deriving a SAR from the MEVM, a 
biological model with inherent error.62  The error in this model is especially large when 
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CEES is used as the proinflammatory agent.  The CEES injury involves excessive edema, 
therefore, collection of the CEES-treated ear punch biopsies can result in the loss of fluid 
and an inaccurate weight.  Furthermore, not every mouse develops edema following 
CEES treatment and/or responds to treatment with a given drug, resulting in inconsistent 
data within a given MEVM experiment.  Besides histological investigations of vesicant-
exposed tissue, there are very few validated animal models of vesication.  The MEVM 
results presented in the subsequent sections of this Chapter have been used as a 
preliminary screen in order to choose candidates for further study.  The data presented in 
Tables 3.4, 3.5, 3.7, and 3.8 can be divided up into four classifications:  (1) very active 
compounds which suppress edema by 70-100%, (2) moderately active compounds which 
suppress edema by 40-70%, (3) slightly active or inactive compounds with 0-40% 
suppression, and (4) compounds which promote irritation (i.e. negative suppression).  It is 
important to note that a dorsal skin nitrogen mustard (NM) mouse model is currently 
being developed by our collaborators at Rutgers University.  In this model, various 
methods are used to assess blister severity, including traditional edema measurements, 
histological examinations, and the generation of blister severity scores.  The NM blister 
obtained in this assay is reproducible; therefore, the overall error of the model is lower.  
The most active compounds chosen from the MEVM pre-screen will be rescreened in the 
NM model in due course.     
3.2 Anticholinesterase Potencies 
3.2.1 Overview of the Structure of AChE 
 AChE is a fast-acting enzyme whose primary function is to hydrolyze ACh at 
neuromuscular junctions.  As described in Chapter 2, AChE substrate hydrolysis involves 
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a Ser200, His440, and Glu327 catalytic triad.110  In all sources of AChE, the active site is 
located at the bottom of a deep and narrow gorge lined with aromatic and hydrophobic 
amino acids such as Trp, Tyr, and Phe.141  This gorge is commonly referred to as either 
the hydrophobic gorge or the aromatic gorge, terminology which will be used throughout 
this dissertation.  The SAR study presented herein suggests that the aromatic gorge is one 
of the structural elements of the enzyme which interacts with the most potent AChEIs of 
the NSAID-AChEI conjugates.        
3.2.2 Structure-activity Relationship of Class 1, 2, and 3 Compounds   
 Anticholinesterase activities were determined for all novel NSAID-AChEI 
conjugates using the Ellman assay (Table 3.1).  As a control, the parent NSAIDs and 
precursors of each compound were screened and were deemed inactive compared to the 
test compounds (IC50 > 1000 µM, data not shown).  Inhibitor potencies range from 0.51-
3400 µM.  The most active inhibitor (7) has an IC50 comparable to that of galantamine, a 
natural alkaloid and potent AChEI which is on the market for the treatment of AD.142   
 Further examination of Class 1 and 2 activities reveals that Class 1 compounds 
are more potent than Class 2 by at least a factor of four. The significant loss in activity 
upon elimination of the linker in Class 2 is likely because the lipophilic aromatic linker is 
needed to maximize π-π stacking interactions143 with the Trp, Tyr, and Phe residues near 
the active site of AChE.144  In Chapters 4 and 5, the specific interactions of NSAID-
AChEI conjugates with aromatic AChE residues are explored in more detail using 
enzyme kinetics and computational studies.  Moreover, Class 1 compounds are at least 10 
times more lipophilic than their Class 2 counterparts, which may increase hydrophobic 
interactions with the active site gorge of the enzyme.  Interestingly, the more hydrophilic 
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nitrogen compounds of Class 2 were at least 20 times less potent than the corresponding 
carbon and silicon analogues, which is consistent with the hypothesis that hydrophobic 
interactions at the active site gorge are responsible for the high potency of Class 1 
compounds.  In most cases, the silicon bifunctionals were slightly more potent than the 
carbon bifunctionals.  These data are in agreement with studies done by Cohen et al. who 
found that 2-(trimethylsilyl)ethanol has a 2.3-fold higher affinity for AChE than 3,3-
dimethylbutanol.109    
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Table 3.1:  Anticholinesterase Activities of Class 1, 2, and 3 Molecules.  
       
   *A precise IC50 was not obtained due to limits in inhibitor solubility. 
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 Based on preliminary results, it is clear that elimination of the lipophilic linker of 
Class 1 is detrimental to in vitro activity.  On the other hand, inclusion of the alkyl aryl 
linker in these molecules may cause unwanted toxicity through the formation of an 
alkylating quinone methide upon hydrolysis of the carbonate bond.  In an attempt to 
optimize anticholinesterase potency while minimizing potential toxicity, a third 
compound class containing less toxic linkers along with linkers with documented anti-
inflammatory activity was designed. 
 HMBA (Figure 3.2), a phenolic small molecule commonly termed vanillyl 
alcohol, was first investigated as an alternative linker.  This compound is found in ginger 
extracts and has demonstrated anti-inflammatory properties in a number of in vivo 
models.  For example, vanillyl alcohol inhibits both COX activity and ROS generation in 
rat basophilic leukemia cells.122  Moreover, when screened in a carrageenan-induced 
model of inflammation, a 30 mg dose of this compound reduced edema by 28% and the 
total number of leukocytes by 61%.145  Anticholinesterase activities of HMBA derivatives 
29 through 32 were comparable to those of their Class 1 counterparts (Table 3.1).  The 
intermediate HMBA-AChEI conjugate (Figure 3.2) was 10-fold less potent than the final 
compounds with an IC50 of 25 µM (data not shown), confirming that linking an NSAID 
to the benzyl alcohol of HMBA enhances in vitro activity.   
 
Figure 3.2:  HMBA (left) and the 3,3-Dimethylbutyl-HMBA Standard (right).   
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 Although the HMBA linker should enhance anti-inflammatory activity, there is 
still a possibility of forming a quinone methide intermediate upon hydrolysis of the 
carbonate bond.  While it is known that the 2-methoxy quinone methide, if formed, 
would be extremely reactive and would be quenched by solvent prior to any interactions 
with biological nucleophiles,146, 147 the complete elimination of this type of alkyl-aryl 
linker was next explored.  In an attempt to circumvent any toxicity issues, amino acids 
(AAs) were investigated as alternate linkers.  AAs are ideal linkers because they are non-
toxic, and several AAs, including Val, Phe, and Gly, have demonstrated anti-
inflammatory and anti-mustard activity.121122  As with the HMBA derivatives, AA 
conjugates 34 through 48 largely maintained potency compared to Class 1, with a more 
pronounced loss of activity in compounds 37, 39, 45, and 46 (Table 3.1).  Furthermore, 
the AA-AChEI precursors lacking the NSAID (Figure 3.3) were all inactive, with IC50 
values greater than 100 µM (data not shown).  These data indicate that the choline 
mimics alone (or AA linked choline mimics) do not have a significant affinity for AChE.  
Submicromolar anticholinesterase activities are obtained only when the choline mimics 
are covalently linked to aromatic and lipophilic NSAIDs such as diclofenac.      
 
Figure 3.3:  Precursors of Class 3 Proline, Glycine, Phenylalanine, and Valine 
Conjugates, Respectively. 
3.2.3 SAR of NSAID Amides  
 NSAID amides were explored in addition to Class 1, 2, and 3 molecules.  Table 
3.2 shows a comparison between the traditional esters of Class 2 and the corresponding 
 106 
amides.  Compounds 49 and 51 maintained anticholinesterase potencies, with only a 
slight loss of activity due to the alteration of the linker.  The potency of compound 50, 
however, was three-fold lower than the corresponding ester.  Although the potency of 
amide 52 was 2.3-fold lower than that of ester 18, it is still the most potent of the series 
and should be considered for further study.  In Section 3.6, MEVM data are presented for 
amides 49 through 52.  The data are then compared to activities observed with the 
traditional Class 2 esters in order to determine whether or not gradual NSAID release was 
more beneficial than the rapid NSAID release observed with the Class 2 esters.  This 
amide series was also generated to investigate whether the molecules as a whole are 
active in vivo or if the combination of NSAID release and AChE inhibition is important.      
Table 3.2:  Comparison of Ester and Amide Anticholinesterase Activities. 
NSAID No. IC50 (µM) No. IC50 (µM) Ester:Amide AChE Selectivity 
  Esters Amides  
Ibuprofen 9 24.6 ± 15 49 31.3 ± 1 1.3 
Naproxen 12 19.7 ± 2 50 59.2 ± 5 3.0 
Indomethacin 15 9.75 ± 0.9 51 10.8 ± 2.5 1.1 
Diclofenac 18 2.69 ± 0.2 52 6.3 ± 0.5 2.3 
  
3.2.4 SAR of n-Butyl Derivatives of Bifunctionals  
 n-Butyl analogues of Class 1 and 2 compounds were also synthesized in order to 
investigate the effect of eliminating the choline mimic on anticholinesterase activity.  As 
presented in Table 3.3, most of the compounds containing the choline mimics were 1.6 to 
100-fold more potent than the corresponding n-butyl compounds.  Among the most 
selective for a choline versus n-butyl substitution were diclofenac conjugates 7, 18, and 
19, as well as ibuprofen derivatives 9 and 10.  It is clear that linking the NSAIDs to a 
choline mimic is essential for potent anticholinesterase activity, although even the n-butyl 
substitution does result in a moderate affinity for the enzyme in most cases.    
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Table 3.3:  Comparison of n-Butyl Analogues to Traditional Bifunctionals. 
*
A precise IC50 was not obtained due to limits in inhibitor solubility. 
3.2.5 Discussion of the High Potency of Diclofenac Conjugates  
 The most active AChEIs in all three compound classes are derivatives of 
diclofenac.  This high potency may be because of the chlorine substituents on the pendent 
aromatic ring of diclofenac which promote an orthogonal orientation of the two rings, as 
shown in the energy-minimized structure of conjugate 7 (Figure 3.4).  This orientation 
allows for enhanced π-π stacking interactions with aromatic residues lining the gorge of 
AChE (Trp84, Phe330, and Trp279 in Torpedo californica (Tc) AChE), as suggested by 
previously reported SAR and computational studies.143  Diclofenac is also the most 
lipophilic NSAID incorporated into Class 1, 2, and 3 compounds.  The high lipophilicity 
promotes hydrophobic interactions with nonpolar amino acids along the active site gorge 
of the enzyme.  Refer to Chapter 5 for a more detailed computational analysis of the 
interactions between diclofenac and AChE.     
 
NSAID No Linkage  AChEI IC50 (µM) No AChEI IC50 
(µM) 
Choline:Butyl 
Selectivity 
Diclofenac 7 Benzyl C 0.51 ± 0.02 60 n-Butyl 2.6
*
 5.1 
Diclofenac 8 Benzyl Si 1.36 ± 0.1 -- --- --- 1.9 
Ibuprofen 9 Ester C 24.6 ± 15 53 n-Butyl NA >100 
Ibuprofen 10 Ester Si 25.7 ± 5 -- --- --- >100 
Naproxen 12 Ester C 19.7 ± 2 54 n-Butyl 31.2 ± 3 1.6 
Naproxen 13 Ester Si 13.9 ± 0.3 -- --- --- 2.2 
Indomethacin 15 Ester C 9.75 ± 0.9 55 n-Butyl 9.51 ± 1 0.98 
Indomethacin 16 Ester Si 5.43 ± 0.3 -- --- --- 1.8 
Diclofenac 18 Ester C 2.69 ± 0.2 56 n-Butyl 50.8 ± 3 19 
Diclofenac 19 Ester Si 2.66 ± 0.3 -- --- --- 19 
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Figure 3.4:  Energy-Minimized Structure of Compound 7 (Generated using Schrödinger 
Software). 
3.3 Mouse Ear Vesicant Model 
3.3.1 SAR of MEVM Activities (CEES)  
 A MEVM was performed by collaborators at Rutgers University to screen for 
effective anti-inflammatory and anti-vesicant compounds.  For comparison, all NSAIDs 
and drug precursors were screened (Table 3.4).  None of the individual NSAIDs screened 
provided significant topical protection against CEES-induced inflammation, and 
ibuprofen enhanced the severity of the blister by 15%.  The topical irritation observed 
with ibuprofen alone may explain the irritating effect of some of the ibuprofen conjugates 
within this series (vide Table 3.4).    
 Many of the novel NSAID-AChEIs reduced vesication between 60 and 98%, 
values at least three times greater than those of the parent NSAIDs alone.  A correlation 
was observed between lipophilicity, measured by calculated partition coefficients 
(clogP), and MEVM results.  In all three classes, the most lipophilic compounds were 
often the most active in the MEVM (Table 3.4).  For example, highly lipophilic 
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candidates 5 and 7 were also the most active Class 1 compounds, while the more 
hydrophilic naproxen conjugates (11, 14, and 17) were two-fold less effective at 
suppressing vesication.  Additionally, the less lipophilic Class 2 compounds were overall 
less active against CEES, with only diclofenac derivative 18 showing promising anti-
vesicant activity (113%).  Galantamine conjugates 23 and 26 did, however, show 75-86% 
suppression, a value comparable to that of galantamine alone.  Several Class 3 
compounds were also active, with conjugates 29, 30, 32, 42-44, and 48 showing activities 
great than 50%.  Once again, the indomethacin and diclofenac derivatives were among 
the most active. 
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Table 3.4:  MEVM Results and ClogP Values for Class 1, 2, and 3 Compounds.  
No. % CEES Red.
a
 ClogP
b
 
Class 1 
1 20 7.37 
2 68 7.60 
3 12 6.89 
4 45 6.76 
5    91
**
 7.87 
6 62 7.09 
7    90
**
 7.87 
8 24 7.74 
Class 2 
9 -35 5.83 
11 38 -0.73 
12 NA 4.99 
13   60
*
 4.86 
15 NA 5.32 
16 38 5.19 
18 113
*
 5.97 
21 60
*
 0.62 
22 76
**
 1.26 
23 86
*
 5.84 
26 75
*
 4.99 
Class 3 
29 51
*
 7.48 
30 67
*
 7.62 
31 24 6.97 
32 58
*
 7.62 
41 -17 7.29 
42 83
*
 6.43 
43 62
*
 7.79 
44 120
**
 8.34 
48 85
*
 7.85 
Standards  
Napro. NA 2.97 
Ibu. -15 3.75 
Indo. 23 3.58 
Diclo. 17 4.12 
GAL 87
*
 -0.33 
PYR 24 -3.16 
NEO NA -2.52 
   a
Values differ from a positive control based on one-way ANOVA, 
*
P < 0.05; 
**
P 
   < 0.005. 
   b
Calculated using ChemDrawUltra 11.0. 
3.3.2 SAR of MEVM Activities (TPA) 
 Presented in Table 3.5 are percent reductions of edema and inflammation relative 
to a positive control (exposure to TPA only). Several novel agents reduced TPA-induced 
inflammation by greater than 70%. Overall, compounds from Class 2 were more potent 
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than Class 1 compounds against TPA. Compounds 13, 21, 23, and 26 had the highest 
degree of an anti-inflammatory effect (72-95%). 
 As with the CEES data, a slight dependence on lipophilicity was observed in the 
TPA results. In this case, however, the hydrophilic esters of Classes 2 and 3 were more 
active against TPA than CEES.  This trend is especially evident when comparing the 
activity of 11, 12, and 15 in the TPA versus CEES models. These agents were either 
inactive or had moderate activity against CEES, yet were especially effective against 
TPA (60-75%). 
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Table 3.5:  Comparison of CEES and TPA MEVM Results for Class 1, 2, and 3 
Compounds.   
No. % CEES Red.
a
 % TPA Red.
a
 
Class 1 
1 20 41
*
 
2 68 17 
3 12 73 
4 45 70
*
 
5    91
**
 21
*
 
6 62 75
**
 
7    90
**
 56 
8 24 31-42
*
 
Class 2 
9 -35 NA 
11 38 73
**
 
12 NA 69-76
*
 
13   60
*
 84
**
 
15 NA 76
*
 
16 38 47
**
 
18 113
*
 29
*
 
21 60
*
 72-80
**
 
22 76
**
 57
*
 
23 86
*
 95
**
 
26 75
*
 89
**
 
 Class 3  
29 51
*
 68
*
 
30 67
*
 62 
31 24 50 
32 58
*
 23 
41 -17 Irritant 
42 83
*
 42 
43 62
*
 79
**
 
44 120
**
 90
**
 
47 59 107
**
 
Standards  
Napro. NA 100
*
 
Ibu. -15 -33 
Indo. 23 75
*
 
Diclo. 17 58
**
 
GAL 87
*
 92
**
 
PYR 24 22 
NEO NA -10 
   
   a
Values differ from a positive control based on one-way ANOVA, *P < 0.05;  
   **P < 0.005. 
   b
NA:  Not active. 
Several compounds in all three classes reduced TPA-induced inflammation and 
edema by at least 50-75%. The potent anti-TPA effects of the simple esters suggest that 
activity is linked to both the rate of NSAID release and skin penetrability. It is important 
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to note that both anti-CEES and anti-TPA activity likely depend upon both the parent 
NSAIDs and the prodrugs themselves, as previous results have shown that NSAIDs have 
different rates of transdermal absorption.148, 149   
3.3.3 Comments on the Statistical Significance of MEVM Data  
 Based on one-way ANOVA analysis, the TPA results were more reliable than the 
CEES results, with a greater number of P-values less than 0.005 (Table 3.5).  For the 
CEES data, a percent suppression of up to 40% was not always statistically significant, 
while the TPA percentages were significant, even when only 20-30% suppression was 
observed.  CEES data lower than 30-40% were not considered significant and it was 
assumed that these compounds were not effective anti-vesicants.  As was noted in Section 
3.1.2, these data serve as a preliminary indicator of anti-vesicant and anti-inflammatory 
activity and the top candidates will be re-screened in a more accurate NM model.          
3.4 Rate of NSAID Release in Plasma  
 To determine the effectiveness of the NSAID-AChEI conjugates as NSAID 
prodrugs, the plasma half-lives of a set of Class 1 and 2 compounds were determined 
using high performance liquid chromatography (HPLC; Figure 3.5).  A plot of 
concentration (determined from the area under the curve of the appropriate HPLC peak) 
versus time for the prodrug and the parent NSAID was generated for candidates from 
each compound class (Figure 3.6).  Next, the plasma half-life was easily calculated from 
a plot of the log of the percentage of the prodrug remaining versus time (Figure 3.7).  The 
semi-log plot also indicates the order of the hydrolysis reaction, with linear correlations 
reflecting first-order kinetics.  Finally, using the linear regression of the semi-log plot, 
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log(50%) is substituted in for the prodrug concentration (y) and the half-life (x) is 
determined.150 
In compounds 1-19, the parent NSAIDs were released with half-lives ranging 
from 5-458 min.95  All of the compounds screened demonstrated first-order hydrolysis 
kinetics.  Direct combination of the two therapeutic components via an ester linkage led 
to faster NSAID release in Class 2 agents (5-111 min) compared to Class 1 (135-468 
min).  The rapid rate of NSAID release observed in the Class 2 esters may explain the 
high efficacy that these agents have against TPA.  (Recall that naproxen, diclofenac, and 
indomethacin alone are 60-100% effective against TPA, as shown in Table 3.5.)  On the 
other hand, the CEES or SM-induced blister is a slow-developing lesion resulting from 
DNA alkylation, protease activation, and an inflammatory response.26 Considering the 
gradual development of SM lesions,5 Class 1 agents seem more appropriate as SM 
therapeutics because of their gradual release of the parent NSAID as well as their high 
lipophilicity which allows for enhanced skin penetration.   
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Figure 3.5:  Example HPLC Chromatogram Showing the Hydrolysis of Compound 7 in 
Plasma. 
 
Figure 3.6:  Plasma Hydrolysis of Prodrug and Release of Diclofenac Over Time for 
Compound 7. 
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Figure 3.7:  Semi-log Plot of the Plasma Hydrolysis of Compound 7.   
 Direct choline esters 11, 14, and 17 were completely hydrolyzed after 10 min, 
suggesting that these compounds would not make suitable prodrugs.  The neostigmine- 
and pyridostigmine-like conjugates also released the parent NSAIDs with half-lives of 
less than 5 min.  Such rapid NSAID release may be due to the quaternary nitrogen 
present in the aforementioned compounds.  The quaternary nitrogen mimics ACh and 
these compounds can be hydrolyzed by serum cholinesterases.  Furthermore, the 
neostigmine and pyridostigmine derivatives are active site inhibitors of AChE (Refer to 
Chapter 4) and are likely rapidly hydrolyzed by esterases present in the plasma and skin.  
Galantamine esters 23 and 26 did not show significant hydrolysis after more than 12 h 
(Table 3.6).  This may be due to the presence of a sterically hindered secondary ester, 
which is resistant to hydrolysis by plasma esterases.  Preliminary results show that 
compound 23 is hydrolyzed slowly in rat skin homogenate (t1/2 of 772 min, data not 
shown),151 suggesting that the galantamine esters would suitably treat SM poisoning via 
the gradual release of two separate anti-inflammatory and anticholinergic moieties.  The 
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mechanism of hydrolysis, however, is complex and the drug was not fully hydrolyzed in 
the duration of the experiment.  These studies suggest that drug 23 is being metabolized 
prior to the complete release of the NSAID and the AChEI.151       
Table 3.6. Hydrolysis of Class 1 and 2 Compounds in Human Plasma.
a 
a
Hydrolysis measured in human plasma (80:20 plasma:PBS) at 37 
o
C. 
b
Half-lives determined by plotting the semi-log of prodrug disappearance.   
3.5 Evidence Supporting the Cholinergic Anti-inflammatory Pathway  
3.5.1 Investigation of n-Butyl Analogues 
 Preliminary in vitro and in vivo investigations of the NSAID-AChEI library 
suggest that many of these compounds are both potent AChEIs and effective suppressors 
of vesication in the MEVM.  Despite these data, it remained unclear whether or not the 
cholinergic anti-inflammatory pathway was the reason for such high anti-vesicant 
activity.  Was it possible that these lipophilic compounds were simply acting as NSAID 
delivery devices?  To answer this question, n-butyl esters and carbonates of each NSAID 
were prepared and screened in the AChE and MEVM assays.  As shown in Table 3.7, 
replacing the choline mimic with an n-butyl group in naproxen ester 12 decreased 
anticholinesterase and anti-CEES activity by 36% and 21%, respectively.  Also, the 2-
(trimethylsilyl)ethyl ester of ibuprofen (10) was active against AChE (IC50 of 26  µM) 
while the n-butyl ester of ibuprofen was inactive up to 100 µM.  Compound 10 was also a 
3.6-fold more potent anti-vesicant than the corresponding n-butyl compound.  Finally, 
Class 1 (Ester-Carbonate Series) Class 2 (Ester Series) 
Compound t1/2
 
(min)
b 
Compound t1/2
 
(min)
b 
1 204 12 38 
3 135 13 63 
4 253 14 < 5 
5 468 18 111 
7 357 21 < 5 
  23 >12 hr 
  24 < 5 
  26 >12 hr 
  27 < 5 
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replacing the 3,3-dimethylbutyl choline mimic with an n-butyl group in diclofenac 
compound 7 led to a 5-fold loss in anticholinesterase activity as well as a complete 
elimination of the anti-CEES activity observed with the original compound.  From these 
data it is clear that, when all other structural elements are conserved, attenuation of 
anticholinesterase activity by replacing a choline mimic with an n-butyl group has a 
negative effect on potency in the MEVM.   
Table 3.7:  Comparison of Anticholinesterase and Anti-CEES Activities of Derivatives 
of Choline Mimics with n-Butyl Analogues.          
Cmpd. No. Choline Mimic n-Butyl Derivative 
 IC50 (µM) % CEES
a
 IC50 (µM) % CEES
a
 
7 0.51 90
**
 2.6 NA 
10 26 50  NA 14 
12 19.7 75 31 59 
16 5.43 38 9.51 9 
a
Values differ from a positive control based on one-way ANOVA, *P < 0.05; **P < 0.005. 
 
3.5.2 MEVM Activity of Known NSAID Prodrugs  
 Known NSAID prodrugs lacking anticholinesterase activities have also been 
screened against CEES in the MEVM.  Acemetacin, the glycine ester of indomethacin 
currently approved for arthritis treatment,152 suppressed CEES-induced inflammation by a 
mere 35%.  The known farnesyl ester of indomethacin153 and the polyethylene glycol 
(PEG) ester of naproxen reduced in vivo inflammation by 53% and 46%, respectively.  
Even though these prodrugs should result in enhanced NSAID delivery and dermal 
penetration, their inflammation suppression is 20-60% lower than that of the NSAID-
AChEI conjugates presented herein.  This evidence suggests that AChE inhibition plays 
an important role in ameliorating CEES-induced injury in vivo.  Specifically, these 
studies indicate that topical administration of AChEIs results in significant blister 
suppression in the MEVM.     
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 Additional support for the cholinergic anti-inflammatory pathway is that the 
known AChEI and anti-Alzheimer’s agent, galantamine, suppressed CEES and TPA-
induced inflammation by 87% and 92%, respectively.  While galantamine has 
documented anti-inflammatory properties, it is unclear whether or not AChE inhibition is 
responsible for this therapeutic effect.  It is known, however, that galantamine suppresses 
circulating levels of proinflammatory cytokines and can relieve inflammation arising 
from sepsis84 and obesity.86  Furthermore, studies by Pavlov et al. suggest that the 
α7nAChR is required for the anti-inflammatory activity of galantamine.85  While multiple 
studies by Tracey et al. suggest that the systemic administration of AChEIs results in 
peripheral inflammation suppression,85, 154-156 additional evidence is needed to support the 
hypothesis that topical administration of AChEIs provides the same effect.  The fact that 
the administration of galantamine results in such a potent anti-inflammatory activity in 
the MEVM (87%) suggests that topical AChE inhibition also has the potential to reduce 
the severity of CEES and SM vesication.  
3.5.3 Effect of the Rate of NSAID Release on MEVM Potency 
 Because many of the NSAID ester-carbonates (Class 1) and simple esters (Class 
2) release their parent NSAIDs in plasma with half-lives of 5-468 min, we have made the 
assumption that at least a portion of the parent molecules is cleaved by the time the 
MEVM ear punch biopsies are taken (5 h post-exposure).  Consequently, the high anti-
inflammatory activity observed for many of these molecules (especially those with very 
short plasma half-lives) may be primarily because of NSAID release, not because of 
AChE inhibition.  To explore the effect of the rate of NSAID release on in vivo anti-
inflammatory activity, a set of NSAID amides was synthesized and studied (Table 3.8).  
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For amide analogues 49, 50, and 51, changing the linkage from an ester to an amide 
significantly improved anti-CEES activity by 70-109%.  The diclofenac amide, however, 
demonstrated considerably lower MEVM activity than the corresponding ester, perhaps 
because of its slightly lower lipophilicity.            
 
Table 3.8:  Comparison of Anti-inflammatory Activities of Esters and Amides.   
NSAID Ester Amide 
 No. IC50 (µM) % CEES
a
 No. IC50 (µM) % CEES
a
 
Ibuprofen 9 24.6 -35 49 31.3 43
*
 
Naproxen 12 19.7 NA 50 59.2 109
**
 
Indomethacin 15 9.75 NA 51 10.8 75
**
 
Diclofenac 18 2.69 113
*
 52 6.3 33 
 a
Values differ from a positive control based on one-way ANOVA, *P < 0.05; **P < 0.005. 
 
 It is well documented that ester bonds are more labile than amide bonds.  For 
example, previously reported kinetic rate constants reflect that polyesters are cleaved 8 
times faster than polyamides.157  Since both the NSAID and the choline mimic (3,3-
dimethylbutanol) are much less active (or inactive) against AChE compared to the parent 
drug, cleavage of the ester or amide bond results in a drastic loss of anticholinesterase 
activity.  Presumably, much of the anti-CEES activity observed with the rapid-releasing 
simple esters is from NSAID release rather than AChE inhibition.  The fact that many of 
the compounds which maintain anticholinergic activity for a longer duration of time (5, 
7, 49, 50, and 51) are also potent anti-inflammatory agents strongly suggests that AChE 
inhibition plays a critical role in suppressing CEES-induced edema and inflammation.     
3.6 Limitations of Novel NSAID-AChEI Conjugates  
 Although many Class 1 compounds are potent against AChE and CEES/TPA, 
several drawbacks to these molecules exist.  While the diclofenac and indomethacin 
derivatives are also the most effective against CEES, their high clogP values (greater than 
5) suggest that these compounds are very lipophilic and could therefore have reduced 
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bioavailability.  Such high lipophilicity is also associated with poor aqueous solubility.  
As a result, there has been much difficulty studying these molecules under true 
physiological conditions, without the need for a cosolvent.   
 Formulating such lipophilic molecules containing labile ester bonds has also 
proven problematic.  Several different types of topical formulations have been explored 
for these molecules.  Hydrogels were first considered since they are drug delivery devices 
suitable for the treatment of severe blisters.  Specifically, hydrogels keep the site of injury 
moist, improve healing, promote a gradual release of the active drug, and require a 
minimal number of applications.158  Anumolu et al. found that administration of an 8-arm-
PEG thiol hydrogel containing the protease and TNF-α converting enzyme (TACE) 
inhibitor doxycycline resulted in improved healing of NM-induced injury in a mouse 
model.158  The doxycycline hydrogel was also sustained on the skin for up to 10 days, 
hence minimizing the number of applications required.  Considering such promising 
results against NM, the hydrogel was one of the first formulations considered for NSAID-
AChEI conjugates.  While the ester and carbonate linkages of these compounds allow for 
in vivo NSAID release, they are also unstable in the presence of nucleophilic compounds 
such as thiols in the presence of heat, which eliminated the possibility of using a hydrogel 
formulation.  Replacing the ester and carbonate linkages of these molecules with amide 
and carbamate linkages will result in enhanced compound stability and will expand the 
formulation possibilities.  Specifically, NSAID amides 49 through 52 are promising 
candidates because of their improved stabilities and potent anticholinesterase and anti-
inflammatory activities.      
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 Two topical formulations have been explored by our collaborators at Rutgers 
University.  The first formulation contained dimethyl isosorbide (DMI), a penetration 
enhancer, with caprylic and capric triglycerides (GTCC).  Briefly, the formulation was 
100 mg/mL of the drug in 83.3% GTCCs, 14.7% DMI, and 1.96% ethanol (used to 
solubilize lipophilic drug candidates).  Although this formulation was suitable for many 
hydrophilic NSAID-AChEI conjugates, one of the top Class 1 leads, compound 5, was 
immiscible in this formulation and separated into two distinct layers.  An alternative 
formulation has been designed and optimized containing 85% ethyl oleate (EO) and 15% 
DMI.  Both of the above formulations were used with candidate Class 1 and 2 molecules.  
It was found that the labile ester bonds of these molecules are maintained upon 
formulation.  As shown in Figures 3.8 and 3.9, compounds 5 and 13 are stable in the 
GTCC:DMI formulation for 2 weeks at room temperature.  Compound 5 is also stable in 
the DMI:EO formulation (Figure 3.10).  These DMI formulations also promote increased 
drug penetration which may lead to improved healing.  Longer stability studies under 
elevated temperature and humidity conditions must be carried out once a final 
formulation is chosen.   
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Figure 3.8:  Stability of Compound 5 in GTCC:DMI Formulation After 2 Weeks at 
Room Temperature. 
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Figure 3.9:  Stability of Compound 13 in GTCC:DMI Formulation After 2 Weeks at 
Room Temperature. 
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Figure 3.10:  Stability of Compound 5 in DMI:EO Formulation After 2 Weeks at Room 
Temperature. 
 
3.7 Conclusions 
 While Class 2 compounds are more synthetically accessible than Class 1 
molecules, in vitro and in vivo screening has revealed that the former are much less 
active.  On average, the simple esters are 10-fold less potent against AChE than the ester 
carbonates (Table 3.1).  In addition, these compounds suppress mustard-induced edema 
and inflammation to a lesser extent in many cases (Table 3.5).  It is likely that the more 
rapid NSAID release observed with Class 2 compounds is detrimental to anti-CEES 
activity.  Class 3 compounds containing amino acid linkers seem to be the most 
promising candidates for future study because (1) their anti-inflammatory and 
anticholinesterase properties are comparable to those of Class 1, (2) many have more 
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desirable solubility and stability properties than Class 1 compounds, and (3) there is no 
possibility for the formation of a toxic quinone methide intermediate upon hydrolysis of 
the carbonate bond.  NSAID amides 50 and 51 are also top candidates from the library of 
NSAID-AChEI conjugates because they inhibit AChE in the low micromolar range, 
suppress inflammation in the MEVM up to 100%, demonstrate enhanced aqueous 
solubility, and provide a more gradual in vivo NSAID release.  From these studies, it is 
clear that the potent anti-vesicant properties observed with several NSAID-AChEI 
conjugates is from a delicate balance between the rate of NSAID release, the 
anticholinesterase activity, and the drug lipophilicity. 
 The observed activities of the n-butyl substituted conjugates provided indirect 
evidence of the cholinergic anti-inflammatory pathway.  In most cases, replacing the 
traditional cholinergic moiety with an n-butyl group leads to a significant decrease in 
anti-vesicant and anticholinesterase activity (Table 3.7).  Additionally, known lipophilic 
NSAID prodrugs without anticholinesterase properties demonstrated much lower 
inflammation suppression in the MEVM compared to NSAID-AChEI conjugates.  While 
it is known that central AChE inhibition suppresses cytokine release, these results suggest 
that potent anti-vesicant effects can be observed upon topical administration of an 
AChEI.       
3.8 Experimental  
3.8.1 Ellman Assay 
 AChE (Type V-S from electrophorus electricus), ATCh iodide, DTNB and 
tacrine hydrochloride were obtained from Sigma-Aldrich (Saint Louis, MO). Methanol 
was obtained from EMD Chemicals (Gibbstown, NJ). Cholinesterase inhibition was 
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assayed spectrophotometrically at 412 nm according to Ellman’s method.135 Assays were 
performed in polystyrene 96-well plates (Corning 96-well flat transparent) and a 
conventional micro-plate reader was employed for kinetic readings (Tecan's Infinite 200 
multimode). The following reagents were added to the wells: 200 µL of 0.5 mM DTNB 
in sodium phosphate buffer (100 mM, pH 8), 30 µL of inhibitor stock solution in 
methanol, 20 µL of 1.25 units/mL of AChE in sodium phosphate buffer (20 mM, pH 7), 
and 50 µL of 3 mM ATCh in buffer (100 mM, pH 8). Immediately after the substrate was 
added, the absorption signal was measured at 30 s intervals over 5 min at 25 °C. 
Percentage inhibition was calculated relative to a negative control (methanol in place of 
the inhibitor).  The background signal was measured in control wells containing every 
reagent except for the substrate. IC50 values were obtained from a minimum of eight 
concentrations in duplicate and by fitting the experimental data with a dose-response 
curve using GraphPad Prism software (Version 5.00, San Diego, CA). 
3.8.2 Mouse Ear Vesicant Model  
 Animal studies were approved by the Rutgers University Institutional Animal 
Care and Use Committee and received human care in compliance with the institution’s 
guidelines, as outlined in the Guide for the Care and Use of Laboratory Animals prepared 
by the National Academy of Sciences. 
 Compounds were assessed as inhibitors of inflammation using the MEVM as 
previously described,61 except that female CD-1 mice (4-6 weeks old) were used.  Either 
CEES (65 µmoles) or TPA (1.5 nmol) was used to induce inflammation. To evaluate 
each compound, ears (3-4 mice per group) were treated with 20 µL of vehicle control 
(CH2Cl2 or acetone) or the test compound (1.5 µmol) in 20 µL of the appropriate vehicle. 
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After 5 h, mice were euthanized and ear punches (6 mm in diameter) were taken and 
weighed. Once the raw data were obtained, masses of ear punches were averaged and the 
percent reduction of vesicant-induced edema and inflammation was calculated using the 
method of Casillas et al.61  Raw data were analyzed using a one-way ANOVA to evaluate 
statistical significance (P < 0.05).  
3.8.3 Plasma Hydrolysis  
 The rates of hydrolysis of the NSAID prodrugs were determined at 37 °C in fresh 
human plasma (80:20 plasma:PBS, pH 7.4).  Human plasma was obtained from the 
pooled, heparinized blood of healthy donors and was stored at -80 °C prior to use.  
Prodrugs (20 µL of a 6 mM solution in DMSO) were added to pre-heated plasma (980 
µL) and mixed gently (300 rpm) at 37 
o
C. Solutions of the same concentration of 
inhibitor in PBS:DMSO (98:2) were kept as a control to track non-enzymatic hydrolysis.  
At suitable intervals, aliquots of 100 µL were withdrawn and 200 µL of cold precipitation 
buffer (90/10 acetonitrile/water with 0.1% formic acid) were added to remove serum 
proteins.  The resulting mixture was filtered through a Mini-Uniprep™ filter (Whatman, 
PVDF membrane, 0.45 µm) and the filtrate was analyzed by HPLC (vide infra).  The 
remaining prodrug and NSAID released were monitored by single determination at 230, 
277, or 289 nm.   
 HPLC method:  Agilent high resolution XDB-C18 column (1.8 μm, 4.6 x 50mm); 
mobile phase: water (A) and methanol (B), both containing 0.1% formic acid; flow rate: 
0.8 mL/min; gradient increase from A/B:85/15 to 15/85 over 8 min, 15/85 to 10/90 over 4 
min, 10/90 to 5/95 over 4 min, 5/95 to 85/15 over 4 min, post-time 5 min; injection 
volume: 30 µL. 
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Chapter 4:  Probing Enzyme-Inhibitor Interactions 
4.1 Introduction 
4.1.1 Structure and Function of Acetylcholinesterase 
 The primary physiological function of AChE is to terminate neural signals via 
hydrolysis of the neurotransmitter, ACh.  Since the catalytic action of AChE is pivotal to 
neurotransmission, this process is rapid, with a near diffusion-limited rate, and is among 
the most efficient enzymatic reactions known.  One well established explanation for such 
rapid ACh hydrolysis is the natural dipole moment of the enzyme, which attracts 
positively charged molecules and funnels them down a long and narrow gorge leading to 
the active site.159, 160  Early studies suggested that changes in ionic strength dramatically 
affect the affinities of cationic substrates for AChE.159, 161, 162  After the crystal structure of 
AChE had been solved, Ripoll and coworkers proposed the mechanism for the 
electrostatic attraction of cationic AChE ligands based on their electrostatic potential 
calculations.  This seminal work revealed a strong dipole aligned with the gorge, leading 
to the catalytic site.160   
 In addition to the catalytic Ser, His, and Glu triad (reviewed in Chapter 2), AChE 
contains an allosteric site located at the entrance of the active site gorge termed the 
peripheral anionic site (PAS) (Figure 4.1).143  The PAS was so named because of the 
Trp286 (human AChE sequence numbering) at the entrance of the gorge which attracts 
cationic ligands and substrates.  The Trp286 residue is particularly important in ligand 
recognition through the formation of cation-π interactions.  PAS binding may be an 
initiating step in AChE-catalyzed substrate hydrolysis.  Evidence for this hypothesis is 
indicated in the work of Szegletes et al. who found that ACh weakly binds to the PAS 
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with a Ki of 1 mM.
163  Once the substrate or ligand is in the correct orientation at the top 
of the gorge, it is directed towards the bottom of the gorge where it can form cation-π 
interactions at the “anionic site” containing an additional tryptophan residue, Trp86.164  
Docking and molecular simulations by Cavalli et al. have also shown that the known 
PAS ligand, propidium, engages in π-π stacking interactions with the indole ring of 
Trp286.165  The central role of PAS residue Trp286 in cationic substrate recognition and 
binding has been confirmed by X-ray crystallography,166 site-directed mutagenesis,167 and 
molecular modeling studies.164   
 
Figure 4.1:  A Picture of Human AChE with the PAS Highlighted in Cyan and the 
Active Site in Green (Taken from Reference 164).  
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 The 20 Å deep gorge leading to the active site is lined with aromatic and 
hydrophobic amino acids such as Trp, Phe, and Tyr.  Such residues participate in 
hydrophobic and π-π stacking interactions with aryl AChE ligands.167  Gorge residues 
Phe295, Phe297, Tyr337 (Phe330 in TcAChE), and Phe338 are also conformationally 
flexible, which allows for the nearly diffusion-controlled hydrolysis of substrate.144, 167  It 
has also been proposed that the quaternary amine of ACh interacts with π-electrons of the 
amino acids lining the gorge via cation-π interactions.168  The kinetic studies herein 
indicate that structural features such as the PAS and hydrophobic gorge of AChE are 
responsible for the potent anticholinesterase activities of Class 1, 2, and 3 molecules.        
4.1.2 Enzyme Kinetics 
4.1.2.1 Reversibility of Inhibition 
 Enzyme inhibitors can be classified based on the reversibility of their action as 
well as the type and site of inhibition.  The reversibility of a given interaction is 
investigated by determining the level of enzyme activity recovered following incubation 
with an inhibitor.  The interaction is reversible if the attempted separation of the enzyme-
inhibitor complex results in complete recovery of enzyme activity.  This separation can 
be achieved using either dialysis or gel filtration chromatography.  If a time- and 
concentration-dependent decrease in enzyme activity is observed following incubation 
with the inhibitor and subsequent purification, the interaction is irreversible.  Such 
inhibition is commonly observed with very reactive compounds which are able to 
covalently modify an enzyme.  For example, pesticides and nerve agents contain reactive 
organophosphate and carbamate groups which can covalently link to the active site Ser of 
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AChE (Figure 4.2).  The irreversible modification of AChE results in a build-up of ACh 
at neuromuscular junctions and induces CNS effects such as headache, nausea, seizures, 
paralysis, and death.169, 170     
 
Figure 4.2:  Chemical Structures of Pesticides (top) and Nerve Agents (bottom).   
 Although some irreversible AChEIs are highly toxic, as observed with pesticides 
and organophosphate nerve agents, reversible inhibitors of AChE can be therapeutically 
useful.  Reversible inhibition minimizes toxic side effects and allows for a more gradual 
and controlled therapeutic effect.  Reversible inhibitors such as pyridostigmine and 
neostigmine (Figure 4.3) are structurally similar to known carbamate pesticides.  When 
exploring the use of AChEIs as drugs, it is important to confirm that the inhibition is 
reversible.   
 
Figure 4.3:  Structures of Reversible Inhibitors of AChE.  
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4.1.2.2 Methods to Determine Inhibition Type 
 The four main types of enzyme inhibition are competitive, noncompetitive, 
uncompetitive, and mixed.  Competitive inhibitors interact with the enzyme’s active site, 
while noncompetitive inhibitors interact with an allosteric site of the enzyme.  
Uncompetitive inhibition is a more complex mechanism involving the binding of an 
inhibitor to the enzyme-substrate complex rather than to the free enzyme.111  In pure 
noncompetitive behavior, binding of the substrate does not affect inhibitor binding and 
vice versa.  “Mixed” inhibition implies that there is a combination of competitive and 
uncompetitive behavior.171  Many recently designed classes of AChEIs are mixed 
inhibitors because these compounds bind to both the active site and the PAS, which 
allows them to target cholinergic and noncholinergic functions of AChE.172, 173  The term 
mixed can be used to either describe AChEIs which have an affinity for both sites 
separately or to describe inhibitors which span the active site gorge and simultaneously 
interact with both sites.   
 Michaelis-Menten kinetics model enzyme saturation and can be used to gain 
information regarding the properties of enzyme inhibition.  In the Michaelis-Menten 
equation (Equation 4.1), ν is the reaction velocity, Vmax is the maximum reaction velocity 
obtained upon enzyme saturation, [S] is the substrate concentration, and Km is the 
Michaelis constant.  As shown in Figure 4.4, the Km is the substrate concentration at 
which the reaction velocity is half of the Vmax.      
     
][
][max
SK
SV
m 
                        (4.1) 
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 Transforms of the Michaelis-Menten equation are commonly used to probe 
whether inhibitors are competitive, noncompetitive, uncompetitive, or mixed.174  One 
such plot is a Lineweaver-Burk plot (Figure 4.4) which is based on Equation 4.2.  In this 
method, the reciprocal of the reaction velocity (1/ ν) versus the reciprocal of the substrate 
concentration (1/[S]) is plotted for a range of substrate and inhibitor concentrations.   
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111
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K
V
m

                      (4.2) 
 
Figure 4.4:  Example Michaelis-Menten Plot (left) and Lineweaver-Burk Plot (right).   
 
 The intersection point(s) on the resulting graph reveal the type of inhibition:  an 
intersection on the ordinate axis (y-axis) reflects competitive inhibition, an intersection 
point on the abscissa (x-axis) reflects noncompetitive inhibition, and parallel lines with 
no intersection points reflect uncompetitive inhibition (Figure 4.5).111  In mixed 
inhibition, there are either multiple intersection points or an intercept above the abscissa, 
in quadrant II.   
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Figure 4.5:  Examples of Double Reciprocal Plots Showing Competitive (left), 
Noncompetitive (center), and Uncompetitive Inhibition (right).   
 Inhibitors can also be classified as linear or nonlinear, depending on the rate 
equation.  One of the simplest examples of linear inhibition is competitive inhibition in 
which the substrate and the inhibitor compete for the same site.  This interaction can be 
described by Equation 4.3, 
     
][
]][[
EI
IE
K i                 (4.3) 
where Ki is the inhibition constant, [E] is the concentration of free enzyme, [I] is the 
inhibitor, and [EI] is the enzyme-inhibitor complex. In linear inhibition, the end result is a 
completely inactivated EI complex (or an ESI complex for uncompetitive inhibition) with 
a reaction rate of zero.   
 Nonlinear inhibition, however, is incomplete:  the velocity of the enzymatic 
reaction does not reach zero, even at high inhibitor concentrations.  This type of 
inhibition does not conform to traditional Michaelis-Menten kinetics.  It results in a 
mixture of EI and ESI complexes, both of which can form the end product (in the 
enzymatic action of AChE, this would be choline).111  The two nonlinear forms of 
inhibition are parabolic and hyperbolic.  In these forms of inhibition, the slopes of the 
lines increase with increasing inhibitor concentration; however, the increase varies either 
hyperbolically or parabolically.  In other words, the Vmax and Km parameters vary 
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nonlinearly based on the inhibitor concentration.111  Some example Lineweaver-Burk 
plots reflecting hyperbolic noncompetitive inhibition are shown in Figure 4.6.     
 
Figure 4.6:  Example Double Reciprocal Plots Showing Hyperbolic Noncompetitive 
Inhibition.   
4.2 Reversibility of AChE-Inhibitor Interactions 
 An investigation of the reversibility of the interactions between AChE and several 
NSAID-AChEI conjugates was carried out because irreversible AChEIs are highly 
toxic.175  Following a 30 min incubation of AChE with inhibitors from Classes 1 and 2, 
gel filtration chromatography resulted in a high recovery of enzyme activity, indicating 
reversible inhibition (Table 4.1).  In these experiments, the ratio between the activity of 
the enzyme incubated with an inhibitor over the activity of the enzyme without an 
inhibitor indicates the percent recovery of activity.  A known reversible AChEI, tacrine, 
was additionally screened and resulted in a 95% restoration of enzyme activity.  
Conversely, previously described reversibility studies of Heindel’s arylcholine carbonate 
pesticides (Chapter 2, Section 2.2) resulted in up to 95% AChE inactivation following a 
15 min incubation.108  In these studies, enzyme activity was not restored upon Sephadex 
gel filtration, a strong indication of irreversible inhibition.          
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Table 4.1:  Reversibility of Enzyme-Inhibitor Interactions for Class 1 and 2 Molecules. 
 
4.3 Site of Enzyme Inhibition:  Competitive versus Noncompetitive  
 The site of enzyme inhibition was probed to gain further insight into the 
mechanism of action of the NSAID-AChEI conjugates.  Previous experiments 
investigating the reversibility of chloroalkyl carbonate pesticides (Chapter 2, Scheme 2.2) 
indicated that these compounds act via an irreversible pathway, with a time- and 
concentration-dependent enzyme deactivation.108  The original hypothesis presented in 
Chapter 2 was that novel Class 1, 2, and 3 compounds were inhibiting the enzyme in a 
competitive manner because of the structural similarity between the uncharged choline 
mimic and the natural substrate of AChE.  Since the NSAID has the potential to act as a 
good leaving group, a reasonable hypothesis was that Class 1 alkylaryl compounds would 
release a quinone methide and irreversibly inactivate the enzyme via a suicide mechanism 
similar to that presented in Chapter 2 (Scheme 4.1).  The studies described in the 
previous section, however, indicated that Class 1 and 2 molecules inhibit the enzyme in a 
reversible manner.  An investigation of which AChE site was being targeted was carried 
out.     
No. NSAID AChEI % Recovery No. NSAID AChEI % Recovery 
Class 1 (Ester-Carbonates) Class 2 (Esters) 
1 Ibu. C 101 ± 8 9 Ibu.  C  107 ± 20 
2 Ibu. Si 88 ± 10 10 Ibu. Si 92 ± 10 
3 Napro. C 99 ± 4 11 Ibu. N
+
 99 ± 5 
4 Napro. Si 98 ± 3 12 Napro. C 117 ± 10 
5 Indo. C 78 ± 2 13 Napro. Si 100 ± 1 
6 Indo. Si 86 ± 1 14 Napro. N
+
 93 ± 10 
7 Diclo.  C 87 ± 10 15 Indo. C 80 ± 2 
8 Diclo. Si 104 ± 20 16 Indo. Si 73 ± 4 
    17 Indo. N
+ 
101 ± 6 
    18 Diclo. C 99 ± 4 
    19 Diclo. Si 90 ± 10 
    Tacrine·HCl (Standard) 95 
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Scheme 4.1:  Proposed Suicide Mechanism of Class 1 Inhibitors of AChE.    
 Based on Lineweaver-Burk plots, all Class 1 and 2 analogues of the choline 
bioisosteres (-CO-O-CH2-CH2-X-(CH3)3; X = C, Si, N
+
) demonstrated noncompetitive 
inhibition, with intersections in the third quadrant (Figures 4.7 and 4.8).111  This behavior 
indicates hyperbolic noncompetitive inhibition, which is a form of nonlinear or partial 
inhibition (Section 4.1.2.2).  Aromatic residues lining the PAS have affinity for the 
lipophilic and aromatic groups of the Class 1 and 2 inhibitors.  This hypothesis is further 
supported by the evidence that Class 1 molecules containing the additional aromatic 
linker are at least four-fold more potent AChEIs than Class 2 compounds.  These 
lipophilic compounds may interact with the PAS and hinder substrate entrance to the 
active site by sterically blockading ACh or by inducing a conformational change in the 
enzyme to slow substrate binding and/or choline release.     
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Figure 4.7:  Lineweaver-Burk Plot of Class 1 Compound 8 which Shows Hyperbolic 
Noncompetitive Inhibition (inhibitor concentrations are in µM).    
 
 
 
Figure 4.8:  Lineweaver-Burk Plot of Class 2 Compound 10 which Shows Hyperbolic 
Noncompetitive Inhibition.    
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 The direct AChEI-NSAID conjugates of Class 2 were also screened along with 
their AChEI standards.  These include the galantamine esters (20, 23, and 26) and the 
neostigmine esters (22, 25, and 28).  As shown in Figure 4.9, the neostigmine standard 
alone demonstrated pure competitive behavior, with a single intersection point on the 
ordinate.  Lineweaver-Burk plots of the neostigmine conjugates revealed that these 
compounds inhibit the enzyme competitively, with the intersection point on the ordinate 
(Figure 4.10).  This behavior was expected because of the quaternary amine of 
neostigmine which may have affinity for active site residue Trp86.  These kinetic data 
also suggest that the neostigmine portion of the Class 2 esters is the primary reason for 
the competitive behavior of these compounds.  While the uncharged, lipophilic 
compounds of Classes 1 and 2 have affinity for the residues of the PAS, the direct 
neostigmine-NSAID conjugates all contain a quaternary amine which interacts with 
Trp86 of the active site via cation-π interactions.143       
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Figure 4.9:  Lineweaver-Burk Plot of the Neostigmine Standard Reflecting Competitive 
Inhibition. 
 
Figure 4.10:  Lineweaver-Burk Plot of 28 Reflecting Competitive Inhibition.  
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 Galantamine alone was screened and demonstrated mixed competitive behavior, 
with intersections on both the ordinate and the abscissa (Figure 4.11).  Interestingly, 
galantamine esters 20 and 23 demonstrated pure noncompetitive behavior, with all lines 
intersecting on the abscissa (Figures 4.12 and 4.13).  It is reasonable that access to the 
active site would be limited by linking an NSAID to a bulky alkaloid such as 
galantamine.  Although the galantamine esters contain a quaternary amine at 
physiological pH, the steric bulk of the ligand is likely the reason for the observed 
noncompetitive behavior.  
 
Figure 4.11:  Lineweaver-Burk Plot of Galantamine Reflecting Mixed Competitive 
Inhibition.  
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Figure 4.12:  Lineweaver-Burk Plot of Compound 20 Reflecting Pure Noncompetitive 
Inhibition.  
 
Figure 4.13:  Lineweaver-Burk Plot of Compound 23 Reflecting Pure Noncompetitive 
Inhibition.  
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 Lineweaver-Burk plots were also generated for several Class 3 amino acid 
conjugates and interesting behavior was observed.  As shown in Figure 4.14, the amino 
acid conjugates are hyperbolic noncompetitive inhibitors of a special type.  This 
inhibition is different from the behavior observed with Class 1 and 2 molecules:  while 
the slopes of the lines increase with increasing inhibitor concentrations for Class 1 and 2 
molecules (Figures 4.7 and 4.8), the opposite trend is observed with Class 3 molecules.  
Additionally, the intersection point for Class 1 and 2 molecules is located in quadrant III, 
while the intersection for Class 3 molecules is located in quadrant I.  The behavior 
observed with Class 3 molecules indicates that the inhibitor decreases the rate of 
enzymatic substrate hydrolysis but also enhances the enzyme’s affinity for the 
substrate.111  So, depending on the substrate and inhibitor concentrations, Class 3 
compounds can act as both enzyme activators and enzyme inhibitors.  It is currently 
unclear how this unique inhibitory behavior will affect the therapeutic action of these 
compounds.  This behavior may be an explanation for the decreased MEVM activity of 
some of the Class 3 agents.           
 The observed difference in inhibition type between the two sets of molecules may 
arise because the amide NH of Class 3 molecules can act both as a hydrogen-bond donor 
and acceptor while the ester and carbonate group of Class 1 and 2 molecules can only act 
as an acceptor.  Moreover, amide bonds are more conformationally flexible than ester 
bonds:  while esters adapt the Z conformation, amides are known to form mixtures of Z 
and E isomers with Z/E ratios ranging from 90:10 to 50:50.176-178  This additional 
flexibility may affect the orientation with which Class 3 molecules interact with the 
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enzyme.  Docking studies which provide further insight into the interactions responsible 
for the two distinct inhibitory mechanisms are presented in Chapter 5.            
 
 
 
Figure 4.14:  Lineweaver-Burk Plot of 48 Reflecting Hyperbolic Noncompetitive 
Inhibition.  
 Finally, the NSAID amide analogues have been investigated for their site of 
interaction with the enzyme (Compounds 49-52).  The NSAID amides all demonstrate 
hyperbolic noncompetitive behavior of the same type as that observed with the amino 
acid conjugates (Figure 4.15).  Again, it is suspected that the amide NH promotes 
different types of interactions with AChE due to additional hydrogen-bonding and 
conformational flexibility.     
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Figure 4.15:  Lineweaver-Burk Plot of 49 Reflecting Hyperbolic Noncompetitive 
Inhibition.  
4.4 Conclusions 
 In this Chapter, the type and reversibility of inhibition was explored for several 
Class 1, 2, and 3 molecules.  Perhaps the most critical finding was that all of these novel 
compounds are reversible inhibitors of AChE, making them suitable for therapeutic use.  
While the original hypothesis was that the choline mimic of Class 1 molecules would 
promote competitive enzyme inhibition, double reciprocal plots revealed that molecules 
containing an uncharged “pseudo-substrate” as the anticholinergic portion demonstrates 
hyperbolic noncompetitive behavior with third quadrant intersections.  This behavior is 
likely because such ligands participate in hydrophobic and π-π stacking interactions along 
the aromatic gorge.  The NSAID amides and Class 3 amino acid conjugates also 
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demonstrated hyperbolic noncompetitive behavior, although of a different type than that 
observed with Class 1 and 2 compounds.  It is suspected that the amide group of these 
compounds results in a slightly different interaction with AChE.  Class 2 neostigmine 
analogues are all competitive inhibitors because of cation-π interactions of the quaternary 
amine of these compounds with Trp86 of the AChE active site.  Interestingly, Class 2 
galantamine conjugates are true noncompetitive inhibitors because of the steric bulk of 
the ligand which limits access to the active site.  In the following Chapter, docking 
studies will be presented which further support these findings.   
4.5 Experimental 
4.5.1 Reversibility Studies 
 Inactivated enzyme was obtained by incubating 20 units of AChE in 1 mL of 
sodium phosphate buffer (20 mM, pH 7) with the inhibitor (55 µL). Stock solutions of the 
inhibitors were prepared in methanol and the final concentration of inhibitor in the assay 
was 52 µM.  A control incubation was run with the enzyme and methanol in the absence 
of an inhibitor. After 30 min incubation at 25 °C, an aliquot of 500 µL was applied to a 
standardized Sephadex G-25 Medium column (PD MiniTrap™) and eluted with 3 mL of 
100 mM sodium phosphate buffer (pH 7) containing 0.1% triton 100X (used to stabilize 
the enzyme).  Protein content was assayed using a micro BCA Protein Assay kit 
(ThermoScientific). Enzyme activity was then measured using Ellman’s method, as 
described in Chapter 3, Section 3.8.1.135  
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4.5.2 Lineweaver-Burk Plots 
 The plots were generated using a fixed amount of enzyme (0.025 units)
*
 with 
varying concentrations of both substrate (50-1000 µM final concentrations) and inhibitor 
(1-100 µM final concentrations).  Enzyme activity was then assayed using Ellman’s 
method (Chapter 3, Section 3.8.1)135 and 1/ν vs. 1/[S] was plotted for each inhibitor 
concentration.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
*
 One unit is equal to the amount of enzyme needed to catalyze the reaction of 1 µmol of substrate per 
minute. 
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Chapter 5:  Docking of Bifunctionals to Acetylcholinesterase and Cyclooxygenase 
5.1 Introduction  
5.1.1 Molecular Modeling and Docking 
 Over the past few decades, molecular modeling has become a powerful medicinal 
chemistry tool which can be used to gain valuable information about ligand-receptor 
interactions.  Docking is a computational method which predicts preferred orientations of 
receptor-ligand complexes and scores the binding affinity of the resulting interaction 
(usually in kcal/mol).179  This method has revolutionized drug discovery and allowed for 
the more rapid screening and optimization of drug candidates.  Various docking packages 
exist, including Glide (Schrödinger, LLC), Sybyl (Tripos), DOCK (University of 
California, San Francisco), and Gold (Cambridge Crystallography Data Center).  The use 
of additional software is required to minimize the energies of ligands and receptors and to 
prepare the receptor site for docking (vide infra).  It is also essential to have sufficient 
knowledge about the receptor in order to ensure that the docking results obtained are 
consistent with known structural information.         
 All data presented in this Chapter have been generated using Schrödinger 
software.  LigPrep was used to minimize ligand energies and Epik was used to predict 
ligand protonation states under biological pH.  The docking calculations were performed 
with Glide (Grid-based LIgand Docking with Energetics).180, 181  Schrödinger software was 
chosen because Glide docked ligands more accurately than other commercially available 
programs in the screening of a training set containing 195 known protein-ligand 
complexes.182    
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 Prior to docking, it is necessary to prepare the crystal structure of the protein or 
enzyme in order to obtain accurate results.  This involves several steps which are 
essentially automated using Schrödinger software.  After the protein-ligand structure is 
imported, it is recommended to delete any multimeric units in order to obtain a monomer 
and to simplify the receptor structure.  Another important step is to add hydrogen atoms 
since they are usually omitted in crystal structures.  In order to further simplify the 
docking calculations, non-essential water molecules present in the receptor (water 
molecules that are more than a chosen distance away from the active site or centroid of 
docking) are removed.  The final step involves an energy minimization of the receptor 
using the optimized potentials for liquid simulations-all atom (OPLS-AA) molecular 
mechanics forcefield.  This minimization reorients side chains of Ser, Thr, Tyr, and Cys 
residues and ensures that the root mean square (rms) deviation of non-hydrogen atoms 
from their original coordinates remains within user guidelines.180            
5.1.2 Glide Docking Software  
 Glide exploits a series of hierarchical filters to rapidly and accurately search the 
position, orientation, and conformation of a given ligand relative to the receptor site.  
First, a prescreening is performed to determine the spatial fit of the ligand into the active 
site of the receptor molecule.  This step minimizes the amount of conformational space 
which will be screened in subsequent calculations.  Unsuitable ligand conformations or 
ligands which do not fit into the site are eliminated.  The remaining ligand poses (i.e. 
position and orientation relative to the receptor) are minimized using the OPLS-AA 
forcefield.  A Monte Carlo simulation is then performed on three to six poses with the 
lowest energies.  Briefly, Monte Carlo simulations are empirical calculations which 
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involve random sampling to predict the behavior of a given system.183  Such calculations 
are used when a large number of degrees of freedom are involved, such as those found in 
biological macromolecules.   
 Following the Monte Carlo simulation, the top ligand poses are scored using an 
empirical scoring function termed GlideScore (Equation 5.1).  
ΔGbind =    Clipo-lipoΣf(rlr) + 
    Lipophilic-Lipophilic Term 
 
Chbond-neut-neutΣg(Δr) h(Δα)+Chbond-neut-chargedΣg(Δr) h(Δα) + Chbond-charged-chargedΣg(Δr) h(Δα)  
H-bonding Term 
 
+           Cmax-metal-ionΣf(rlm)          +                 CrotbHrotb          +            
                       Metal-Ligand Term     Frozen Rotatable Bonds  
 
      Cpolar-phobVpolar-phob            +             CcoulEcoul                                                    
Polar, Non-H-Bonding Atom in Hydrophobic Region       Coulomb Energies                                                                                                                                      
    CvdWEvdW            +         Solvation Terms                       (5.1) 
            vdW Energies  
The GlideScore equation contains several terms which together provide a reasonable 
prediction of ligand-receptor binding affinities.  The first term is the lipophilic-lipophilic 
term which is based on the van der Waals (vdW) radii of lipophilic ligand (l) and receptor 
(r) atoms (rlr).  The hydrogen bonding (H-bonding) term is separated into three weighted 
functions which depend upon the charges of the donor and acceptor atoms.  In this 
function, Δr is the deviation of the H-bond length from 1.85 Å and Δα is the deviation of 
the hydrogen bond (H-bond) angle from 180
o
.  Variables g and h account for the 
deviation of H-bonding distances and angles from 1.85 Å and 180
o
, respectively.  These 
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parameters incorporate a 1.00 kcal/mol score for distances within 0.25 Å and angles 
within 30
o
 of the stated parameters.  Partial scores (< 1.00 kcal/mol) are applied when 
distances or angles are outside of this range.  The metal-ligand interaction term is based 
on rlm which is the distance between the ligand (l) and the metal (m).  The fourth term 
describes frozen rotatable sp
3
-sp
3
 or sp
2
-sp
3
 bonds in which both sides of the bond are in 
contact with the receptor.184  The fifth term is unique to the Glide docking algorithm and 
it involves an energy reward for polar, non-H-bonding atoms in hydrophobic regions.  
The next two terms involve contributions from Coulombic and vdW ligand-receptor 
energies.  Finally, several solvation terms are incorporated into this scoring function.  
Overall, the solvation model rewards the solvation of charged and polar protein and 
ligand groups.  This model also incorporates penalties for water molecules which are 
trapped in hydrophobic pockets of the protein.  These GlideScore parameters have been 
described extensively by Friesner et al. and are beyond the scope of this work.180         
 Glide software quantifies vdW, Coulombic energy, H-bonding, hydrophobic, 
cation-π, π-π stacking, and electrostatic interactions.  The scoring is additionally based on 
rewards and penalties.  For example, a ligand with a low molecular weight (< 500 
Daltons) receives a reward.  Penalties can be given for solvent-exposed hydrophobic 
groups, as well as unfavorable rotations, desolvation, and intra-ligand contacts.  The 
overall docking score for a given ligand-receptor complex is a combination of the 
contributions from all of the above interactions in kcal/mol.  More negative docking 
scores reflect stronger receptor affinities and more stable receptor-ligand complexes.   
 Three docking precision levels are available with Schrödinger software:  high-
throughput virtual screening precision (HTVS), standard precision (SP), and extra-
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precision (XP) docking.  HTVS is mainly for very large ligand libraries, while SP and XP 
Glide are used for smaller sets of ligands.  SP or XP Glide can also be performed on the 
top ligand poses generated from HTVS because the SP and XP modes are more precise, 
however they also require more central processing unit (CPU) time than the HTVS 
method.  Because a relatively small ligand library was screened in the docking studies 
presented in this Chapter, XP Glide was used to obtain the most refined results.  This 
equated to 6-8 h of CPU time to screen the entire library, depending on the receptor.  It is 
also important to note that, while there are more intensive algorithms available to dock a 
flexible ligand to a flexible receptor,185 the receptor is rigid in all of the docking 
experiments presented in this Chapter.  Finally, since silicon is not supported by this 
software, the studies presented herein are limited to derivatives of the carbon-containing 
choline mimics as well as the Class 2 NSAID-AChEI conjugates.  Class 1 and 2 
compounds containing silicon-based choline mimics could not be explored using this 
method.         
5.1.3 AChE Crystal Structures 
 Many receptors of therapeutic interest have crystal structures in the protein 
database (PDB) and can be studied computationally.  There is a plethora of structures of 
AChE (from Torpedo californica, mouse, human) complexed with a wide range of 
known inhibitors.  The conformation of AChE can vary depending on the ligand with 
which it complexes.  Crystallographic studies by Harel and coworkers revealed that 
conformational flexibility of Phe330, located along the active site gorge, is responsible 
for the three main AChE conformations observed:  open, half open, and closed gate.186  
These three conformations have been observed in AChE complexes with galantamine, 
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edrophonium (EDR), and tacrine (TAC), respectively.  The open gate conformation 
observed with galantamine is likely due to steric bulk of the alkaloid ligand.  In order to 
gain the most information about the preferred poses of novel NSAID-AChEI conjugates, 
docking was performed against multiple PDB structures of AChE, including AChE 
complexes with active site ligands such as tacrine (1ACJ) and edrophonium (2ACK), 
PAS ligands such as propidium diiodide (PI; 1N5R), as well as gorge-spanning ligands 
such as decamethonium (1ACL) and decidium (1J07).  These ligands are depicted in 
Figure 5.1.  
 
Figure 5.1:  Structures of Active Site, PAS, and Mixed Inhibitors of AChE. 
 In this Chapter, docking studies are used to complement conclusions from the 
SAR studies presented in Chapter 3.  To summarize the in vitro studies previously 
presented:  (1) Class 1 compounds containing a lipophilic and aromatic linker are the 
most potent inhibitors of AChE, (2) Class 2 compounds without the linker are at least 
four times less active than their corresponding Class 1 counterparts, (3) in every 
compound class, the diclofenac conjugate is the most active, and (4) the most lipophilic 
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conjugates are among the most active AChEIs.  Additionally, Lineweaver-Burk and 
reversibility studies in Chapter 4 revealed that Class 1 and 2 compounds linked to choline 
mimics are reversible, hyperbolic noncompetitive AChEIs, Class 2 neostigmine esters are 
competitive inhibitors, Class 2 galantamine conjugates are pure noncompetitive 
inhibitors, and Class 3 amino acid conjugates along with the NSAID amides are 
hyperbolic noncompetitive inhibitors of a different type than that observed with Classes 1 
and 2.  The docking results presented in this Chapter are an in depth theoretical 
investigation of the AChE-inhibitor interactions responsible for the potent activities and 
SAR studies observed in the previous two Chapters.  Since compounds in these three 
classes are all NSAID conjugates, these compounds were also docked against COX-1 and 
COX-2, two enzymes involved in the regulation of inflammation.                    
5.2 Docking to Acetylcholinesterase  
5.2.1 Docking of Standards  
 Known inhibitors of AChE were first docked to both the active site and the PAS 
in order to gain insight into the accuracy of the docking method used.  The inhibitors 
were docked to a PDB crystal structure of TcAChE complexed with EDR.  Crystal 
structures from this particular enzyme source were chosen because of the structural 
similarities with AChE from Electrophorus electricus, the enzyme used to determine in 
vitro anticholinesterase activities.  Prior to docking, EDR was removed and the receptor 
was prepared as described in the experimental section of this Chapter (Section 5.4).  
Table 5.1 presents the docking scores for each standard.  TAC docked with a score of -
12.2 kcal/mol, supporting the known high affinity of this ligand for AChE.  This affinity 
is primarily from vdW energy and electrostatic interactions, which account for 62% of 
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the overall score.  EDR also scored well in this model (-9.54 kcal/mol), which was in part 
from the π-cation interaction with Trp84 (Trp86 in human AChE), a residue which is 
known to interact with quaternary amines (Figure 5.2).164  The scores of pyridostigmine 
(PYR) and neostigmine (NEO) were slightly less negative (-6.27 to -7.12 kcal/mol), 
mainly because of a lack of H-bonding and hydrophobic interactions.  The relative rank 
of docking scores among the known actives is similar to previously reported Ki or IC50 
values.  Out of this set, TAC has the highest affinity for AChE, with reported IC50s 
ranging from 12-40 nM.187
,188  The other docked ligands have less potent IC50 and Ki 
values which range from 0.8-6.6 µM for EDR,189-196 3.1-4.7 µM for NEO,197, 198 and ~0.9 
µM for PYR,199 which is roughly consistent with the docking scores observed.  
Furthermore, the cation-π interaction observed between EDR and Trp84 was observed, 
suggesting that this is a good model for the prediction of affinities of known active site 
ligands for AChE.        
 
Figure 5.2:  Cation-π Interactions Between Quaternary Amine of EDR and Aromatic 
Residues of the Active Site of AChE. 
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 Table 5.1:  Docking Scores (in kcal/mol) of Known Standards with the Active Site of 
AChE. 
 
Ligand Lit. Ki/IC50 Score VdW Energy Hydrophob. 
Enclosure 
H-bonding Electro. Π-Cat 
TAC 12-40 nM -12.18 -5.08 -1.62 -0.70 -2.53 -0.25 
EDR 0.8-6.6 µM -9.54 -3.73 -0.90 -0.70 -2.07 -1.88 
PYR 0.9 µM -7.12 -3.75 -2.22 0 -0.19 -0.42 
NEO 3.1-4.7 µM -6.27 -3.22 0 0 -1.96 -0.76 
 
 
 The standards above were also docked to the PAS of AChE to explore the affinity 
that these ligands have for the peripheral site of the enzyme.  There is literature precedent 
for weak interactions of competitive AChEIs with the PAS of the enzyme prior to 
entering the active site gorge.163, 164  Table 5.2 summarizes all of the docking scores for the 
four ligands discussed.  The PAS inhibitor PI was also docked.  EDR and NEO both 
participate in cation-π interactions with PAS residues Trp286 and Tyr72, as shown in 
Figure 5.3.  Cation-π interactions between quaternary amines and Trp286 are well 
documented and it is a common hypothesis that the interaction of cationic ligands with 
this residue is a preliminary interaction which facilitates entrance of the ligand into the 
active site.163, 164  All compounds seem to have a relatively weak affinity for the PAS, with 
EDR showing the highest affinity and PYR and TAC showing the lowest.  Since the 
known standards scored well and docked in a reasonable orientation to both the active 
site and the PAS, this docking procedure was considered to be a good model for the 
investigation of novel NSAID-AChEI conjugates.      
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Table 5.2:  Docking Scores (in kcal/mol) of Known Standards with the PAS of AChE. 
Ligand Score VdW 
Energy 
Hydrophob. 
Enclosure 
H-bonding Electro. Π-Cat 
EDR -7.95 -2.31 0 -0.97 -2.45 -1.97 
NEO -6.74 -2.26 0 0 -1.91 -2.25 
PI -6.30 -3.89 -1.55 0 -2.24 0 
TAC -5.95 -2.04 -0.94 -0.06 -2.56 0 
PYR -5.75 -2.25 -0.50 -0.55 -2.15 0 
    
 
Figure 5.3:  Cation-π Interactions Between Quaternary Amine of EDR and Aromatic 
Residues of the PAS of AChE. 
  
 In addition to known AChEIs, synthetic precursors and other molecules related to 
Class 1, 2, and 3 compounds were screened (Table 5.3).  The first standard screened was 
ACh, shown in Figure 5.4.  This standard scored moderately (-6.51 kcal/mol), with vdW 
energy, electrostatic, and π-cation interactions providing the most stabilization.  The 
known cation-π interaction between the quaternary amine of ACh and the indole ring of 
Trp84 accounts for approximately one-third of the overall score.  An additional cation-π 
interaction was observed with Phe330, an interaction which has been observed previously 
in the crystal structure of TcAChE with a non-hydrolyzable ACh derivative (4-oxo-
N,N,N-trimethylpentanaminium iodide; OTMA) and with excess ATCh (Figure 5.5).200  It 
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should be noted that a crystal structure of the physiological AChE-ACh complex has not 
been obtained because of the near diffusion-limited rate of ACh hydrolysis.  Furthermore, 
in Figure 5.4, the carbonyl group of ACh is in proximity to the active site serine residue 
(Ser200) which strongly suggests ACh is in the correct orientation for enzymatic 
hydrolysis.  More importantly, this result shows that -6.5 kcal/mol is a reasonable score 
for an AChEI or substrate since ACh is the natural ligand.     
Table 5.3:  Docking Scores (in kcal/mol) of ACh and Synthetic Precursors with AChE. 
Ligand Score VdW 
Energy 
Hydrophobic 
Enclosure 
H-bonding Electro. Π-Cat 
Acetylcholine  -6.51 -2.01 0 -0.35 -1.99 -1.88 
3,3-Dimethylbutyl methyl 
carbonate 
-3.99 -1.95 -1.2 -0.7 -0.25 0 
3,3-Dimethylbutyl 4-
(hydroxymethyl)phenyl 
carbonate 
-5.88 -2.8 -1.88 -1.0 -0.74 0 
 
 
Figure 5.4:  Cation-π Interactions of ACh with the Active Site of AChE (PDB:  2ACK). 
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Figure 5.5:  Chemical Structures of ACh Analogues.  
 To investigate whether or not cationic PAS ligands would interact with Trp279 in 
this model, ACh was docked to an enzyme complex already containing one molecule of 
ACh in the active site.  As expected, when the AChE active site is already occupied, the 
quaternary amine of ACh interacts via cation-π interactions with PAS residue Trp279 
(Figure 5.6).  These results are also consistent with the hypothesis that ACh binding to 
the PAS initiates substrate hydrolysis (discussed in Chapter 4, Section 4.1.1).  More 
importantly, the results presented in this section suggest that reasonable AChE-ligand 
poses can be obtained at both the active site and the PAS.          
 
 
Figure 5.6:  Cation-π Interactions of a Second Molecule of ACh with the PAS of AChE 
(PDB:  2ACK). 
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 Additionally, a carbon analogue of ACh (3,3-dimethylbutyl methyl carbonate; 
Figure 5.7) was screened and scored with a 2.5 kcal/mol lower affinity (i.e. less negative 
score) than ACh.  This decrease in binding affinity is from elimination of the stabilizing 
π-cation effects observed with ACh as well as a decrease in the stabilization energy from 
electrostatic interactions (Table 5.3).  There are additional hydrophobic interactions 
observed with this standard which are not present in the ACh complex (Figure 5.4).  
These interactions are between the quaternary carbon of the standard and several Phe, 
Trp, and Tyr PAS residues.  There is no interaction of this molecule with any active site 
residues, including Trp84.  This supports the supposition that replacing the quaternary 
amine with a quaternary carbon promotes hydrophobic interactions along the active site 
gorge, although at the cost of π-cation and electrostatic interactions.   
 
Figure 5.7:  Hydrophobic Interactions of ACh Mimic with PAS of AChE (PDB:  2ACK). 
 
 Finally, the direct synthetic precursor of Class 1 molecules was docked to AChE 
(3,3-dimethylbutyl 4-(hydroxymethyl)phenyl carbonate; Figure 5.8).  This precursor has 
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an enzyme affinity that is 0.6 kcal/mol lower than ACh, with a score of -5.88 kcal/mol.  
This score reflects a moderate AChE affinity which was also observed in vitro (IC50 of 60 
± 7 µM).  Interestingly, conjugating an aromatic group to the quaternary carbon choline 
mimic results in a complex which is 1.9 kcal/mol more stable than the choline mimic 
itself.  The increased stability observed with the aromatic standard is from additional 
vdW interactions (0.85 kcal/mol), hydrophobic enclosure (0.68 kcal/mol), H-bonding (0.3 
kcal/mol), and electrostatic interactions (0.49 kcal/mol).  Once again, hydrophobic 
interactions contribute the most to the stabilization of this AChE-ligand complex.  These 
results are consistent with SAR results from Chapter 3 which show that the direct 
NSAID-AChEI conjugates (Class 2) are at least four-fold less potent inhibitors compared 
to those containing the aryl linker (Class 1).   
 
  
Figure 5.8:  Docked Structure of 3,3-Dimethylbutyl 4-(Hydroxymethyl)phenyl 
Carbonate to PAS of AChE (PDB:  2ACK). 
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5.2.2 Docking of Class 1 and 2 Compounds to Acetylcholinesterase 
 The library of NSAID-AChEI conjugates was next docked to several PDB 
structures of AChE in order to gain further insight into the orientation of ligand binding.  
Table 5.4 presents a summary of the docking scores obtained for several Class 1 and 2 
compounds which have been docked to the PAS of AChE (PDB code:  2ACK).  Scores 
ranged from -10.34 to -7.45 kcal/mol, with major contributions from vdW energy and 
hydrophobic enclosure rewards.  Since the ibuprofen used to synthesize NSAID-AChEI 
conjugates was a racemic mixture, both enantiomers of ibuprofen conjugates 1 and 9 
were screened separately.  In general, Class 1 bifunctionals had higher affinities for the 
PAS of the enzyme than the Class 2 esters.  This is consistent with SAR results presented 
in Chapter 3, where Class 1 compounds containing the lipophilic linker demonstrated 
more potent AChE inhibition than compounds missing the linker.  Specifically, the vdW 
energies of compound 1, 3, 5, and 7 contribute approximately 2 kcal/mol additional 
stabilization to the corresponding enzyme-ligand complexes than the Class 2 compounds.  
Also, while conjugates 1 and 3 had a reasonable contribution from H-bonding, 
electrostatic interactions, and a hydrophobically-enclosed H-bond, Class 2 esters 9, 12, 
and 18 did not have a significant stabilization from these types of interactions.  
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Table 5.4:  Docking Scores (in kcal/mol) of Class 1 and 2 Compounds with the PAS of 
AChE.   
Ligand Score VdW 
Energy 
Hydrophobic 
Enclosure 
Hydrophob. 
H-bond 
H-bonding Electro. 
Class 1 
1 (R isomer) -10.34 -5.95 -2.38 -1.00 -0.84 -0.44 
1 (S isomer) -9.78 -5.91 -2.17 -1.00 -0.74 -0.44 
3 -7.86 -6.03 -2.67 0 -0.86 -0.36 
5 -6.94 -5.03 -1.68 0 0 -0.05 
7 -9.75 -6.22 -2.27 -0.88 -0.64 -0.14 
Class 2 
9 (S isomer) -7.52 -3.89 -1.27 0 -0.60 -0.22 
9 (R isomer) -7.30 -3.89 -1.39 0 -0.28 -0.17 
12 -6.24 -4.66 -2.67 0 -0.35 -0.14 
15 -7.15 -4.01 -2.08 0 -1.28 -0.17 
18 -7.45 -4.78 -2.10 0 -0.18 -0.16 
 
 The docked structures of compounds 1 (R-enantiomer) and 9 (R-enantiomer) are 
presented in Figures 5.9 and 5.10.  The isobutyl-substituted ring of both conjugates 
participates in hydrophobic interactions with Phe, Tyr, and Trp residues in the active site 
gorge, for overall scores of -10.34 and -7.30 kcal/mol, respectively.  The 3 kcal/mol 
higher stabilization of the AChE complex with ligand 1 is primarily from enhanced vdW 
interactions (2.0 kcal/mol) and hydrophobic enclosure rewards (1.0 kcal/mol; Table 5.9).  
The same trend was observed between naproxen conjugates 3 and 12, indomethacin 
conjugates 5 and 15, as well as diclofenac conjugates 7 and 18.  Again, these results are 
consistent with the higher in vitro enzyme affinity observed with Class 1 compounds 
compared to Class 2.  They also suggest that the 3,3-dimethylbutyl choline mimic is not 
the only portion of these molecules responsible for anticholinesterase activities.  In the 
cases of ligands 1 and 9, the hydrophobic portion of ibuprofen itself is responsible for 
hydrophobic interactions with the enzyme.  This translates to the dramatic difference in 
scores observed between the synthetic precursor of Class 1 compounds, 3,3-
dimethylbutyl 4-(hydroxymethyl)phenyl carbonate (Figure 5.8), and conjugate 1.                
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Figure 5.9:  Docked Structure of Compound 1 (R-enantiomer) with PAS of AChE (PDB:  
2ACK). 
 
 
 
Figure 5.10:  Docked Structure of Compound 9 (R-enantiomer) to PAS of AChE (PDB:  
2ACK). 
 
5.2.3 Rationale for the High Potency of Diclofenac Conjugates 
 The docking results for diclofenac derivatives 7 and 18 correlate well with the 
anticholinesterase potencies determined in Chapter 3:  these compounds scored among 
the highest (most negative scores) in each set.  In Class 1, the score for 7 was only 0.6 
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kcal/mol less negative than the R-ibuprofen conjugate and 0.03 kcal/mol less negative 
than the S-ibuprofen conjugate.  Similarly, in Class 2, the score for diclofenac conjugate 
18 was only 0.07 kcal/mol less negative than the highest scoring compound in the set (the 
S-enantiomer of 9).  This small difference in scores is likely due to experimental error 
both in the docking model and in the Ellman assay.   
 
Figure 5.11:  Docked Structure of Compound 7 with PAS of AChE (2ACK). 
 Shown in Figure 5.11 is a complex between AChE and diclofenac conjugate 7, 
the most potent NSAID-AChEI conjugate.  Hydrophobic interactions (vdW energy and 
hydrophobic enclosure) with aromatic residues provided the largest contribution to the 
overall docking score of -9.75 kcal/mol, while H-bonding was of minimal importance and 
contributed only -0.88 kcal/mol.  VdW interactions are very important in ligand-AChE 
complexes and have been observed in crystal structures of mouse AChE with the 
polypeptide snake venom, fasciculin-2 (Fas2),201 as well as with the PAS ligands 
decidium, PI, and gallamine (Figures 5.1 and 5.12).166  The observed hydrophobic 
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interactions support the SAR from Chapter 3 suggesting that the most lipophilic NSAID-
AChEIs were also the most potent AChEIs due to hydrophobic interactions with aromatic 
residues along the active site gorge.  Specifically, Figure 5.11 depicts the hydrophobic 
enclosure of the 2,6-dichloro ring of diclofenac by Tyr, Phe, and Trp amino acids.  This 
interaction suggests that the 2,6-dichloro group does not participate in π-π-stacking 
interactions.  Instead, this compound participates in hydrophobic interactions with 
aromatic gorge residues.  This finding does not confirm our original hypothesis presented 
in Chapter 3 (Section 3.2.5) suggesting that enhanced π-π-stacking interactions are 
responsible for the high potency of diclofenac conjugates.  Instead, it appears that in this 
model, the 2,6-dichloro moiety contributes to the high AChE affinity of these compounds 
by facilitating hydrophobic interactions along the gorge.       
 
Figure 5.12:  Structure of Gallamine Ligand. 
 To gain further insight into the high potency of diclofenac derivatives and the role 
of the 2,6-dichloro substitution, non-chlorinated diclofenac analogues were also docked.  
The docked structures of 7 with and without the 2,6-dichloro substitution are overlaid in 
Figure 5.13.  While a similar orientation is observed for a majority of the molecules, two 
specific areas do not coincide:  the 3,3-dimethylbutyl moiety and the aromatic ring 
containing the 2,6-dichloro substitution in the original analogue.  As a result, the docking 
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scores of these two compounds are different, with the chlorinated derivative scoring -9.75 
kcal/mol and the non-chlorinated compound scoring 1.12 kcal/mol less negative 
(reflecting a weaker affinity).  There is a rotation of the bond adjacent to the 3,3-
dimethylbutyl group which may result in steric clashes in the non-chlorinated derivative.  
Additionally, there is a significant change in conformation in the 2,6-dichloro ring which 
has resulted in a near-orthogonal orientation.  This orientation was not observed with the 
non-chloro analogue and may account for the higher affinity of 7 for the enzyme.  These 
results indicate that the orientation of 7 may allow it to more easily fit into the aromatic 
gorge and more favorably interact with PAS residues.  It is important to note that steric 
effects in combination with electronic effects play a role in the high affinity of compound 
7 for AChE.       
 
Figure 5.13:  Structures of 7 and the Non-chlorinated Analogue of 7 Following Docking 
to AChE. 
 When diclofenac derivative 18 was docked, a dramatic conformational change 
was not observed between the original compound and the non-chlorinated version, as 
shown in Figure 5.14.  There is still a change in the orientation of the 2,6-dichloro ring; 
however, the 3,3-dimethylbutyl group is in a similar orientation for both structures.  The 
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docking scores also reflect this similarity in orientation, with compound 18 scoring -7.5 
and the non-chlorinated analogue scoring -7.9 kcal/mol.  It seems that this conformational 
change is not drastic enough to induce a significant change in enzyme affinity.  Further 
studies are underway to explore whether or not these preliminary in silico results translate 
to in vitro anticholinesterase activities.                    
 
Figure 5.14:  Structures of 18 and the Non-chlorinated Analogue of 18 Following 
Docking to AChE. 
5.2.4 Docking of Class 3 Compounds to Acetylcholinesterase 
 Class 3 derivatives containing Phe, Val, and amide intermediate linkers have also 
been docked to structures of AChE which originally contained PI (1N5R; Table 5.5) and 
TAC (1ACJ; Table 5.6).  Overall scores of Class 3 compounds docked to 1ACJ were 2-4 
kcal/mol more negative than scores observed from 1N5R docking.  These data provide 
insight into the conformation of the receptor upon binding to these molecules since the 
conformation of AChE changes depending on the bound ligand (Refer to Section 5.1.3).  
Since Class 3 compounds demonstrated in vitro anticholinesterase potencies similar to 
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Class 1 molecules, the scores observed with TAC complex 1ACJ seem to be more 
indicative of the binding orientation and affinity of Class 3 molecules for AChE.  Similar 
H-bonding, vdW, and hydrophobic interactions were observed in both sets of complexes 
(vide infra).  The less negative (lower affinity) scores for 1N5R are mainly due to 
additional penalties from ligand-receptor steric clashes as well as the destabilizing 
enclosure of polar groups in hydrophobic areas of the protein.202  Again, these data 
suggest that the specific conformation of the TAC-AChE complex can more easily bind 
to Class 3 molecules.         
Table 5.5:  Docking Scores (in kcal/mol) of Class 3 Compounds with AChE (PDB:  
1N5R). 
Ligand Score VdW Energy Hydrophobic Enclosure H-bonding Electro. 
41 (S isomer) -6.25 -4.05 -1.62 -0.7 -0.24 
41 (R isomer) -5.35 -4.65 -1.43 0 0.08 
43 -5.79 -4.73 0 -1.38 -0.56 
45 (R isomer) -5.29 -3.32 -0.85 -1.89 -0.75 
46 -5.69 -3.47 -0.3 -1.66 -0.83 
29 (R isomer) -5.54 -4.18 -1.28 0 -0.19 
29  (S isomer) -5.52 -3.99 -0.18 -0.62 -0.18 
42 -5.12 -4.3 -0.47 -0.83 -0.37 
50 -4.91 -3.8 -0.45 -0.7 -0.25 
47 -4.55 -4.36 -1.25 0 -0.05 
44 -4.48 -4.22 -1.47 -0.68 -0.16 
30 -3.6 -4.42 -0.88 0 0.02 
48 -3.98 -3.9 -0.96 -0.7 -0.17 
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Figure 5.15:  Hydrophobic Enclosure of 41 with the PAS of AChE (PDB:  1N5R). 
 Based on the SAR study in Chapter 3, Phe conjugates 41 through 44 are the most 
potent AChEIs out of the AA conjugates.  Docking results observed for these molecules 
are consistent with their high in vitro potencies, with three of the four Phe derivatives 
demonstrating the highest in silico affinity for AChE (Table 5.5).  Figure 5.15 depicts 
hydrophobic enclosure rewards for phenylalanine conjugate 41.  The aromatic ring of Phe 
participates in hydrophobic interactions with PAS residues such as Trp286, Phe297, and 
Tyr124, providing an additional 1.6 kcal/mol in stabilization.  The amide group of these 
molecules can also form H-bonds with water molecules in the gorge, as well as with 
Tyr124 (Figures 5.16).  The additional H-bonding interactions observed with Class 3 
molecules may explain the difference in the inhibition type of these molecules compared 
to Classes 1 and 2, as predicted in Chapter 4 (Section 4.3).      
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Figure 5.16:  H-Bonding Interactions of 43 with AChE (PDB:  1N5R). 
 
Figure 5.17:  H-Bonding Interactions of 46 with the PAS of AChE (PDB:  1N5R). 
 In vitro data from Chapter 3 indicate that, when the NSAID is conserved, an 
inhibitor with a Phe linker is 130-200% more potent than the corresponding Val 
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derivative.  These data are consistent with the AChE docking results which reflect a 0.5 
to 1 kcal/mol higher stability for Phe versus Val compounds (Table 5.5).  As with the Phe 
conjugates, H-bonding interactions of the amide hydrogen were observed with 46 and 48 
which provided 1.66 and 0.7 kcal/mol in stabilization, respectively (Figures 5.17 and 
5.18).  It should be noted that both compounds formed H-bonds with the known PAS 
residues Tyr72 and Trp286, which supports their noncompetitive behavior reported in 
Chapter 4.     
 
Figure 5.18:  H-Bonding Interaction of 48 with Trp286 of AChE (PDB:  1N5R). 
 Finally, NSAID amides 49 through 52 were docked against AChE, with scores 
ranging from -4.9 to -4.1 kcal/mol.  It is worth noting that the model would not dock the 
indomethacin and diclofenac amides (51 and 52) to the AChE receptor because of 
unfavorable steric clashes between ligand and receptor molecules.  Once again, H-
bonding interactions between the amide hydrogen of conjugate 50 and Trp286 of the PAS 
were observed (Figure 5.19).  These data suggest that additional H-bonding interactions 
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of the amide group of Class 3 compounds and amides may be responsible for the special 
type of hyperbolic noncompetitive behavior observed in Chapter 4.   
 
Figure 5.19:  H-Bonding Interactions of 50 with Trp286 of AChE (PDB:  1N5R).   
Table 5.6:  Docking Scores (in kcal/mol) of Class 3 Compounds with AChE (PDB:  
1ACJ). 
Ligand Score VdW Energy Hydrophob.  
Enclosure 
H-bonding Electro. 
42 -10.82 -5.28 -2.7 -0.69 0.01 
30 -9.25 -5.56 -2.7 -1.03 -0.11 
41 (R isomer) -8.91 -5.6 -2.7 -0.57 0.13 
46 -8.26 -4.39 -2.7 -1.11 0.21 
29 (S isomer) -6.7 -4.59 -2.7 0 0.15 
45 (S isomer) -6.18 -3.34 -2.52 -0.1 0.07 
 
 Docking results for Class 3 compounds against AChE complex 1ACJ are 
presented in Table 5.6.  Although many of the 1ACJ:ligand interactions are consistent 
with those observed with the 1N5R docking results presented above, the 1ACJ scores 
were overall much more negative (Table 5.6).  Some discrepancies in binding orientation 
were observed between the two docking models.  When docked to 1ACJ, the quaternary 
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carbon choline mimic of compound 45 participates in hydrophobic interactions with 
Trp279, Phe330, Phe331, and Tyr121 (Figure 5.20).  On the other hand, when docked to 
1N5R, the isobutyl-substituted phenyl ring of ibuprofen is responsible for the 
hydrophobic enclosure rewards of this compound (Figure 5.21).  It is unclear which 
orientation is preferred; although the more negative score observed with 1ACJ docking 
suggests that this complex is more stable than the 1N5R complex.  An alternative 
explanation for the discrepancy in binding modes is that the two receptor structures are 
from different sources of AChE.  The literature indicates that a range of inhibitor 
potencies can be observed with different sources of AChE.203            
 
Figure 5.20:  Hydrophobic Enclosure of 45 with PAS of AChE (PDB:  1ACJ). 
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Figure 5.21:  Hydrophobic Enclosure of 45 with PAS of AChE (PDB:  1N5R). 
 H-Bonding interactions of the amide hydrogen of Class 3 molecules with PAS 
residues were also observed upon docking to 1ACJ.  For example, both the amide 
hydrogen and the ester oxygen of Val conjugate 46 participate in H-bonding with Tyr121, 
resulting in 1.11 kcal/mol in stabilization (Figure 5.22).  It should be noted that for this 
particular inhibitor, H-bonding occurs with Tyr121 in the 1ACJ structure but with Tyr72, 
H2O1159, and H2O1193 in the 1N5R model.  A crystal structure of compound 46 with 
AChE would provide additional insight into the correct binding orientation of this 
particular inhibitor.        
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Figure 5.22:  H-Bonding Interactions of 46 with Tyr121 of AChE (PDB:  1ACJ). 
5.2.5 Limitations to Acetylcholinesterase Docking 
 While the results presented in this section are generally consistent with the SAR 
study from Chapter 3, there are some limitations to this docking model.  First of all, an 
inherent property of Glide software is to maximize H-bonding and electrostatic ligand-
receptor interactions.  This may present a problem when scoring highly lipophilic 
molecules such as the NSAID-AChEI conjugates.  Incorrect binding orientations in order 
to form a favorable H-bond may result using this method.  Schrödinger, LLC is currently 
addressing this issue by adding AChE to their library of experimental receptors.  By 
screening a training set, or a large library of known actives and inactives, perhaps an 
improved algorithm for AChE docking can be obtained.   
 One important question arose in this Chapter:  are hydrophobic interactions or π-
π-stacking interactions responsible for the high potency of diclofenac conjugates?  
Previously reported SAR and computational studies by Kapkova et al. suggest that the 
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2,6-dichloro substitution allows for enhanced π-π stacking interactions with gorge 
residues.143  However, the docking results herein suggest that the 2,6-dichloro ring 
participates in hydrophobic enclosure interactions with aromatic PAS residues (Figure 
5.11).  These hydrophobic interactions provide an alternative rational for the high 
anticholinesterase potencies observed for these compounds.  A crystal structure of one of 
the diclofenac conjugates with AChE is required to further investigate this hypothesis.     
5.3 Docking to Cyclooxygenases 
5.3.1 Structure and Function of Cyclooxygenase-1 and -2 
 The physiological role of COX is to catalyze the conversion of arachidonic acid to 
precursors of prostaglandins and thromboxanes, species which regulate important 
processes such as inflammation, pain, and platelet aggregation (discussed in Chapter 1, 
Section 1.2.1).46  While the physiological form of COX (COX-1) has been known for 
decades, an inducible COX isoform was discovered in the early 1990s.49, 50  Although the 
two isoforms are 67% homologous and the active site is well conserved, important 
structural differences exist.  X-Ray crystallography studies by Luong et al. revealed that 
the COX-2 binding site is 25% larger than the COX-1 binding site.  The larger COX-2 
site is primarily from a Val substitution in place of an Ile at position 523.204  Structural 
differences between the two COX isoforms have allowed for the design of COX-2 
selective NSAIDs in the hopes of minimizing the GI side effects observed with COX-1 
inhibitors (Chapter 1, Section 1.2.1.2).         
 Tyr385, positioned at the top of the COX active site, plays a vital role in 
arachidonic acid metabolism.  Site-directed mutagenesis revealed that replacing this 
residue with a Phe results in a loss of COX activity.  Additionally, indomethacin, a 
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competitive COX inhibitor, prevents the inactivation of COX by blocking the nitration of 
Tyr385 by tetranitromethane.205  Dietz et al. proposed that the Tyr385 radical abstracts a 
hydrogen atom from the C-13 of AA in the initial step of the COX pathway.206  Residues 
Arg120, Tyr355, and Glu524 also play important roles in COX function and NSAID 
binding.  Crystal structures of several NSAIDs with COX-1 and COX-2 show a H-
bonding network between the NSAIDs and these residues.204, 207, 208     
 The parent NSAIDs of Class 1 and 2 compounds are released with plasma half-
lives ranging from 5 min to 8 h (Chapter 3, Section 3.4).  It was hypothesized that 
NSAID release in combination with AChE inhibition play a role in the high MEVM 
activities observed with such compounds.  It remained unclear, though, whether or not 
the NSAID-AChEI conjugates themselves had any affinity for the cyclooxygenases.  
Docking was used as a tool to investigate binding affinities of the intact bifunctionals for 
COX-1 and COX-2.         
5.3.2 Docking of NSAID Standards to Cyclooxygenase-1 and -2  
 To determine the accuracy and precision of the Glide docking program, the 
NSAID standards diclofenac, ibuprofen, indomethacin, and naproxen were docked to 
both COX isoforms.  Listed in Table 5.7 are the scores for each NSAID-COX-1 complex, 
which range from -7.7 to -10.0 kcal/mol.  In all four docked structures, the well known 
H-bonding network between Tyr355 and Arg120 of COX and the carboxylate of the 
NSAID was observed, as shown in the ibuprofen-COX-1 complex (Figure 5.23).209  A 
similar H-bonding network was observed with naproxen, indomethacin, and diclofenac 
(not shown).  H-bonding interactions were important to the stabilization of these 
complexes, contributing about 20% to the overall docking score.  VdW and hydrophobic 
 180 
interactions were also very important, accounting for more than half of the stabilization 
energy.   
 
Figure 5.23:  Ibuprofen Docked to Active Site of COX-1 for a Score of -10 kcal/mol. 
Table 5.7:  Docking Scores (in kcal/mol) of COX-1 Complexed with NSAID Standards. 
Ligand Score VdW 
Energy 
Hydrophob. 
Enclosure 
H-bonding Electro. 
(R)-Ibuprofen -10.04 -4.82 -2.23 -2.15 -0.67 
(S)-Ibuprofen -9.87 -4.80 -2.19 -2.02 -0.69 
(S)-Naproxen -9.59 -5.28 -1.52 -1.79 -0.64 
Diclofenac -9.10 -4.43 -1.69 -2.12 -0.63 
Indomethacin -7.70 -3.54 -1.03 -1.30 -1.38 
 
 The NSAID standards were also docked to COX-2 (Table 5.8).  The resulting 
scores for ibuprofen and naproxen were very close to those obtained with COX-1 and the 
H-bonding network with Arg120 and Tyr355 was maintained (Figure 5.24).  The scores 
for indomethacin and diclofenac, however, were significantly less negative, suggesting a 
weaker affinity of these NSAIDs for COX-2.  Studies exploring relative COX 
selectivities revealed that indomethacin and naproxen are 78-, and 3-fold selective for 
COX-1, respectively, while ibuprofen is completely nonselective.  Diclofenac is the only 
NSAID out of the set that is two-fold selective for COX-2.210  The relative scores for 
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COX-1 and -2 docking with ibuprofen, naproxen, and indomethacin are consistent with 
the selectivities reported by Warner et al.  In the docking model used in this dissertation, 
however, the diclofenac docking scores reflected a significantly higher affinity for COX-
1.  These data suggest that the model used may not be appropriate for the docking of 
diclofenac to COX-1 or COX-2.  Consequently, docking scores of many of the diclofenac 
conjugates may not accurately reflect their COX-2 affinities and should be carefully 
considered.    
Table 5.8:  Docking Scores (in kcal/mol) of COX-2 Complexed with NSAID Standards. 
Ligand Score VdW Energy Hydrophob. 
Enclosure 
H-bonding Electro. 
(R)-Ibuprofen -9.40 -4.66 -1.45 -2.12 -1.00 
(S)-Naproxen -9.32 -4.96 -1.28 -1.99 -0.74 
(S)-Ibuprofen -9.17 -4.54 -1.51 -2.15 -0.81 
Indomethacin -5.54 -2.77 -0.60 -1.34 -0.48 
Diclofenac -5.52 -3.81 -1.56 -0.09 0.17 
      
 
Figure 5.24:  Ibuprofen Docked to Active Site of COX-2 for a Score of -9.4 kcal/mol. 
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5.3.3 Docking of Lead Compounds to Cyclooxygenase-1 and -2 
 Table 5.9 presents docking scores for a set of Class 1 and 2 molecules with COX-
1.  Figure 5.25 shows the complex of ibuprofen conjugate 1 with COX-1.  Conjugation of 
the NSAID to the choline mimic enhanced affinity for COX, reflected by a significant 
change in docking score from -10 to -14 kcal/mol.  The higher affinity of 1 for COX-1 
can be explained by enhanced hydrophobic and vdW ligand-receptor interactions which 
contribute an astounding -10.7 kcal/mol to the overall score.  This trend was also 
observed with NSAID conjugates 3 and 5, suggesting these compounds may be 
equivalent or higher in anti-COX potency compared to the NSAIDs alone.  It is 
interesting to note that, while Class 1 compounds 1, 3, and 5 had scores in the range of 
their parent NSAIDs, Class 2 compounds 9 and 18 had 2-3 kcal/mol less affinity for 
COX-1 than ibuprofen and diclofenac alone.  This activity difference may be an alternate 
explanation for why Class 1 compounds are more potent in the MEVM than Class 2 
compounds.  An in vitro COX inhibition assay showing the potencies of these 
compounds is necessary to confirm these preliminary results.   
Table 5.9:  Docking Scores (in kcal/mol) of COX-1 Complexed with Class 1 and 2 
Compounds.                              
No. Score Score  
(NSAID alone) 
VdW  
Energy 
Hydrophob. 
 Enclosure 
H-bonding Electro. 
1 (R isomer) -13.96 -10.04 -7.98 -2.70 -1.40 -0.22 
1 (S isomer) -11.28 -9.87 -8.15 -2.70 -0.96 -0.11 
3 -10.76 -9.59 -8.21 -2.00 -1.02 -0.17 
5 -9.36 -7.70 -5.13 -1.46 -1.23 -0.21 
7 -7.00 -9.10 -5.07 -1.43 -1.00 -0.05 
9 (R isomer) -8.92 -10.04 -6.24 -1.84 -1.19 -0.26 
9 (S isomer) -8.75 -9.87 -6.15 -1.81 -1.16 -0.25 
15 -8.77 -7.70 -5.42 -1.88 -1.12 -0.23 
18 -6.87 -9.10 -5.50 -2.03 -0.38 -0.13 
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Figure 5.25:  Compound 1 Docked to Active Site of COX-1 for a Score of -14 kcal/mol. 
 
 Class 1 and 2 compounds were also docked to COX-2.  Overall, the docking 
scores were slightly less negative against COX-2 compared to COX-1 (Table 5.10).  
Once again, Class 1 compounds 1, 3, and 7 demonstrated a 1-4 kcal/mol higher affinity 
for COX-2 compared to Class 2 (9, 15, and 18).  Additionally, the NSAID-AChEI 
conjugates had a higher affinity for COX-2 compared to the parent NSAIDs.  
Conjugating the NSAIDs to a choline mimic either directly or via an alkyl-aryl linker 
resulted in a 0.69 to 4.44 kcal/mol higher COX-2 affinity.  The dramatic difference in 
scores between diclofenac conjugate 7 and diclofenac itself may be due to an incorrect 
binding orientation of diclofenac itself, a point noted earlier herein.       
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Table 5.10:  Docking Scores (in kcal/mol) of COX-2 Complexed with Class 1 and 2 
Compounds.                              
No. Score Score  
(NSAID alone) 
VdW 
Energy 
Hydrophob.  
Enclosure 
H-bonding Electro. 
1 (S isomer) -10.56 -9.17 -6.93 -1.80 -1.70 -0.47 
1 (R isomer) -10.56 -9.40 -7.55 -1.81 -1.21 -0.20 
3 -10.01 -9.32 -7.88 -1.97 -0.53 0.05 
7 -9.96 -5.52 -7.14 -2.70 0 0 
12 -8.49 -9.32 -6.18 -0.97 -1.08 -0.22 
9 (S isomer) -8.47 -9.17 -5.99 -1.79 -1.05 -0.25 
9 (R isomer) -8.21 -9.40 -5.71 -1.50 -1.29 -0.32 
15 -7.79 -5.54 -4.12 -2.02 -1.26 -0.37 
18 -6.77 -5.52 -4.38 -1.79 -0.66 -0.11 
 
 
Figure 5.26:  Compound 1 Docked to Active Site of COX-2 for a Score of -10.6 
kcal/mol. 
 The same Tyr355/Arg120 H-bonding network observed in the COX-1 docking 
results was also observed with the COX-2 complexes (Figure 5.26).  H-bonding and 
electrostatic interactions contributed only moderately to the overall score (0.5 to 1.7 
kcal/mol; Table 5.10).  Once again, for all of the NSAID conjugates, vdW interactions 
and hydrophobic enclosure rewards accounted for a large majority of the overall score 
(79 to 98%).  The results presented in this section were somewhat unexpected.  Instead of 
observing moderate COX activity for the NSAID conjugates, these novel compounds 
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show significantly higher affinity for COX-1 and COX-2 due to enhanced hydrophobic 
interactions.  In vitro studies are needed to further investigate these results.    
5.4 Conclusions 
 Docking to AChE, COX-1, and COX-2 revealed interesting information regarding 
the novel NSAID-AChEI conjugates presented in this dissertation.  In both studies, 
docking of known actives to each receptor using Glide resulted in reasonable scores and 
ligand poses, validating the use of this platform to aid in the design and screening of new 
AChE and COX ligands.  In most cases, known or experimental inhibitor potencies 
correlated well with the observed docking scores.  For AChE docking, Class 1 molecules 
demonstrated higher enzyme affinities compared to Class 2, a result which correlates well 
with the SAR studies presented in Chapter 3.  This high receptor affinity is primarily due 
to hydrophobic interactions with aromatic gorge residues, as it was initially hypothesized.  
Interestingly, π-π-stacking interactions of the 2,6-dichloro moiety of diclofenac 
conjugates were not observed.  Instead, it appears in this model that this moiety 
participates in hydrophobic interactions with Phe, Tyr, and Trp PAS residues.  This 
conflicts with previously reported SAR studies which suggest that π-π-stacking 
interactions are responsible for the high AChE affinity of 2,6-dichloro-substituted 
aromatics.143  Additional H-bonding interactions with the NSAID amides (49 through 52) 
and the Class 3 amino acid conjugates were observed, which may explain the different 
type of inhibitory behavior of these compounds compared to Classes 1 and 2 (Chapter 4).   
 In all of the docking studies with COX, the previously reported H-bonding 
network between the carboxyl group of the NSAID and Tyr355/Arg120 was observed.  
Surprisingly, many Class 1 and 2 conjugates demonstrated significantly higher affinities 
 186 
for COX-1 and -2 compared to the NSAIDs alone.  Diclofenac alone did not score well 
against COX-2 even though the literature suggests that this NSAID is slightly COX-2 
selective.210  As a result, docking scores of diclofenac conjugates with COX-2 may not be 
reliable using this model.  Together, the studies herein provide computational support for 
the in vitro SAR studies presented in Chapter 3.  These results also complement nicely 
the kinetic investigations presented in Chapter 4.  X-Ray crystallography is required to 
gain additional insight into the correct binding orientations of these novel molecules.            
5.5 Experimental 
5.5.1 General 
 Schrödinger software was used to perform all docking studies.  Specifically, the 
Maestro interface was used for visualization, LigPrep was used for the energy 
minimization of ligands, the Protein Preparation Wizard was used to prepare the receptor, 
and Glide was used for ligand docking.   
5.5.2 Docking to Acetylcholinesterase  
 Crystal structures of AChE were prepared by removing the originally complexed 
ligand, adding missing hydrogen atoms, optimizing the H-bonding network, and deleting 
unwanted water molecules.  Ligands of interest were drawn and minimized using the 
OPLS2005 forcefield.  A specific zone of 1000 Å
3
 was chosen for ligand docking and the 
centroid of docking was set as the same location as the original ligand.  In some cases 
where a ligand was docked to the PAS of an AChE structure containing an active site 
ligand, PAS residues Trp279 and Phe330 were chosen as the docking centroid.     
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5.5.3 Docking to Cyclooxygenase-1 and -2 
COX-1 
 The crystal structure of ovine COX-1 complexed with ibuprofen (PDB file:  
1EQG) was prepared by removing the ibuprofen, adding missing hydrogen atoms, 
optimizing the H-bonding network, and deleting unwanted water molecules.  Ligands of 
interest were drawn and minimized using the OPLS2005 forcefield.  A specific zone of 
1000 Å
3
 was chosen for ligand docking and the centroid of docking was set as the same 
location as the original ligand (ibuprofen). 
COX-2 
 The crystal structure of mouse COX-2 complexed with naproxen (PDB file:  
3NT1) was prepared by removing the naproxen, adding missing hydrogen atoms, 
optimizing the H-bonding network, and deleting unwanted water molecules.  Ligands of 
interest were drawn and minimized using the OPLS2005 forcefield.  A specific zone of 
1000 Å
3
 was chosen for ligand docking and the centroid of docking was set as the same 
location as the original ligand (naproxen). 
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Chapter 6:  Utility of Dual-Action Compounds as Treatments for Alzheimer’s Disease 
6.1 Introduction  
6.1.1 Overview of Alzheimer’s Disease  
 AD is a debilitating and incurable form of dementia affecting an estimated 18 
million people worldwide.211  This number is growing exponentially with the aging 
population.  Hallmarks of AD include loss of cognitive function, neurodegeneration, 
neuroinflammation, the accumulation of senile plaques composed of amyloid-β (Aβ) 
peptide, and the formation of neurofibrillary tangles (from hyperphosphorylated tau 
protein).212  Current AD treatments are symptomatic and do little to prevent disease 
progression.  Recently, multifunctional drugs have emerged as the only viable treatment 
option for such a complex disease.  Based on preliminary results, novel NSAID-AChEI 
conjugates should target multiple symptoms and causes of AD through the restoration of 
cholinergic balance, treatment of neuroinflammation, and inhibition of Aβ plaque 
formation.   
6.1.2 Role of Inflammation 
 Although it is well accepted that inflammation is a symptom of AD, numerous 
studies suggest that chronic inflammation further exacerbates the primary effects of 
AD.213  AD patient brains often contain various inflammatory mediators as well as 
activated astrocyte and microglial cells which play essential roles in inflammation.214-217  It 
has been proposed that both local and systemic inflammation can contribute to the 
neurodegeneration and cognitive decline resulting from Alzheimer’s.  For example, 
epidemiological studies reveal that local inflammation in the form of head trauma can 
enhance the risk for AD development.218  Systemic inflammation in lipopolysaccharide-
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treated mice has also resulted in elevated activated microglia and enhanced 
neurodegeneration.219   
 Various inflammatory mediators are implicated in AD pathology.  Although IL-1 
is traditionally associated with an immune response, this cytokine also plays a role in 
neural function and homeostasis.220, 221  This inflammatory mediator upregulates 
expression of the Aβ precursor protein (APP) gene in human endothelial cells and may 
promote the formation of amyloid deposits in the brain.222  AD patients with systemic 
infections suffered from an enhanced rate of cognitive decline due to higher plasma 
levels of IL-1β cytokine.223, 224  Griffin et al. also found an overexpression of IL-1 in tissue 
sections of AD patient brains, suggesting that this inflammatory mediator may directly 
contribute to AD pathology.225  The cytokines TNF226 and IL-6227-230 as well as the 
cytokine receptor IL-2R231, 232 are also upregulated in AD brain microglia.  Emerging 
evidence suggests that an inflammatory response is required for Aβ-promoted 
neurodegeneration (e.g. role of IL-1 in APP expression)233 and inflammatory mediators 
colocalize with toxic Aβ fibrils.213  Based on these studies, it is clear that inflammation 
contributes to AD-associated neurodegeneration via multiple mechanisms.  In this 
Chapter, the clinical efficacy of NSAIDs in AD prophylaxis and treatment will be 
described.  Preliminary studies suggesting the advantages of novel NSAID-AChEI 
conjugates over traditional AD treatments will also be presented.     
6.1.3 The Effect of NSAIDs on AD Progression  
 For decades, NSAIDs such as indomethacin and flurbiprofen have been explored 
as AD treatments; however, many clinical studies suggest that NSAIDs are only effective 
as prophylactic agents.234-237  There is evidence suggesting that NSAIDs may slow AD 
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disease progression and make viable AD therapies.  For example, a small study exploring 
AD patients who took NSAIDs compared to those who did not revealed that those taking 
NSAIDs performed better on mental exams measuring cognitive decline.238  Furthermore, 
AD patients treated with indomethacin exhibited slightly improved cognitive function, 
while those with a placebo declined cognitively by about 11%.239 
 The NSAID, flurbiprofen, has recently been explored for AD treatment; however, 
clinical trials for flurbiprofen were recently terminated due to a lack of efficacy.240, 241  
This lack of efficacy may be, in part, due to the poor ability of NSAIDs to cross the 
blood-brain barrier (BBB), a membrane formed by endothelial cells junctions in the 
brain.  NSAIDs such as flurbiprofen, ibuprofen, naproxen, and indomethacin bind tightly 
to plasma proteins which reduces the amount of free NSAID in the blood to 5% or less 
and results in decreased brain uptake.242  Nitro esters of flurbiprofen have recently been 
found to facilitate BBB penetration and improve bioavailability in vivo.243  Lipophilic 
NSAID prodrugs such as those presented in Chapters 2 and 3 may also be suitable for the 
delivery of NSAIDs to the brain while dually regulating cholinesterase activity.   
6.1.4 The Amyloid Hypothesis 
6.1.4.1 Role of Beta Amyloid Peptide 
 The amyloid cascade hypothesis244, 245 is emerging as an additional explanation for 
AD progression and has attracted significant scientific attention over the past few 
decades.  The hypothesis states that APP, a transmembrane protein found primarily at 
neural synapses, can be cleaved by β- and γ-secretases to form small peptides which can 
aggregate and ultimately form neurotoxic plaques.246  APP fragments Aβ1-40 and Aβ1-42 
are the main components of such plaques, with Aβ1-42 being the most neurotoxic.
247  Since 
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the mechanism of Aβ aggregation is complex and poorly understood, the development of 
a clinically effective anti-amyloidogenic drug has proven unfruitful thus far.   
 In recent years, it has been proposed that the mechanism of Aβ aggregation 
involves the transient formation of small molecular weight oligomers (dimers and 
trimers), the formation of larger soluble oligomers, the formation of higher molecular 
weight oligomers and protofibrils, and ultimately the formation of neurotoxic fibrils 
(Figure 6.1).  Throughout the aggregation process, there is a pronounced shift from either 
an α-helix or a random coil-rich conformation (depending on the solvent, temperature, 
and pH conditions) to a β-sheet rich conformation.  This conformational transition has 
been confirmed using analytical techniques such as circular dichroism (CD),248 a method 
used to determine the secondary structures of peptides and proteins.  In this Chapter, CD 
will be used to investigate the effect of selected NSAID-AChEI conjugates on the 
kinetics of Aβ aggregation.         
 
Figure 6.1:  Proposed Mechanism of Aβ Fibril Formation.248    
6.1.4.2 Anti-Amyloidogenic Properties of NSAIDs   
 Compelling results suggest that NSAIDs may target AD pathologies other than 
inflammation.  The common NSAIDs ibuprofen, indomethacin, and sulindac sulfide 
significantly inhibit production of Aβ1-42 peptide in Chinese hamster ovary (CHO) cells 
and human neuroglioma cells.  Moreover, short-term oral ibuprofen administration 
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reduced levels of brain Aβ1-42 in transgenic mice by up to 39%.  Interestingly, this effect 
did not correlate with anti-COX activity since NSAIDs such as naproxen and meloxicam 
did not demonstrate antiamyloidogenic effects.249  Following this seminal work, Zhou and 
coworkers hypothesized that the mechanism by which NSAIDs suppress Aβ1-42 levels is 
mediated by inhibition of Rho,250 a small G protein involved in the regulation of cell 
signaling, growth, and movement.251           
 According to studies by Weggen et al., in order to have significant anti-amyloid 
effects, NSAIDs would have to be administered at much higher doses than those required 
for complete COX inhibition.249  It is well established that the long-term use of NSAIDs 
can lead to GI irritation, ulcer formation,47 and hepatotoxicity.252  The carboxylic acid 
group common to most NSAIDs is responsible for the GI side effects because it interacts 
with stomach mucosal and parietal cells.253  Such toxicity would be enhanced, then, at 
higher NSAID doses.  As discussed in detail in Chapter 1 of this dissertation, NSAID 
ester and amide prodrugs commonly show reduced GI irritation compared to the parent 
NSAIDs.100, 253  The compounds presented herein are hence a viable approach towards 
reducing NSAID-induced GI toxicity and may be a safer alternative to treat 
neuroinflammation associated with AD.     
6.1.4.3 Challenges of Anti-amyloidogenic Therapies 
 Much work has gone into developing inhibitors of Aβ aggregation into anti-AD 
drugs, although a successful drug has not yet been FDA-approved.  It is likely that a lack 
of mechanistic understanding of Aβ aggregation has hindered the development of a 
suitable AD treatment.248  Another challenge in this area is the intricate dose-response 
relationship commonly observed with inhibitors of protein or peptide aggregation.  For 
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example, a parallel can be drawn to the effect of Congo Red on tau aggregation in 
Huntington’s disease.  At low concentrations, this azo dye inhibits protein aggregation.  
At higher doses, though, Congo Red becomes an agonist and promotes aggregation.  
Finally, at very high concentrations, no considerable effect is observed.254  It is proposed 
that aggregation of the ligand itself may result in the observed dose-response relationship.  
The initial aggregation state (monomeric, dimeric, protofibril) of the protein or peptide 
also determines the efficacy that a given inhibitor will have on aggregation.  
Disturbingly, in vitro studies by Necula et al. suggest that drugs such as curcumin and 
indomethacin inhibit oligomer formation but promote fibril formation.255  Such issues 
complicate the search for effective inhibitors of Aβ aggregation because in vitro and in 
vivo models are not always reproducible or predictive of the clinical income.       
6.1.5 Role of the Cholinesterases   
6.1.5.1 The Cholinergic Pathway 
 The cholinergic hypothesis, stating that depleted levels of ACh lead to cognitive 
impairment in AD, is one of the most widely accepted theories describing AD 
pathology.256-258  Several AChEIs, including tacrine, galantamine, and donepezil, are 
FDA-approved for AD treatment, although the clinical outcome of AChEI-treated 
patients has been disappointing.259  As a result, there is an ongoing search for more 
effective AD treatments.        
6.1.5.2 Connections Between the Amyloid and Cholinergic Pathways 
 Several links exist between the amyloid and cholinergic pathways, suggesting that 
drugs targeting one pathway may also affect the other.260  Recent data suggest that 
neurotoxic APP fragments Aβ1-40 and Aβ1-42 interact with neuronal nAChRs.
261-264  This 
 194 
interaction may both inhibit ACh release and alter Ca
2+
 homeostasis, two processes 
which regulate cognitive function.  The most compelling evidence suggests that the 
α7nAChR and Aβ bind with high affinity and this binding interaction can be inhibited by 
ligands of α7nAChR.  Furthermore, Wang et al. found Aβ1-42 colocalized with α7nAChR 
in neurotoxic plaques and cortical and hippocampal neurons of AD patient brains.264          
 AChE may also be connected to the processing and regulation of APP and Aβ 
peptide.  Several known inhibitors of AChE have been investigated for their effects on 
APP secretion in a range of cell lines.  Some of these studies suggest that the effect a 
given inhibitor has on APP can vary depending on the cell type.265, 266  Interestingly, 
tacrine decreased APP secretion in fibroblast, glioblastoma, neuroblastoma, and 
phaeochromocytoma cells.  On the other hand, 3,4-diaminopyridine increased APP 
secretion in glioblastoma cells, but had no effect in several other cell lines. 265, 267-270    
 Recent studies suggest that AChEIs which interact with the PAS inhibit Aβ 
aggregation, while active site inhibitors have no effect.  Inestrosa et al. found that AChE 
alone accelerates Aβ aggregation and colocalizes with amyloid fibrils in the brains of AD 
patients.  It seems that AChE acts as a chaperone protein which increases the toxicity of 
Aβ.271  While this aggregation was unaffected by edrophonium, propidium suppressed 
AChE-induced peptide aggregation by 75%.272  These results suggest that a site at or near 
the PAS of this enzyme may be involved in Aβ peptide aggregation.  Following this 
seminal work, the emphasis of AD therapy has been placed on PAS or dual-binding (PAS 
and active site) ligands which target both cholinergic and amyloidogenic pathologies of 
AD.  Many of the NSAID-AChEI conjugates presented in this dissertation have affinity 
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for the PAS, as suggested by their noncompetitive inhibitory behavior, and may inhibit 
Aβ aggregation.              
6.1.5.3 Role of the α-7 Nicotinic Subunit of the ACh Receptor 
 Emerging literature suggests that the α7nAChR plays a crucial role in 
inflammation.273, 274  Stimulation of the α7nAChR results in neuroprotection259 and 
activation of this receptor leads to reduced production of insoluble Aβ peptide 
aggregates,275-279 making it a reasonable therapeutic target for AD.  Studies by Nordberg et 
al. have shown that repeated administration of nicotine, the endogenous substrate of 
α7nAChR, resulted in an 80% reduction of plaques containing Aβ1-42 in the brains of 
transgenic mice overexpressing Aβ.276, 277  Other in vitro and in vivo studies revealed 
consistent results.  Nicotine may either destabilize the characteristic β-sheet structure 
found in Aβ aggregates278 or stabilize the α-helical conformation of Aβ monomers.279  
These studies indicate that there is an intricate relationship between the amyloid pathway 
and the cholinergic pathway of AD development.   
6.1.5.4 Clinically-Approved Cholinesterase Inhibitors 
 Inhibitors of the cholinesterases are among the only FDA-approved AD 
treatments.  The clinical efficacy of these compounds varies.  In some studies, significant 
improvement in cognitive function has been observed.280-282  In others, though, results for 
patients treated with known AChEIs are only slightly better than those treated with a 
placebo.283-285  In addition, drugs such as tacrine and physostigmine are poorly tolerated 
due to hepatotoxicity.286  It is important to consider that most approved AChEIs only 
target one aspect of AD even though the disease is a result of the dysfunction of several 
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pathways and neurotransmitters.259  Multifunctional drugs such as NSAID-AChEIs are 
better candidates for AD therapy.    
6.1.6 Role of Butyrylcholinesterase in AD  
 The role of butyrylcholinesterase (BuChE) in AD has also been extensively 
explored.  BuChE is an enzyme which is 65% homologous with AChE,287 although the 
physiological function of BuChE remains unknown.  Plasma BuChE hydrolyzes ACh 
along with cocaine,288, 289 organophosphates,290 pesticides,291, 292 and other ester-containing 
toxins, making this enzyme and mutants thereof therapeutically interesting.   
 Conflicting literature exists as to whether or not BuChE inhibition is an effective 
approach for AD therapy; however, emerging literature suggests that BuChE is present in 
various regions of the brain such as the hippocampus, thalamus, and amygdala.293-295  The 
relationship between AChE and BuChE is complex because, although BuChE has been 
found colocalized with AChE in amyloid plaques, recent in vitro studies suggest that 
BuChE may reduce the rate of Aβ fibril formation in vitro.296, 297  Specifically, Soreq and 
coworkers found that the addition of BuChE to Aβ peptide (1:100 molar ratio) attenuated 
the rate of fibril formation and could potentially slow AD progression.  Conversely, the 
addition of AChE decreased the lag time of fibril formation by 90 min, thus potentially 
enhancing disease progression. 296  If Soreq’s findings are correct, it would appear that 
dual cholinesterase inhibition may actually advance disease progression by promoting Aβ 
fibril formation, although this result has not yet been tested in vivo.     
 Other studies, however, suggest a contradicting finding that BuChE inhibition 
improves cognitive function and may suppress Aβ fibril formation.  Greig et al. found 
that, in human SK-N-SH neuroblastoma cells, selective BuChE inhibition resulted in 
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reduced levels of APP and Aβ peptide.  Furthermore, BuChE inhibition led to improved 
cognitive performance in a maze and elevated levels of brain ACh in aged rats.  Reduced 
APP, Aβ1-40, and Aβ1-42 levels in transgenic mice overexpressing Aβ were also 
observed.298, 299  In another study, mice injected with Aβ1-40 were treated with the selective 
AChEI, donepezil, the dual cholinesterase inhibitor, rivastigmine, and the selective 
BuChE inhibitor, N1-phenethyl-norcymserine (PEC), to determine which type of 
inhibition provided the greatest amelioration of cognitive dysfunction.  Treatment with 
the three types of inhibitors provided significant improvement of memory retrieval and 
memory consolidation, suggesting that both selective and dual cholinesterase inhibition 
are viable approaches to treating AD.299                            
 Alternately, clinical evidence suggests that switching from a selective AChEI 
such as donepezil to a dual cholinesterase inhibitor improves cognitive function in AD 
patients.300  Andrisano et al. have hypothesized that this clinical improvement upon 
switching to a dual inhibitor is because, in later stages of AD, AChE activity decreases 
while BuChE activity increases.301, 302  Moral-Naranjo and coworkers have also found that 
peripheral neurons undergoing neurodegeneration experience a 45% reduction in AChE 
activity with a simultaneous two-fold increase in BuChE levels.303  Based on these 
studies, patients who have stopped responding to treatment with selective AChEIs may 
benefit from dual cholinesterase inhibition.  From the clinical results discussed above, 
dual cholinesterase inhibition may be a viable AD therapy.                    
6.1.7 Circular Dichroism to Investigate Beta Amyloid Aggregation   
 CD spectroscopy is commonly employed to track protein and peptide secondary 
structure in solution.  This technique can be used to obtain important information 
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regarding structural changes, including protein and peptide aggregation.  The far UV 
spectra (~180-240 nm) of proteins are strongly dependent upon the geometries of the 
protein backbone.  Electronic n→π* and π→π* transitions of amide bonds (Figure 6.2) 
can be observed in this spectral window and provide information regarding the secondary 
structure of a protein.304  CD can be used to detect α-helices, β-sheets, β-turns, and 
random coils, as shown in Figure 6.3.  α-Helices are depicted by two negative bands at 
~210 and 220 nm along with a positive band at around 190 nm.  β-Sheets have a single 
negative band at around 215 nm along with a positive peak at around 195 nm.  β-Turns 
have a negative peak around 190 nm and a positive peak at 210 nm.  Finally, the CD 
spectra for random coils consist of a negative peak at about 195 nm along with a small 
positive band at ~210 nm.        
 
Figure 6.2:  Electronic Transitions Observed in CD Spectroscopy.
304 
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Figure 6.3:  CD Spectra of Different Secondary Structures (solid line:  α-helix; long 
dashes:  β-sheets; dots:  β-turn; dots + short dashes:  random coil).  (From Reference 
305).  
 
 Recent CD, microscopy, and fluorescence studies by Andrisano and coworkers 
provided tremendous insight into the mechanism of Aβ aggregation and revealed that it 
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consists of a lag phase, an exponential phase, and a plateau phase.306  In the monomeric 
state, Aβ peptide adopts either an α-helical or random coil conformation, depending on 
the temperature, buffer, and cosolvent.  The peptide eventually forms small molecular 
weight oligomers and adopts a β-sheet rich conformation.  Since CD can detect changes 
in secondary structure, it is an ideal tool to track the early stages of peptide aggregation.  
Figure 6.4 shows a previously reported example of the time course of Aβ aggregation 
where there is a clear shift in secondary structure, depicted by a sigmoidal increase of the 
negative band at 215 nm.306   
           
Figure 6.4:  Time-course of Aβ Aggregation (left) and Increase of Negative Peak at 215 
nm (right).   
 
6.2 NSAID-AChEI Conjugates as Inhibitors of Beta Amyloid Aggregation 
6.2.1 Preliminary Circular Dichroism Screen   
 Using a procedure adapted from Andrisano et al.,306 Aβ1-42 peptide was analyzed 
for β-sheet formation following a 30 oC incubation at 1, 5, 8, and 24 h (Figure 6.5).  The 
initial peptide conformation observed was α-helical, with two minima around 212 and 
215 nm.  At 30 
o
C, a time-dependent increase in the negative band at 215 nm was 
observed in the Aβ blank, suggesting a shift in secondary structure to a β-sheet rich 
conformation.  These results are similar to those observed by Andrisano et al. (Figure 
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6.4), although the initial peptide conformation is slightly different.  This is not surprising 
because both acetonitrile (4.8%) and DMSO (0.83%) were used as cosolvents in this 
assay, while Andrisano only used acetonitrile (4.8%) cosolvent.  DMSO is well known to 
alter protein conformation and even protonation states.307, 308  It is likely that the small 
percentage of DMSO had an effect on the secondary structure of the peptide.   
 
Figure 6.5:  Time Course of Aβ Aggregation.      
 Once it was determined that the desired transformation in peptide structure was 
occurring, several novel AChEIs were chosen and screened to determine their effects on 
Aβ aggregation.  Curcumin, a known Aβ aggregation inhibitor, was the positive control255 
while the active site AChEI, tacrine, was chosen as the negative control.  As per the 
method of Andrisano et al., 10 µM of each control was incubated with of Aβ1-42 (50 µM) 
and analyzed for β-sheet content via CD.  Prior to each scan, an aliquot was withdrawn 
from the incubated peptide and diluted by 5 with sodium phosphate buffer.  A 0.5 cm 
cuvette was used in these experiments.  At 24 h, a negative band at 215 nm for the 
negative control and a baseline signal for the positive control was observed, as shown in 
Figure 6.6.   
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Figure 6.6:  Aβ1-42 Incubations with Tacrine and Curcumin.  
 
 When screened in the same assay, several Class 1, 2, and 3 compounds 
suppressed aggregation at a 10 µM concentration.  Lipophilic Class 1 compounds 3, 6, 
and 7 all suppressed β-sheet formation following a 24 h incubation (Figure 6.7).  Class 2 
compounds 16 and 18 also significantly suppressed Aβ aggregation, as shown in Figure 
6.8.  Finally, indomethacin amide 51 and Class 3 conjugate 48 were very active, showing 
suppression similar to that observed with the positive control, curcumin (Figures 6.8 and 
6.9, respectively).   
 
Figure 6.7:  Spectral Overlay of Aβ Incubated with Class 1 Compounds 3, 6, and 7. 
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Figure 6.8:  Spectral Overlay of Aβ Incubated with Compounds 16, 18, and 51. 
 Not every NSAID-AChEI conjugate demonstrated potent anti-aggregating 
properties.  Inhibitors 2 and 42 did not significantly suppress β-sheet formation compared 
to the peptide blank (Figure 6.9).  These compounds are ibuprofen and naproxen 
conjugates.  It should be noted that the active compounds are all potent inhibitors of 
AChE which interact with the PAS, as reported in Chapters 3, 4, and 5 of this 
dissertation.  This study supports the hypothesis that the most lipophilic NSAID 
conjugates (i.e. derivatives of indomethacin and diclofenac) are the most active PAS 
AChEIs because of enhanced hydrophobic interactions along the active site gorge.  As a 
result, the most potent PAS inhibitors suppressed Aβ aggregation the most effectively in 
this assay.   
 
 
Figure 6.9:  Spectral Overlay of Aβ Incubated with Compounds 2, 42, and 48.  
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 The deconvolution of CD spectrawas next used to quantify the conformational 
transitions of the peptide.  The software used is termed SOMCD since it is based on 
Kohonen’s self-organizing maps (SOM).309  SOMs are algorithms for artificial neural 
networks and are used to organize input signals into two-dimensional grids.  For CD data, 
a SOM arranges the spectrum on a 2-D map which can be used to estimate the 
percentages of structural elements such as α-helices and β-sheets.  Shown in Table 6.1 are 
the data for Aβ alone as well as for Aβ samples incubated with several NSAID-AChEI 
conjugates.  After 24 h, the peptide blank had 45% β-sheet content compared to less than 
2.5% β-sheet content at 1 h.  Similarly, peptide samples with tacrine and inhibitors 2 and 
42 show 32, 35, and 43% β-sheet content following a 24 h incubation.  These data 
suggest that these compounds are ineffective at suppressing Aβ aggregation.  Active 
compounds 6, 7, 16, 18, 48, and 51 all suppressed β-sheet formation from 45% of the 
total peptide conformation (observed with the blank) to 0-24%.  Indomethacin and 
diclofenac derivatives 6, 16, and 51 all fully suppressed Aβ aggregation.    
 Table 6.1:  Deconvolution of CD Data for 24 Hour Time Points.
*
 
Sample % Alpha Helix % Beta Sheet % Beta Turn % Random Coil 
Aβ, 1 h < 1.5 < 2.5 < 1.5 95.3 ± 20 
Aβ, 24 h 6.5 ± 2 44.9 ± 1 8.2 ± 2 40.4 ± 4 
Aβ + 2 12.4 ± 3 35.2 ± 3 13.1 ± 2 39.3 ± 3 
Aβ + 6 95.8 ± 8 0 < 2 < 2 
Aβ + 7 38.7 ± 2 23.6 ± 4 10.2 ± 2 27.5 ± 2 
Aβ + 16 84.7 ± 3 0 6.2 ± 0.5 9.0 ± 3 
Aβ + 18 43.5 ± 7 12.2 ± 6 13.9 ± 5 30.4 ± 7 
Aβ + 42 12.5 ± 9 43.2 ± 5 10.6 ± 1 33.7 ± 4 
Aβ + 48 40.4 ± 5 17.4 ± 7 13.7 ± 3 28.4 ± 2 
Aβ + 51 95.8 ± 8 0 < 2 < 2 
Controls 
Aβ + Tacrine 14.9 ± 3 32.2 ± 2 12.0 ± 2 40.8 ± 2 
Aβ + Curcumin 95.8 ± 8 0 < 2 < 2 
 *Data generated using SOMCD software:  http://geneura.ugr.es/cgi-bin/somcd/index.cgi. 
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6.2.2 Optimization of the Beta Amyloid Assay 
 Although the results presented in the previous section suggest that some of the 
NSAID-AChEI conjugates effectively inhibit Aβ aggregation, considerable noise was 
observed in the CD spectra, especially at wavelengths below 200 nm.  The large amount 
of noise observed in this region masked any conformational transitions between 190 and 
200 nm.  In the next set of experiments, the noise was minimized by optimizing the CD 
parameters, increasing the final Aβ peptide concentration (from 10 to 50 µM), decreasing 
the pathlength, and eliminating DMSO as a cosolvent.  First of all, eight CD scans were 
averaged together in order to minimize spectral noise.  Also, a cuvette with a smaller path 
length (0.1 cm rather than a 0.5 cm) was used to decrease solvent absorbance in the far 
UV region.  Solvent blanks (with or without an inhibitor) were also subtracted for each 
sample.  Smoothing functions and FFT analyses were used to process each spectrum and 
to minimize noise.   
 Organic cosolvents such as DMSO can complicate Aβ aggregation kinetics by 
solubilizing peptide oligomers and fibrils.255  For this reason, the percentage of cosolvent 
should be minimized when performing Aβ assays.  All of the NSAID-AChEI conjugates 
are highly lipophilic and have poor water solubility, even at low micromolar 
concentrations.  The elimination of DMSO also improved spectral noise since this 
particular cosolvent can absorb at wavelengths below 252 nm.310  Ultimately, a small 
increase in the percentage of acetonitrile cosolvent used compared to the studies by 
Andrisano et al.306 was chosen.  The buffer used in the optimized experiments contained 
sodium phosphate buffer (10 mM), sodium chloride (11 mM), and acetonitrile (5.7%), all 
solvents which are transparent in the far UV range (180-260 nm).  It is important to note 
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that all buffers and cosolvents were filtered with 0.2 µm membrane filters prior to use in 
order to remove any small particles which may interfere with the CD spectrum.  Finally, 
an essential step was the careful cleaning of cuvettes between samples.  This step 
involved several washes with 6 M HCl, a dilute solution of detergent (Starna Cells), 
distilled water, milli-Q water, and ethanol.  The cuvettes were dried with a stream of 
nitrogen prior to use.   
 Assay reproducibility has been a major impediment in these studies.  The 
preliminary results presented in the previous section were not easily reproduced and the 
Aβ aggregation kinetics varied from one experiment to the next.  This lack of 
reproducibility is inherent to the study of Aβ peptide and has been the root of conflicting 
literature results.  The high hydrophobicity and low aqueous solubility of Aβ1-42 explain 
the aggregating properties of this peptide.  These properties also present a challenge when 
studying Aβ peptide under physiological conditions.  Either an organic solvent or a very 
acidic or basic buffer is often required to promote peptide solubility.  Filtration of peptide 
samples to obtain an aggregate-free solution is another technique commonly used to 
study these peptides in a reproducible manner.311  Filtration, though, results in low peptide 
recovery and is not a practical approach.  Furthermore, the initial peptide conformation 
can vary significantly depending on the reconstitution procedure used and is an additional 
cause of the variations observed in previously reported results. 
 One straightforward method which has been incorporated into Aβ assay 
procedures is the pre-treatment of peptide samples with hexafluoroisopropanol (HFIP).  
This fluorinated solvent disrupts any pre-existing β-sheets and promotes an α-helical 
peptide conformation.312, 313  Andrisano et al. have reported reproducible aggregation 
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kinetics using this HFIP pretreatment procedure.306  This assay protocol was chosen as a 
starting point for future aggregation experiments.  Following a 16.5 h room temperature 
incubation, the peptide sample can either be lyophilized from HFIP or the volatile solvent 
can be removed under a stream of nitrogen.  Both modifications were used in preliminary 
studies.  The lyophilization procedure provided better control of the solvent removal and 
was ultimately chosen for future studies.     
 Another significant modification to the aggregation assay involved the HFIP 
pretreatment of a larger lot of peptide (5 mg) followed by separation into aliquots for 
future use.  It was initially supposed that preparation of a larger lot would eliminate the 
experimental error involved in repetition of the pretreatment step for individual peptide 
samples.  Furthermore, all samples would be acquired from the same lot, thus eliminating 
any lot-to-lot variations in purity and peptide content commonly observed with 
commercial peptide samples.314                        
 After the assay conditions had been optimized, Aβ aggregation kinetics were 
tracked via CD once again.  As shown in Figure 6.10, a clear time-dependent transition 
from a random coil-rich conformation to a β-sheet conformation was observed.  The large 
amount of spectral noise present in the preliminary experiments had also been eliminated, 
making both the appearance of the negative band at 215 nm and the disappearance of the 
negative band at 195 nm more evident.                  
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Figure 6.10:  Time Course of Aβ Aggregation with Revised Procedure.   
 These aggregation kinetics were also reproducible, as shown in Figures 6.11 and 
6.12.  While the CD spectra did not completely overlay for these two experiments, the 
peaks at 195 and 215 nm were of the same magnitude, within 0.25 mdeg at 3 h and 0.4 
mdeg at 20 h.  It should be noted that the assay reproducibility reported by Andrisano 
was for the magnitude of the negative band at 215 nm and not necessarily for the entire 
spectrum.  It is possible that slight conformational changes in the rest of the CD spectrum 
were present in these previously reported studies.306   
 
Figure 6.11:  Three Hour Time Points for Two Separate Aggregation Experiments.   
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Figure 6.12:  Twenty Hour Time Points for Two Separate Aggregation Experiments.       
  It quickly became apparent that while Aβ aggregation kinetics were reproducible 
for 1-2 weeks following the original HFIP pretreatment, the percentage of β-sheet content 
at a given time point progressively increased after two weeks.  This enhanced aggregation 
was observed even when the peptide samples were stored at either -20 
o
C or -78 
o
C.  As 
an example, CD spectra from the first two experiments (shown in Figures 6.11 and 6.12) 
are shown overlaid with data from an aggregation experiment performed 4 weeks 
following the initial experiment.  As shown in Figures 6.13 and 6.14, experiments 
performed within a few weeks of the HFIP pretreatment yielded reproducible results.  
Any experiments performed more than three weeks following the initial peptide 
preparation resulted in inconsistent aggregation kinetics, as shown by significant 
variations in the negative band at 215 nm.         
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Figure 6.13:  Three Hour Time Points for Three Separate Aggregation Experiments.   
 
 
Figure 6.14:  Twenty Hour Time Points for Three Separate Aggregation Experiments. 
 Although it has been reported that HFIP-pretreated Aβ samples are stable when 
stored at -20 
o
C for several months,306 this was not observed in the above studies.  This 
observation suggests that the HFIP pretreatment does not last for more than a few weeks 
and that aggregates begin to form even when the pretreated peptide samples are stored at 
low temperatures.  To address this issue, the HFIP pretreatment was performed 
immediately prior to a particular aggregation experiment.  Unfortunately, this assay 
modification reintroduced some of the error observed with the individual preparation of 
peptide samples. 
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 It should be noted that, at this point in the experiments, the commercial peptide 
source was also switched from Anaspec to Bachem in an attempt to address assay 
reproducibility issues.  Aβ peptide from Bachem was chosen for additional studies 
because it has a significantly higher peptide content (~94-97%) compared to samples 
from Anaspec (~60-75%).  The kinetics of aggregation were clearly different from those 
observed with the Anaspec peptide.  Figure 6.15 shows a time-dependent increase in β-
sheet formation which plateaued between 17 and 20 h.  Furthermore, the magnitude of 
the 215 nm peak was reproducible at the 20 h time point, as shown in Figure 6.16.  The 
variation in this peak was less than 0.9 mdeg.                 
 
Figure 6.15:  Aggregation Kinetics Observed with Aβ Peptide from Bachem. 
  
Figure 6.16:  Overlay of Twenty Hour Time Points for Two Separate Aggregation 
Experiments. 
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 Finally, under the optimized assay conditions, Aβ peptide was incubated with 
curcumin (positive control) and indomethacin conjugate 6, an NSAID-AChEI conjugate 
which demonstrated anti-aggregating properties in the preliminary screen.  As shown in 
Figure 6.17, both curcumin and compound 6 suppressed Aβ aggregation.  In this 
experiment, β-sheet formation was suppressed by 4.91 and 1.70 mdeg for curcumin and 
6, respectively.  The magnitude of this change is similar to that observed by Andrisano 
and coworkers, which was on the order of 2-2.5 mdeg (Figure 6.18).  This 2 mdeg shift at 
20 h was seen upon incubation of Aβ peptide with 50 µM of Congo Red, a known 
aggregation inhibitor.  These data suggest that at low 10 µM concentrations, both 
curcumin and AChEI 6 suppress β-sheet formation as effectively (or more effectively in 
the case of curcumin) as Congo Red.              
 
Figure 6.17:  Overlay of Twenty-One Hour Time Points for Two Separate Aggregation 
Experiments. 
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Figure 6.18:  Previously Reported Aggregation Kinetics of Aβ Alone (Grey line) 
Compared to Aβ in the Presence of 50 µM Congo Red (Blank line).306  The CD signal at 
215 nm is plotted versus time. 
 
 
6.3 Potencies of NSAID-AChEI Conjugates Against Human Acetylcholinesterase  
 In order to further explore the utility of NSAID-AChEI conjugates as anti-
Alzheimer’s drugs, the potencies of these compounds against human AChE (huAChE) 
compared to Electrophorus electricus AChE (eeAChE) were determined.  When 
comparing IC50 data from different AChE sources, the potency of a given inhibitor may 
vary from 5- to 40-fold.203  For example, the known AChEI tacrine inhibits eeAChE at 50 
nM but inhibits huAChE at 500 nM.  As shown in Table 6.2, many Class 1 compounds 
inhibit huAChE in the lower micromolar range, with selectivities ranging from 1.3 to 8.7.  
These data suggest that the Class 1 compounds maintain a high level of potency against 
huAChE and may be effective AD treatments.        
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Table 6.2:  Selectivities of Class 1 Compounds for Human AChE.   
Compound IC50 (µM) Selectivity (ee:hu) 
 eeAChE huAChE  
1 1.93 ± 0.6 2.51 ± 0.3 1.3 
3 1.74 ± 1 7.82 ± 3 4.5 
4 0.83 ± 0.1 5.48 ± 1 6.6 
6 0.72 ± 0.13 3.63 ± 1.7 5.0 
7 0.51 ± 0.02 4.45 ± 1 8.7 
 
6.4 Investigation of Cholinesterase Selectivities 
 Recent evidence suggests that BuChE plays a complex role in AD.  
Epidemiological studies have shown that switching from an AChE selective inhibitor to a 
dual cholinesterase inhibitor can improve cognitive function, as described in Section 
6.1.6 of this Chapter.  The AChE:BuChE selectivities of several NSAID-AChEI 
conjugates were next investigated in order to gain further insight into the potential use of 
these compounds as AD treatments.   
 Like AChE, BuChE contains a catalytic Ser, His, and Trp (Ser198, Trp82, and 
His438 in human BuChE) in its active site, although the catalytic gorge of this enzyme is 
much larger than that of AChE.315  Several differences also exist between the PAS of the 
two cholinesterases.  For example, the crucial Trp279 residue which participates in π-π 
and cation-π interactions with substrate is replaced by an Ala in BuChE.316  Similarly, 
Phe288 and 290 (in TcAChE) are replaced with non-aromatic Leu and Val residues in 
BuChE.315  Considering the structural differences between the active and peripheral sites 
of the two cholinesterases, the NSAID-AChEI conjugates discussed herein may have 
varying cholinesterase selectivities. 
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Table 6.3:  Cholinesterase Selectivities of Class 1, 2, and 3 Molecules.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      *
A precise IC50 was not obtained due to limits in inhibitor solubility. 
      **
Weak agonist at high concentrations. 
 
 Cholinesterase selectivities for a set of Class 1, 2, and 3 molecules are presented 
in Table 6.3.  AChEIs 1 and 3 did not inhibit BuChE, while all other Class 1 molecules 
inhibited the enzyme in the low micromolar range.  All Class 1 molecules are slightly 
AChE selective.  Class 2 compounds 10, 13, 15, 16, 18, and 19 also demonstrated some 
No. AChE IC50 
(µM) 
BuChE IC50 
(µM) 
AChE:BuChE Selectivity 
Class 1 
1 1.93 ± 0.6 NA >100 
2 1.19 ± 0.2 10.6 ± 3 8.9 
3 1.74 ± 1 NA >100 
4 0.83 ± 0.2 11.1 ± 4 13.4 
5 2.29 ± 0.9 6.99 ± 1 3.1 
6 0.72 ± 0.1 4.59 ± 1 6.4 
7 0.51 ± 0.02 3.82 ± 0.5 7.5 
8 1.36 ± 0.1 5.26 ± 0.5  3.9 
Class 2 
9 24.6 ± 15 NA >100 
10 25.7 ± 5 55.2 ± 30 2.1 
12 19.7 ± 2 NA >100 
13 13.9 ± 0.3 47.8 ± 13 3.4 
15 9.75 ± 0.9 16.1 ± 4 1.7 
16 5.43 ± 0.3 13.1 ± 3 4.0 
18 2.69 ± 0.2 24.8 ± 6 9.2 
19 2.66 ± 0.3 10.6 ± 3 4.0 
20 40.4 ± 4 41.2 ± 9 1.0 
23 35-45  9.48 ± 2 0.25 
Class 3 
37 27.9 ± 2.7 8.88 ± 2 (EC50) --- 
39 6.63 ± 0.4 3.28 ± 0.8 (EC50) --- 
41 4.34 ± 0.2 Agonist
**
 --- 
42 4.77 ± 0.2 36.0 ± 20
*
 7.5 
43 2.55 ± 0.7 Agonist
**
  --- 
44 1.31 ± 0.1 9.14 ± 1 7.0 
45 8.91 ± 0.4 Agonist
**
 --- 
46 18.6 ± 3 NA >100 
47 3.29 ± 0.3 Agonist
**
 --- 
48 1.85 ± 0.1 34.4 ± 27
*
 18.6 
n-Butyl Analogues 
56 50.8 29.3 0.58 
60 2.6
*
 6.28 ± 0.8 2.4 
Standards 
GAL 1.12 ± 0.3 32.5 ± 8.5 29.0 
TAC 0.05 ± 0.005 5.0 ± 0.5 nM 0.1 
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BuChE inhibition, with AChE selectivities ranging from 1.7 to 9.2.  The bulky 
galantamine conjugates demonstrated interesting selectivities.  Galantamine conjugate 20 
is equally selective for both cholinesterases and conjugate 23 is four-fold more selective 
for BuChE.  This SAR can be rationalized by the larger aromatic gorge of BuChE 
compared to AChE.315  Since these bulky conjugates are both active site (competitive) 
AChEIs, it is likely that they are also competitive inhibitors of BuChE and are able to 
more easily fit into the larger, more accommodating BuChE gorge. 
 Interestingly, Class 3 conjugates 37, 39, 41, 43, 45, and 47 were all partial 
agonists of BuChE, showing enzyme activation in the high micromolar range.  Gly 
conjugates 37 and 39, however, were full BuChE agonists with EC50 values in the low 
micromolar range.  The activation observed with 37 and 39 can be explained by the 
structural similarity of these compounds with the known activator of BuChE, as shown in 
Figure 6.19.  A mechanism for BuChE activation by the 3,3-dimethylbutyl substrate 
analogue has been proposed by Chiou et al. (Scheme 6.1).317  Briefly, this mechanism 
involves binding of the activator to a site proximal to the enzyme PAS, inducing a 
conformational change which widens the active site gorge.  This conformational change 
allows for easier substrate access and hence enhances the activity of BuChE.           
 
Figure 6.19:  Structural Similarity of Gly Conjugate 39 with BuChE Activator.   
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Scheme 6.1:  Proposed Mechanism of BuChE Activation.   
 n-Butyl conjugates 56 and 60 are also moderate inhibitors of BuChE.  The 
diclofenac n-butyl ester (56) is about 2-fold more selective for BuChE.  It is possible that 
this particular inhibitor can be more easily recognized by BuChE because of the 
structural similarity of this moiety with the natural BuChE substrate, butyrylcholine 
(BuCh; Figure 6.20).  The results presented herein indicate that by making minor 
structural modifications to these conjugates, either potent and moderately selective 
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cholinesterase inhibition or dual-cholinesterase inhibition can be achieved.  Furthermore, 
some of the amino acid conjugates demonstrated both AChE inhibition and BuChE 
activation.  It would be interesting to investigate the effect that these in vitro 
cholinesterase activities demonstrate in an animal model of AD.            
 
Figure 6.20:  Structural Similarity of Diclofenac Conjugate 56 with BuChE Activator.   
6.5 Prediction of Blood-Brain Barrier Penetration 
 Polar surface area (PSA) is a calculation of the sum of the surface area of polar 
atoms such as nitrogen and oxygen and is commonly used to predict passive transport 
across a cellular membrane.  This descriptor is used in medicinal chemistry to predict 
both intestinal absorption318 and BBB penetration.319  As a general rule, drug candidates 
with PSA values greater than 120 Å
2
 are unlikely to be intestinally absorbed while 
candidates with PSAs above 60 Å
2
 are unlikely to penetrate the BBB.320  Presented in 
Table 6.4 are PSA values for all candidate NSAID-AChEI conjugates.  Besides a few 
exceptions, most Class 1, 2, and 3 compounds have PSA values below 60 Å
2
, suggesting 
that they would effectively penetrate the BBB.  Compounds with high PSA values (60-75 
Å
2
) include indomethacin conjugates 5, 6, and 31.  
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Table 6.4:  PSA Values for Class 1, 2, and 3 Compounds.
*
 
Compound PSA (Å
2
) Compound PSA (Å
2
) 
Class 1 Class 3 
1 47.09 29  52.96 
2 47.07 30 60.00 
3 54.06 31 72.53 
4 53.55 32 62.04 
5 66.68 33 35.40 
6 66.58 34 42.44 
7 55.37 35 55.54 
8 56.09 36 39.22 
Class 2 (Choline Mimics) 37 45.80 
9 20.53 38 51.23 
10 20.52 39 66.66 
11 18.86 40 49.63 
12 28.34 41 44.79 
13 27.87 42 51.47 
14 18.86 43 50.81 
15 41.47 44 44.84 
16 41.46 45 44.54 
17 40.18 46 50.96 
18 29.83 47 65.13 
19 29.99 48 39.10 
Class 2 (AChEIs)   
20 36.23   
21 19.99 Amides and n-Butyl Analogues 
22 20.61 49 25.78 
23 43.22 50 30.95 
24 27.00 51 44.62 
25 28.52 52 34.56 
26 53.77 53 20.32 
27 40.25 54 28.27 
28 41.88 55 41.34 
NSAID Standards 56 25.55  
Indomethacin 54.42 57 47.16 
Ibuprofen 34.24 58 54.10 
Naproxen 41.74 59 67.64 
Diclofenac 38.98 60 56.49 
   *PSA values calculated using Spartan ’06 V102. 
 
 Plots of clogP versus PSA values are an alternate way to determine BBB 
penetrability.319318  These plots are commonly referred to as “egg plots” because 
compounds which penetrate the BBB fall into a specific area of the graph.  ClogP values 
for known CNS active drugs range from -2 to 5 units while PSA values are generally less 
than 60 Å
2
.  While the lipophilicities of many of the Class 1 and 3 analogues are too high 
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for BBB penetration, several Class 2 molecules fall within the desired clogP and PSA 
range, as shown in Figure 6.21.  While PSA values and egg plots are common tools for 
the prediction of BBB penetrability, these calculations will need to be supported by in 
vitro membrane permeability assays.  The NSAID-AChEI conjugates which fall in the 
desired range of the “egg plot” should be the first candidates chosen for study in the 
permeability assay.        
                
 
 
Figure 6.21:  ClogP versus PSA Values for NSAID-AChEI Conjugates. 
 
 
 
 
              
                6.6 Conclusions 
 Evidence presented in this Chapter supports the use of novel NSAID-AChEI 
conjugates for AD drugs.  First of all, a majority of these compounds inhibit both 
eeAChE and huAChE in the low micromolar range, with potencies comparable to those 
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observed with AChEIs on the market.  Additionally, several of the most potent PAS 
inhibitors suppress Aβ peptide aggregation at a level comparable to the known anti-
aggregating agent, curcumin.  A range of cholinesterase selectivities was also observed 
for these compounds.  Since there is literature precedent that BuChE plays a role in AD, 
dual cholinesterase inhibition may be a viable approach for AD therapy.  Finally, 
calculated PSA values and egg plots suggest that many of these compounds will penetrate 
the BBB.  The top compounds of this NSAID-AChEI library should be screened in an 
AD animal model to determine their in vivo efficacies.             
6.7 Experimental 
6.7.1 General  
 HFIP was obtained from TCI America (Portland, OR).  HPLC grade acetonitrile, 
sodium phosphate buffer salts, and glycine were purchased from EMD Chemicals 
(Gibbstown, NJ).  Sodium hydroxide solution (0.5 M) was purchased from Alfa Aesar 
and sodium carbonate was purchased from Fisher Scientific.  Buffer reagents used were 
of the highest purity available.  All buffers were prepared using MilliQ-H2O and stored at 
4 
o
C until use.  Buffers were filtered through a 0.2 µm cellulose acetate membrane 
(Thermo Scientific) and organic solvents were filtered through a 0.2 µm 
polytetrafluoroethylene (PTFE) membrane (VWR International).   
 It should be noted that several 0.5 and 1.0 mg lots of Aβ1-42 peptide were 
purchased from Anaspec (Fremont, CA) for preliminary studies.  Since Bachem supplies 
the same peptide at a much higher peptide content (97.5% compared to 65-75% with the 
peptide from Anaspec), the Bachem peptide was used for the final studies presented in 
this Chapter.   
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6.7.2 Preparation of Amyloid Beta Peptide 
 Aβ1-42 peptide was purchased from Bachem (5 mg, 95.2% HPLC purity, 97.5% 
assay, Lot No. 1031807) and used without further purification.  The following procedure 
has been adapted from the work of Andrisano et al.248  It should be noted that the kinetics 
of Aβ aggregation are very sensitive to any slight changes in pH, ionic strength, 
incubation time, cosolvent, and temperature, hence these exact conditions were used for 
each experiment in order to obtain reproducible results.  The entire lot of peptide was 
brought to room temperature in a dessicator containing Drierite (anhydrous-indicating 
calcium sulfate) for 10 min.  HFIP (4.641 mL) was then added to the peptide to form a 
1.0 mg/mL solution which was sonicated in an ice bath for 30 s and then vortexed for 30 
s (cycle repeated 5x).  The sonication was carried out in a cold room using an analog 
Branson Sonifier 450 (Danbury, CT) with an output of 10 and a duty cycle of 30%.  
Vortexing was carried out using a Lab-line Super-Mixer from Arthur H. Thomas Co. 
(Philadelphia, PA) at a mixing control of 4.  Following sonication and vortexing, the 
solution appeared very cloudy, suggesting that aggregates were present.  The sample was 
incubated in a dessicator at room temperature for 23 h, upon which a clear solution was 
obtained.  The peptide was then cooled on ice for 4 min.  The chilled solution was 
divided into 0.65 mL siliconized polypropylene micro-centrifuge tubes (Bio Plas. Inc, 
San Rafael, CA) in 373.1 µL (0.25 mg) aliquots.  The fractions were concentrated in a 
dessicator under a stream of nitrogen for 9 h.  The peptide fractions were then stored in a 
box containing Drierite at -20 
o
C until use.     
 After a few experiments, CD revealed that the HFIP treatment did not last for 
more than one week.  Freezing the peptide fractions may create nuclei or seeds from 
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which aggregates can form.  HFIP pretreatment was then repeated on each fraction the 
day before an experiment to ensure that aggregates were not present at time zero.  The 
0.25 mg aliquot was brought to room temperature in a dessicator for 10 min.  HFIP 
(373.1 µL) was added and the peptide was sonicated in an ice bath for 30 s and then 
vortexed for 30 s (cycle repeated 5x).  The sample was incubated in a dessicator at room 
temperature for 17 h and 30 min, upon which a clear solution was obtained.  The peptide 
was then lyophilized from HFIP for 3 h and 30 min.  Aggregation experiments were 
carried out immediately following lyophilization using the procedure below (Section 
6.7.4).                           
6.7.3 Preparation of Assay Buffers 
 Reconstitution Buffer:  The reconstitution buffer consists of 48.3% acetonitrile, 
48.3% Na2CO3 (300 µM), and 3.4% NaOH (250 mM).  It should be noted that the 
reconstitution buffer was prepared freshly prior to each experiment. 
 Sodium Phosphate Buffer:  10 mM sodium phosphate (pH 7.7) buffer containing 
11 mM of NaCl was prepared by dissolving 0.176 g/L of sodium phosphate 
monohydrate, 2.338 g/L of sodium phosphate heptahydrate, and 0.643 g/L of sodium 
chloride into 1.0 L of MilliQ water.  Under the assay conditions (at 30 
o
C), the pH of this 
buffer is 7.8.       
6.7.4 Circular Dichroism Parameters 
 All CD experiments were carried out using a Jasco J-815 CD (Easton, MD).  A 
0.1 cm path length quartz cuvette (Starna Cells, Atascadero, CA) was used with a 1 nm 
data pitch, 2.00 nm band width, 100 µm slit width, and 0.25 s digital integration time.  A 
peltier connected to the instrument maintained the sample temperature at 20.00 ± 0.10 
o
C.  
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A blank containing 90.5% of sodium phosphate buffer, 5.7% of acetonitrile, 4.0% of 300 
µM Na2CO3, and 0.3% of 250 mM NaOH, with or without the appropriate inhibitor, was 
subtracted for each CD reading.  Smoothing using the Savitzky-Golay method 
(convolution width of 5) was performed followed by a fast Fourier transform (FFT) to 
process all CD spectra.  Deconvoluted data were generated using SOMCD software 
based on Kohonen’s self-organizing maps.321     
6.7.5 Assay Procedure 
 The lyophilized peptide was reconstituted using the CH3CN:Na2CO3:NaOH 
buffer described above to form a 600 µM solution.  To ensure the peptide was dissolved, 
it was sonicated in an ice bath for 30 s and then vortexed for 30 s (cycle repeated 5x).  
Sonication and vortexing were performed in a cold room at 4 
o
C.  The reconstituted 
peptide was diluted by 10 with sodium phosphate buffer to form a 60 µM solution.  The 
peptide was then diluted by 1.2 with either an inhibitor (60 µM in 90:10 sodium 
phosphate buffer:CH3CN) or an inhibitor blank (90:10 sodium phosphate buffer: 
CH3CN).  For each assay, the final concentration of the peptide was 50 µM and the final 
concentration of the inhibitor was 10 µM.  As soon as the inhibitors and blanks were 
added, the peptide samples were incubated at 30 
o
C without mixing.  Aliquots (150 µL) 
were taken at appropriate intervals and read using the above CD parameters.  In between 
readings, cuvettes were rinsed several times with 6 M HCl, dilute detergent (Starna cells), 
distilled water, MilliQ water, and ethanol.  Finally, cuvettes were dried using a stream of 
nitrogen.                              
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6.7.6 Butyrylcholinesterase Assay 
 BuChE from equine serum, (S)-butyrylthiocholine (BuTCh), DTNB, and tacrine 
hydrochloride were obtained from Sigma-Aldrich (Saint Louis, MO) and used without 
further purification.  Methanol was obtained from EMD Chemicals (Gibbstown, NJ). 
Cholinesterase inhibition was assayed spectrophotometrically at 412 nm according to 
Ellman’s method.135 Assays were performed in polystyrene 96-well plates (Corning 96-
well flat transparent) and a conventional micro-plate reader was employed for kinetic 
readings (Tecan's Infinite 200 multimode). The following reagents were added to the 
wells: 200 µL of 1.5 mM DTNB in sodium phosphate buffer (100 mM, pH 8), 30 µL of 
inhibitor stock solution in methanol, 20 µL of 1.25 units/mL of BuChE in sodium 
phosphate buffer (20 mM, pH 7), and 50 µL of 6 mM BuTCh in buffer (100 mM, pH 8). 
Immediately after the substrate was added, the absorption signal was measured at 30 s 
intervals over 5 min at 25 °C. Percentage inhibition was calculated relative to a negative 
control (methanol). The background signal was measured in control wells containing 
every reagent except for the substrate. IC50 values were obtained from a minimum of 
eight concentrations in duplicate and by fitting the experimental data to a dose-response 
curve using GraphPad Prism software (Version 5.00, San Diego, CA). 
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Chapter 7:  Back-Scattering Interferometry as a Tool for the Investigation of AChE-
ligand Interactions 
7.1 Introduction 
7.1.1 Acetylcholinesterase as an Important Therapeutic Target 
 As described in detail in Chapter 6, AChE plays important cholinergic258 and non-
cholinergic272 roles in AD.  Potent inhibitors of AChE such as galantamine, rivastigmine, 
and donepezil, are among the most commonly prescribed AD medications.  Aside from 
regulating cholinergic neurotransmission, AChE has been shown to accelerate Aβ 
aggregation,272 a key step in the development of the neurotoxic plaques characteristic of 
AD (Chapter 6).  Previous results have shown that inhibitors with affinity for the PAS 
(e.g. propidium) inhibit Aβ plaque formation.322  Classes of mixed inhibitors able to 
interact with both the PAS and the active site of AChE are promising targets since they 
may treat multiple AD pathologies.172, 323-325
,173  A rapid and sensitive screen for potent, 
dual-binding AChEIs is of the utmost importance in the search for an effective AD 
treatment.     
 AChE also plays a role in inflammatory processes via the cholinergic anti-
inflammatory pathway (discussed in Chapter 1, Section 1.3).82, 154  Administration of 
centrally acting AChEIs such as galantamine suppresses circulating pro-inflammatory 
cytokines and ameliorates severe inflammation associated with sepsis84 and 
endotoxemia.85  Results from Chapter 3 indicate that AChEIs conjugated to common 
NSAIDs demonstrate powerful anti-vesicant and anti-inflammatory activity against 
CEES.96  A sensitive AChE detection method may be useful for the screening of anti-
vesicant compounds.   
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 Carbamates and organophosphates (OPs) are commonly employed as pesticides 
and chemical warfare agents.  These molecules irreversibly bind to AChE, causing a 
build-up of ACh at neuromuscular junctions and leading to seizures, paralysis, and death 
at high doses.169, 170  Considering the current global political climate, the ability to detect 
such agents at submicromolar levels is of national security interest.  An ultrasensitive 
AChE detection method may allow for the low level detection of OP nerve agents.     
7.1.2 Back-Scattering Interferometry for the Detection of Acetylcholinesterase  
 Considering the various therapeutic indications for AChEIs, the development of a 
sensitive, straightforward, and rapid screen for this enzyme is of paramount 
pharmaceutical and biochemical importance.  Traditional methods used to detect AChE 
focus on the indirect measurement of substrate hydrolysis, and require specialized probes, 
laborious procedures, and significant quantities of enzyme.  One alternative detection 
method is back-scattering interferometry (BSI), an emerging biosensing technique which 
has recently been used to investigate multivalent aptamer-thrombin interactions,326 free 
solution and surface-immobilized 30-mer DNA hybridizations,327 carbohydrate-lectin 
binding,328 carbonic anhydrase-inhibitor interactions,329 and lysine-specific demethylase 1 
(LSD1)-folate binding.330  Intermolecular hydrogen bonding interactions between 
tetramethylammonium benzoate and substituted ureas have also been studied using the 
BSI platform.331  This technique can be used to detect intermolecular interactions 
traditionally probed by isothermal titration calorimetry (ITC), surface plasmon resonance 
(SPR), and fluorometric assays.  BSI has many advantages over these techniques, 
including:  (1) a multipass configuration, which allows for the analysis of very small 
sample volumes (pL) and requires low protein/ligand concentrations (nM to µM); (2) 
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binding can be measured in free solution, without the need for surface immobilization, 
specialized reagents, or fluorescent probes; and (3) cosolvents such as DMSO329 and 
acetonitrile331 can be used without assay interference. 
 As part of a collaboration with Professors Robert A. Flowers and Darryl J. 
Bornhop (Vanderbilt University) along with Gabrielle L. Haddad, BSI has been used to 
detect AChE-inhibitor interactions.  The BSI instrumental setup utilizes a multipass 
configuration, as shown in Scheme 7.1.  Briefly, a laser beam is reflected off of an angled 
mirror where the signal is refracted within a microfluidic channel containing the ligand, 
protein, or ligand-protein mixture.  It is important to note that the amount of sample 
analyzed by the laser in each experiment is 360 pL,331 which allows for subnanomolar 
detection limits and requires only a few microliters of each sample. The channel 
refraction creates an interference fringe pattern which can be collected by a basic charge-
coupled device (CCD) camera and is subsequently analyzed in real-time using a FFT.332  
This setup allows for the quantification of refractive index (RI) changes based on phase 
shifts of the laser.  Several studies have shown that these shifts correlate well with ligand-
receptor binding interactions and are a result of solvation/desolvation, conformational 
changes, dipole moments, polarizability, and dilution effects.327, 328, 332-335  From these data, 
an equilibrium dissociation constant (Kd; described in the next section) can be obtained 
by fitting the average signal shift generated at each concentration to an exponential rise to 
max equation. 
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Scheme 7.1:  Diagram of BSI Setup (Taken from Reference 329). 
7.1.3 Methods for the Quantification of Protein-Ligand Interactions 
 One parameter which is used to quantify the affinity of a protein for a given 
ligand is a Kd value.  For a ligand (L) and protein (P) complex, 
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the equilibrium association constant (Ka) is equal to the ratio between the rate of 
association of the P·L complex (kassociation or ka) and the rate of dissociation (kdissociation or 
kd) (Equation 7.2).  The Kd is equal to the reciprocal of the Ka.  This parameter represents 
the ligand concentration at which exactly half of the protein is populated with ligand and 
is frequently used in biochemistry to measure the affinity of a ligand for a given protein 
(the lower the Kd, the higher the affinity).336  Methods commonly used to determine Kd 
values focus on the measurement of the fraction of free and bound protein using 
spectroscopic methods, competitive displacement assays, or calorimetry.               
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 Two parameters which specifically describe inhibitor potencies and enzyme-
inhibitor affinities are IC50 values and equilibrium enzyme-inhibitor dissociation 
constants (Ki).  As described in Chapter 3 (Section 3.1.1), IC50s are determined from 
measuring the rate of substrate hydrolysis for a range of inhibitor concentrations for the 
same substrate concentration.  These values, however, vary depending on experimental 
conditions such as the substrate and enzyme concentrations.337   
 Ki values can be described by different rate equations for each type of inhibition111 
and these values remain constant for a particular inhibitor, unlike IC50 values.  While Ki 
values are very informative, determinations of these values are time-consuming and 
require several rate measurements.338  In order to determine Ki values, enzymatic rates are 
measured for a range of substrate and inhibitor concentrations and graphical methods are 
used.  Experimentally, IC50 values are much more easily determined and hence are better 
suited for the screening of large ligand libraries.   
 The mathmatical relationship between the Ki and the IC50 is complex and depends 
upon the type of inhibition.  Generally speaking, this relationship is a function of the 
substrate concentration ([S]) and the Michaelis constant (Km).  The Ki/IC50 dependence 
for competitive, uncompetitive, noncompetitive, and mixed inhibition has been described 
previously by the Cheng-Prusoff relationship.339     
7.2 Results and Discussion 
7.2.1 BSI of AChE Standards 
 All BSI data presented herein have been generated by Gabrielle Haddad at Lehigh 
University.  The structures of a set of known AChEIs screened using BSI are shown in 
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Figure 7.1.  Edrophonium, a competitive inhibitor, propidium, a PAS inhibitor, and 1,5-
bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide (BW284c51), a mixed 
inhibitor, were the standards screened to validate BSI as a method for the detection of 
AChEIs.   
 
Figure 7.1:  Structures of Known Inhibitors of AChE Screened using BSI. 
 For all three standards screened, the Ki values obtained using BSI are in 
agreement with previously reported values (Table 7.1).  The propidium-AChE binding 
curve is shown in Figure 7.2.  For this particular ligand, equilibrated samples containing 
1.0 µM of enzyme with a range of propidium concentrations resulted in signal shifts of 
up to 0.04 radians and a Ki which agreed well with literature values between 0.58 and 1.5 
µM.  A binding curve for the potent dual-binding inhibitor, BW284c51, is shown in 
Figure 7.3.  A low enzyme concentration of 25 nM with varying ligand concentrations 
resulted in signal shifts of about 0.02 radians and a Ki value which is consistent with 
previously reported values (3.2-50 nM).   
 
Table 7.1:  Literature and Experimental Ki Values for Known Inhibitors of AChE. 
Ligand Lit. Ki 
(µM) 
BSI Ki 
(µM) 
Ref. 
Edrophonium 0.054-3.8 1.27 ± 0.4 189-196 
Propidium 0.58-1.5 0.64 ± 0.09 193-195, 340-343 
BW284c51 0.0032-0.05 0.0077 ± 0.0016 192 
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Figure 7.2:  Binding Curve of Propidium with AChE.   
 
 
Figure 7.3:  Binding Curve of BW284c51 with AChE.   
7.2.2 Approximation of the BSI Detection Limit 
 To approximate the BSI limit for the detection of AChE, a series of dilutions of 
the enzyme were analyzed.  A linear correlation between the phase shift and the enzyme 
concentration was observed with up to 5 nM of AChE, after which the signal plateaus 
(Figures 7.4 and 7.5).  It is currently unclear why there is a plateau, but it may be 
attributed to channel clogging or enzyme precipitation.  An enzyme concentration as low 
as 100 pM was detected using BSI which, for a probe volume of 360 pL, equates to an 
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astonishing 22,000 molecules of enzyme.  This LOD surpasses the sensitivity of recently 
reported AChE detection methods such as the use of chemiluminescent dioxetane 
probes,344 aggregation-induced emission (AIE) of tetraphenylethylenes (TPE),345, 346 
cyano-substituted poly(p-phenylenevinylene) (PPV) probes347 and other fluorescence 
assays,347-349 as well as the detection of gold nanoparticles (AuNP)350 (Table 7.2).  These 
studies validate the use of BSI for the low-level detection of AChE and for the 
determination of accurate Ki values for known inhibitors.      
 
Figure 7.4:  Linear Correlation Between Phase Shift and AChE Concentration at Low 
Levels. 
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Figure 7.5:  Phase Shift versus AChE Concentration at Low Levels (Average of 3 
Trials). 
 
Table 7.2. Comparison of the limit of detection (LOD) of BSI to previously reported 
AChE detection methods. 
Technique ATCh (Y/N) LOD (mU/mL) LOD (moles) Ref. 
BSI N 24 3.6x10
-20
 --- 
Ellman Assay Y --- 1.85x10
-18
 344 
Chemiluminescence Y 30-40 2.5x10
-19
 344 
AIE of TPE Y 5 --- 346 
AIE of TPE N 500 --- 345 
Conjugated polymer Fluor. N 50 --- 348 
Cyano-PPV Fluor. N 12,500 --- 347 
Laser-induced Fluor. Y 75 --- 349 
Electrochemical AuNP 
detection 
N 1,000 --- 350 
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7.2.3 BSI of NSAID-AChEI Conjugates 
 
Figure 7.6:  Structures of Novel NSAID-AChEI Conjugates Screened via BSI.    
 Figure 7.6 shows the structures of a small set of NSAID-AChEI conjugates 
screened using the BSI platform.  IC50 values determined using the Ellman assay have 
been compared to BSI-generated Kie values for these noncompetitive inhibitors, as shown 
in Table 7.3.95 Interestingly, while the Kie value for Class 2 compound 18 correlates 
directly with the IC50 value, Class 1 ligands containing the aromatic linker (5, 7, and 8) 
have BSI Kie values 5-10 times lower than their IC50 values.  
Table 7.3:  Correlation of BSI Ki Values with Anticholinesterase Activities.   
No. Kies / IC50
a 
Kie (BSI) 
5 2.29 ± 0.9 µM 0.21 ± 0.07 µM 
7 0.51 ± 0.02 µM 0.11 ± 0.02 µM 
8 1.36 ± 0.1 µM 0.12 ± 0.04 
13 13.9 ± 0.3 µM Dual-Binding 
18 2.69 ± 0.1 µM 2.18 ± 0.4 µM 
52 6.34 ± 0.5 µM Dual-Binding 
                a
Determined via Ellman’s method, as described in Chapter 3.135 
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 This trend can be rationalized by considering the Ki/IC50 relationship, as described 
by Cheng and Prusoff.339  The equation for mixed (and noncompetitive) inhibition is 
dependent upon the inhibition constants for binding to the enzyme alone (Kie) and to the 
enzyme-substrate complex (Kies), as shown in Equation 7.4.                             
                 (7.4) 
For mixed inhibition, 
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Since [S] >> Km under traditional Ellman assay conditions, Equation 7.4 can be 
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Finally, since [S] >> Km at high substrate concentrations, the ][S
Km  term approaches 
zero, leaving Kies (Equation 7.7).  It should be noted that for pure noncompetitive 
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inhibition, the Ki is equal to the IC50 in all three cases ([S] = Km, [S] >> Km, or [S] << Km) 
and assumes that the Kie and the Kies are the same.337, 339   
 The Kie/IC50 relationship observed with Class 1 ligands 5, 7, and 8 suggests that 
these compounds are able to bind to both the active and peripheral sites in the absence of 
competing substrate.  When the IC50 is measured (at high [S]), the portion of the ligand 
with affinity for the active site is not able to compete with the substrate.  However, under 
BSI conditions, these ligands are free to interact with both AChE sites, hence resulting in 
higher enzyme affinities (lower Kie values) for 5, 7, and 8.  This result is profound 
because it suggests that, by measuring both the IC50 and the BSI Kie value (two easily 
determined thermodynamic parameters), one can gain valuable insight into the relative 
affinities that a given compound has for the active site and the PAS of AChE.   
 
Figure 7.7:  Binding Curve of NSAID Conjugate 18 with AChE.   
 The BSI-generated binding curve for diclofenac conjugate 18 is shown in Figure 
7.7.  This AChE-ligand interaction resulted in considerable phase shifts between 0.07 and 
 238 
0.08 radians with 2.0 µM of enzyme.  As shown in Table 7.3, the BSI Kie directly 
correlates with the Kies.  This suggests that ligand 18 has affinity for the PAS alone since 
there is no difference between the ligand’s affinity for the enzyme and the affinity of the 
ligand for the ES complex.  In other words, since Kie is equal to Kies, ligand 18 is a pure 
noncompetitive (PAS) inhibitor.338   
 It is worth noting that these lipophilic ligands required either 10% methanol or 
5% 2(2-ethoxyethoxy)ethanol (Carbitol) cosolvent.  Methanol was used for many of the 
initial experiments while Carbitol was used in later experiments.  It was initially 
hypothesized that switching to a higher-boiling cosolvent would reduce the evaporation 
and precipitation of lipophilic ligands in the microfluidic channel.  Unfortunately, the 
error in BSI Kie values did not improve upon switching to either Carbitol or DMSO.   
Table 7.4:  Correlation of BSI Kie Values with Anti-CEES Activities.   
No. Kie (BSI) MEVM
a
  
5 0.21 ± 0.07 µM 91% 
7 0.11 ± 0.02 µM 98% 
8 0.12 ± 0.04 24% 
13 Dual-Binding 46-55% 
18 2.18 ± 0.4 µM Slight/NA 
52 Dual-Binding 33% 
             a
Percent suppression of CEES-induced edema, as described in Chapter 3.
61
 
 
 A rough correlation is present between BSI Ki values and MEVM data (Table 
7.4).  The ligands with the highest affinity for AChE (5 and 7) also suppress vesicant-
induced inflammation by greater than 90%.  Alternately, compound 18, which has a 10 to 
20-fold lower Ki value than the aforementioned compounds, has only a slight anti-
inflammatory effect.  Surprisingly, inhibitor 8 did not effectively suppress CEES 
vesication, even though BSI and Ellman assay results both suggest potent AChE 
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inhibition.  A more thorough in vitro and in vivo investigation of this particular 
compound is necessary.  These preliminary data are roughly consistent with the 
cholinergic anti-inflammatory pathway, stating that attenuation of AChE regulates the 
release of peripheral pro-inflammatory cytokines and suppresses inflammation.154  
 Interestingly, two binding events were clearly observed with naproxen conjugate 
13 and diclofenac conjugate 52 (Figure 7.8), suggesting that BSI has the potential to 
screen for dual-binding AChEIs, compounds which have shown high efficacy against 
AD.173, 323, 324  For these inhibitors, the two binding curves had very similar Kie values, 
making it difficult to Kie values for both binding events.  The Kie for the second binding 
curve was calculated as 0.47 ± 0.07 µM.  Additional experiments are necessary to 
deconvolute the Kie value for the first curve.  Using BSI, both the potency and the type of 
inhibition could be determined in one experiment, eliminating the need for complex 
kinetic assays and fluorescence displacement assays which are labor intensive340, 351 and 
prone to error.352, 353   
 
Figure 7.8:  Dual-Binding Curve of Conjugate 52 with AChE.   
 240 
7.2.4 Elimination of False Signals 
 Non-enzymatic substrate hydrolysis can result in ambiguity when investigating 
the efficacy of oxime reactivators.354-356  For example, pralidoxime (2-PAM) hydrolyzes 
ATCh,355 leading to a spurious signal and misleading cholinesterase activity in the 
traditional Ellman assay.  It is assumed that false positives may also be observed with any 
AChE detection methods which rely on the quantification of ATCh hydrolysis (Table 
7.2).  BSI and Ellman assay results have been compared for two known oximes:  2-PAM 
and vanillin oxime, an oxime with no documented anticholinesterase properties (Figure 
7.9).  As expected, under Ellman assay conditions, a time- and concentration-dependent 
increase in ATCh hydrolysis was detected with both oximes in the absence of AChE 
(Figure 7.10).  On the other hand, no BSI signal was observed following incubations of 
AChE with either oxime.  This experiment suggests that BSI is a useful tool to screen 
diverse compound libraries for AChEIs, including oximes and other potent nucleophiles, 
without the potential for false signals.    
 
 
Figure 7.9:  Oxime Structures.   
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Figure 7.10:  Time- and Concentration-dependent ATCh Hydrolysis Observed with 
Vanillin Oxime and 2-PAM.     
 
7.3 Conclusions 
 As was seen with both the standards and the experimental ligands, competitive, 
noncompetitive, and mixed AChEIs with a range of potencies can be effectively screened 
using BSI.  By comparing BSI-generated Kie values to Kies (IC50) values for a set of novel 
AChEIs, valuable information regarding the mechanism of action of these compounds 
was gained.  Specifically, the level of interaction that these particular inhibitors have with 
both the active site and the PAS has been quantified.   
 Signal changes can be detected at AChE concentrations as low as 100 pM, 
requiring much less enzyme than other screening techniques.  The cost effectiveness of 
BSI is especially evident when studying AChE, an enzyme whose price varies from 
hundreds to thousands of dollars per mg, depending on the source.  Moreover, the study 
of AChE mutants will be more accesible as the preparation and isolation of large 
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quantities of these mutants will not be required.  BSI is a platform for the study of AChE 
in an unperturbed free-solution system and will allow for additional insight into such a 
critical biomolecule.        
 In summary, BSI can be used as a highly sensitive and straightforward assay to 
detect AChE and to screen for anticholinesterases.  This technique is unlike previously 
reported methods in that substrate is not required for signal generation.  Using the 
multipass configuration of BSI, AChE detection limits of 100 pM (3.6 x 10
-5
 fmol) were 
obtained, a limit which surpasses that of previously described colorimetric, fluorescent, 
chemiluminescent, and electrochemical techniques (Table 7.2).  Furthermore, two distinct 
binding interactions of inhibitors 13 and 52 were detected in one experiment, 
demonstrating that BSI is well suited for the high-throughput screening for dual-binding 
AChEIs, important AD drug targets.  In addition, the method described herein should be 
broadly applicable to other protein-ligand interactions and may ultimately be useful to 
screen libraries for ligands of orphan receptors.     
7.4 Experimental 
7.4.1 General 
 AChE (Type VI-S from electrophorus electricus), propidium diiodide, 
BW284c51, and PBS packets were purchased from Sigma-Aldrich (Saint Louis, MO).  
Methanol was obtained from EMD Chemicals (Gibbstown, NJ) and 2(2-
ethoxyethoxy)ethanol was purchased from Acrōs Organics (Geel, Belgium).  
Edrophonium chloride was purchased from MP Biomedicals (Solon, Ohio).  PBS was 
prepared with MilliQ-H2O and both PBS and organic cosolvents were filtered using 0.2 
µm membrane filters prior to use.   
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7.4.2 BSI Setup  
 The previously reported instrumental setup contains a helium-neon (HeNe) laser 
(λ = 632.8 nm) directed onto a poly(dimethylsiloxane) (PDMS) chip containing a 
semicircular microfluidic channel (90 μm wide, 40 μm deep, cross-sectional area of 2.9 
nm
2
).328, 332-335  The HeNe laser and temperature controller were allowed to equilibrate for 
at least 1 h before experiments were run.  Chip silanization was performed using the 
procedure described in Section 7.4.3.  The microfluidic channels were rinsed with 
MilliQ-H2O and PBS prior to each run.  BSI experiments of lipophilic NSAID-AChEI 
conjugates were run in PBS with either 10% methanol or 5% 2(2-ethoxyethoxy)ethanol 
as a cosolvent.  The AChE concentration was held constant (0.01-9.5 µM) while the 
ligand concentrations were varied based on either the IC50 value or the literature Ki value.  
Enzyme and ligand blanks were additionally prepared to correct for concentration-
dependent RI shifts.  AChE:ligand samples were prepared in advance and allowed to 
equilibrate at 4 
o
C for at least three hours prior to each experiment.  The signal was 
measured for 45 to 60 s at 25 
o
C.  Once the data were collected for each ligand 
concentration, the resulting binding curve was fit to an exponential rise to max equation 
using GraphPad Prism (Version 4).  
 
7.4.3 Chip Silanization  
 Prior to silanization, the microfluidic channels were filled with concentrated 
H2SO4 for 1 h to clean.  Next, they were rinsed with MilliQ water, dried with compressed 
air, and filled with a 10% KOH in methanol solution for 30 min, followed by another 
rinse with MilliQ water, then a rinse with toluene.  They were then filled with 2% 3-
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mercaptopropyltriethoxysilane (MEPTES, Sigma Aldrich) in toluene and left to soak for 
1 h.  Finally they were rinsed with toluene followed by MilliQ water. 
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Appendix II:  
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Appendix III:  
1
H and 
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Appendix IV:  
1
H and 
13
C NMR Spectra of Additional Bifunctionals (Compounds 49-
60)  
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Appendix V:  
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